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Summary 
 
Background  
 
One of the key features of clinical pain is central sensitization, which is an enhanced activity 
in the central nervous system (CNS). It underlies a common pain-related neurological 
phenomenon, called hyperalgesia.   
 
Previous studies mainly focused on testing the analgesic effects of acupuncture in healthy 
humans using transient painful stimulation, the lack of central sensitization in the pain test 
rendered these studies with limited clinical implication. To solve this problem, hyperalgesia 
model needs to be introduced into acupuncture studies. 
 
Aims 
The current project aimed to bridge this gap by employing a validated human hyperalgesia 
model to assess the analgesic effect of acupuncture.   
 
This project consists of three stages: at the first stage, literature regarding acupuncture and 
hyperalgesia was critically reviewed to identify the optimal acupuncture parameters. At the 
second stage, an experiment was designed to assess the reproducibility of the topical capsaicin 
model, a commonly used hyperalgesia model in humans for this study. At the final stage, a 
validated hyperalgesia model, called heat/capsaicin model was used to evaluate the anti-
hyperalgesia effect of electroacupuncture.  
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Methodology 
For the literature review, “acupuncture”, ”electroacupuncture”, “hyperalgesia” 
and ”allodynia” and their combinations were used to search the major databases including 
PubMed, Proquest and CINHAL. Inclusion and exclusion criteria were applied to select 
relevant papers. .  
 
The pilot experiment (Stage 2) was a two-session, non-randomised study. Twelve (12) healthy 
human subjects were recruited and completed two sessions of test. In each session, capsaicin 
solution (0.1 ml, 1mg/ml) was applied topically onto the non-dominant forearm (1×1 cm²) for 
45 minutes. Area of secondary hyperalgesia, mechanical pain threshold and the visual 
analogue scale (VAS) were used to determine the time-course of the hyperalgesia in these 
subjects. The two sessions were undertaken with a minimum of one month interval. The data 
from the two sessions were analysed to determine the within group reproducibility of this 
model.  
 
Experiment 2 (The Final Stage) was a one-session, randomised, sham electroacupuncture-
controlled study in healthy human subjects. Twenty (20) subjects were recruited and 
completed the experiment without any dropouts. The heat/capsaicin model was induced by 
heating (45˚C) an area of skin (3×3 cm²) in the middle of the forearm for 5 minutes followed 
with application of a thick layer of capsaicin cream (0.075%) in the sensitised site for 30 
minutes. The sensitised area was then rekindled with heat stimulation (40˚C for 5 minutes) for 
four times. Real or sham electroacupuncture (REA or SEA) intervention was given for 25 
minutes on eight acupuncture points located on the four extremities. Pain rating to long 
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thermal stimulation (40˚C for 1 minute), area of secondary hyperalgesia and heat pain 
threshold were measured once before and twice after EA after the rekindling.   
 
Results 
The current project was reviewed and approved by the Human Research Ethic Committee of 
RMIT University (Reference No. 13/07) 
 
In the literature review, 32 papers were selected. All of them were animal studies in rats. 
There was no human study regarding the anti-hyperalgesia effect of acupuncture. All studies 
used EA as the intervention. Hyperalgesia models used in these studies included 
inflammatory pain, neuropathic pain, and irritable bowel syndrome (IBS) and cancer models. 
Overall, EA significantly reduced both mechanical and heat hyperalgesia compared with 
sham procedures. The optimal EA parameter was identified for two specific types of 
hyperalgesia model; however, no universal optimal EA parameter was identified. 
 
It was found in the pilot experiment, the overall reproducibility of the topical capsaicin model 
was not appropriate to assess the anti-hyperalgesia of acupuncture.  The area of secondary 
hyperalgesia in the two sessions correlated well only at the first post-capsaicin measurement 
(Pearson r = 0.643, p = 0.024), but not at the second measure (Pearson r = 0.456, p = 0.136). 
Mechanical pain threshold, on the other hand, correlated well only in the second post-
capsaicin measurement (Pearson r = 0.745, p = 0.005 in the primary hyperalgesia area; 
Pearson r = 0.644, p = 0.024 in the secondary hyperalgesia area).  Only VAS ratings to three 
out of five von Frey filaments showed moderate correlation during both post-capsaicin 
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measurements. 
 
As a result, a previously validated heat/capsaicin model was used in Experiment 2. It was 
found that both mechanical and thermal hyperalgesia decreased significantly in the REA and 
SEA groups with a similar magnitude. Area of secondary hyperalgesia (mechanical 
hyperalgesia) decreased to 30% of the baseline in REA group and 24% of the baseline in SEA 
group.  Two-way ANOVA showed statistically significant reduction in the area in both groups 
(F (2, 36) = 10.209, p < 0.001) but without difference between the groups (F (2, 36) = 2.146, 
p = 0.988). Similar result was found in the heat pain threshold and pain rating to long thermal 
stimulation.   
 
Conclusion 
There was strong evidence in the animal studies supporting REA being associated with 
significantly better anti-hyperalgesia effect when compared with SEA. The current 
experiment 2 was the first one to assess the anti-hyperalgesia effect of acupuncture using a 
human hyperalgesia model (heat/capsaicin model). However, REA was not better than SEA in 
suppressing hyperalgesia. Further studies need to address a few short-comings (including the 
lack of the use of suprathreshold stimulation high frequency EA parameter) of the current 
experiment and to verify this finding. 
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Chapter 1 introduction 
1.1 What is pain? 
According to the International Association for the Study of Pain (IASP), pain is defined as 
“an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage”. Pain has its biological function for alarming the body of potential tissue damage. 
However, it can become so intense that it impairs other function of the body, and severely 
reduces the quality of life (Ferrell 1995; Tuzun 2007). 
 
1.2 Acupuncture in treating pain 
Acupuncture, an ancient treatment, has been using in China for more than two thousands 
years. Nowadays this therapy is accepted and practiced around the world. A review by the 
WHO in 2002 concluded that ‘acupuncture has been proved effective’ for 28 medical 
conditions, of which 15 are painful conditions (Zhang 2002).  
 
1.3 Neural mechanisms of electroacupuncture analgesia 
The current understanding of the analgesic effect of acupuncture is mainly based on neural 
mechanisms of endogenous pain control and endogenous opioid peptides (Han and Terenius 
1982). 
 
Three popular neurophysiologic theories have been used to explain the analgesic effect of 
acupuncture: gate control theory or segmental inhibition (Bekkering and Bussel 1998), diffuse 
noxious inhibitory control (Le Bars, Dickenson et al. 1979) and limbic system attenuation 
(Campbell 1999).  
 16 
 
Gate control theory hypothesise that high frequency EA activates large myelinated afferent 
fibres (A-β) and prevent pain transmission by inhibiting signes from small afferent (C) fibres 
(Melzack 1984). Segmental inhibition theory, which is developed from gate control theory, 
suggests that EA not only reduces pain at the spinal segment level, but also suppress 
subsequent actions such as withdrawal reflex and local muscle contraction, following a 
painful stimulation (Bekkering and Bussel 1998). These theories explain the immediate 
analgesic effect of acupuncture in and around the area of treatment. 
 
Diffuse noxious inhibitory control theory, which suggests painful stimuli applied to one part 
of the body inhibit pain responses in another part of the body (Le Bars, Dickenson et al. 1979), 
can explain why EA can produce widespread analgesic effect (Zaslawski, Rogers et al. 1997).  
 
The third theory “limbic system attenuation” suggests that the deactivation effect of 
acupuncture on the limbic system could contribute to the feelings of calm and relaxation 
(Campbell 1999), consequently reduces the impact of pain. 
 
Apart from the above mentioned theories, studies suggest that EA stimulation can induce the 
release of opioid peptides in the central nervous system (Cheng and Pomeranz 1979). This 
theory explains why acupuncture has effects lasting beyond the time of stimulation and up to 
a few days as often seen in the clinic.    
 
All of these theories could play important roles in the overall analgesic effects of EA. 
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1.4 Laboratory research about acupuncture and pain  
Though there is traditional Chinese medicine theory explaining and guiding the practice of 
acupuncture, its fundamental mechanism for treating pain remains unclear. Previous human 
studies mainly focused on acupuncture’s effect on pain threshold in healthy subjects (Lin, 
Chandra et al. 1981; Himuro, Tubaki et al. 1987; Cao, Wang et al. 1990; Farber, Tachibana et 
al. 1997; Wang and Hui-Chan 2003; Downs, Kirk et al. 2005). However, the test of transient 
pain sensation has little clinical relevance, as most pain conditions tend to last for a long time, 
from days to years. One of the key features that differentiate clinical pain from normal pain is 
central sensitization, a heightened state of activity in the central nervous system (CNS). For 
this reason, it is important to conduct acupuncture study on models that mimic clinical pain 
and reproduce central sensitization state.  
  
1.5 Animal hyperalgesia models and acupuncture study 
A feasible way to reproduce clinical pain condition is using animal models, in which, a 
neurological phenomenon called hyperalgesia is produced, with central sensitization being its 
key underlying mechanism. It is defined as an increased response to a stimulus which is 
normally painful. It can appear in a simple skin cut or as referred pain from heart disease. 
 
In the past several decades, animal hyperalgesia models of persistent inflammatory pain and 
neuropathic pain have been developed and successfully used in the pharmaceutical researches 
to evaluate the efficacy of analgesics (Helyes, Szabo et al. 2004; Hsueh, Lu et al. 2004; 
Menendez, Lastra et al. 2004; Xu, Huang et al. 2007; Dong, Jia et al. 2008). Inspired by their 
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success in pharmaceutical studies, researchers began to use these animal models to evaluate 
the anti-hyperalgesia effect of acupuncture, and to investigate its possible neurological 
mechanism in treating pain (LaMotte 1992; Oliveira 2000; Dai 2001; Cui 2005).  
 
1.6 Aims of the project  
Despite the increasing evidence in the animal studies suggesting the anti-hyperalgesia effect 
of acupuncture, there is little human study being conducted. The present study aimed to assess 
the anti-hyperalgesia effect of acupuncture in human subjects.  
The specific objectives were  
1) To review current literature to identify an ideal set of acupuncture parameters for the anti-
hyperalgesia effect;  
2) To identify a stable and reproducible human model for testing anti-hyperalgesia effect of 
acupuncture; 
3) To conduct a human study testing anti-hyperalgesia effect of acupuncture using the 
identified hyperalgesia model and parameters; and 
4) To provide directions for future research in this area.  
 
1.7 Outline of the thesis  
Chapter 2 has two main parts: the first part reviews the available literatures regarding 
hyperalgesia and its neurological mechanism, and some commonly used human hyperalgesia 
models and their application in the clinical trial for analgesic evaluation. The second part 
reviews the all studies assessing anti-hyperalgesia effect of acupuncture using various models, 
providing a set of optimal parameters of acupuncture for the human study. 
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Chapter 3 describes the methodology of the two experiments, including overall design, 
subjects recruitment and screening, producing of hyperalgesia models, outcome 
measurements, intervention, blinding and statistical methods. 
 
Chapter 4 presents the result from experiment 1 in which the reproducibility of the commonly 
used topical capsaicin model was assessed. 
 
Chapter 5 presents the finding of experiment 2 in which the anti-hyperalgesia of REA and 
SEA was compared using heat/capsaicin model. 
 
Chapter 6 summarizes the whole projects, discusses its strength and limitation, interprets the 
findings and provides recommendation for future study.  
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Chapter 2 Literature review 
2.1 Hyperalgesia 
2.1.1 Definition of hyperalgesia 
Hyperalgesia means beyond (hyper) pain (algesia). Willis 1992 described the history of the 
term hyperalgesia and indicated this term first appeared in the late 19th century (Willis 1992) 
and was defined as “a state of increased intensity of pain sensation induced by either noxious 
or ordinarily non-noxious stimulation of peripheral tissue” (Hardy, Wolff et al. 1950). 
According to the International Association for the Study of Pain (IASP), the definition of 
hyperalgesia has been revised several times since 1979. In 1994 hyperalgesia was defined as 
"an increased response to a stimulus which is normally painful".  Furthermore, it has also 
been described as a leftward shift of the stimulus-response function (Figure 2.1), resulting in a 
lowering of pain threshold and /or an increase in pain intensity to suprathreshold stimuli 
(Campbell, Raja et al. 1988). 
 
 
 
Figure 2. 1 Diagram of stimulus-response function 
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2.1.2 Hyperalgesia in clinical pain 
Willis 1992 described the history of hyperalgesia and indicated this term first appeared in the 
late 19th century, the phenomenon of hyperalgesia has been recognised clinically for several 
centuries (Willis 1992). There are several references dating back to the 17th and 18th centuries 
that refer to cutaneous tenderness with visceral disease and nerve injuries (Bonica 1992). 
 
From a functional point of view, hyperalgesia serves as a protective mechanism, alerting the 
individual to avoid contact with noxious stimulus to the injured site (Treede, Meyer et al. 
1992). Hyperalgesia, by itself, is not a disease, but a neurological phenomenon or feature 
associated with a range of clinical pain syndromes and visceral diseases. However, in cases 
such as chronic pain, hyperalgesia can be a major clinical problem.  
 
In clinical settings, hyperalgesia is observed in inflammatory and neuropathic conditions of 
both superficial and deep somatic structures, such as injury to skin and mucous membranes, 
diseases of peripheral and central nervous system, referred pain caused by visceral diseases, 
certain types of systemic disorders and certain psychological and psychiatric disorders 
(Bonica 1992). 
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2.1.3 Types of hyperalgesia 
Experimentally, hyperalgesia can be classified as primary vs. secondary hyperalgesia and 
thermal vs. mechanical hyperalgesia 
 
2.1.3.1 Primary and secondary hyperalgesia 
In 1935, Lewis was the first to discover the two distinctive areas following an experimentally-
induced cutaneous injury, i.e. electrical stimulation, the site of injury and the undamaged skin 
around the injury site (Lewis 1935). He hypothesized that there might be a peripheral 
mechanism underlying this phenomenon. . Later, in 1950, another pioneer Hardy, further 
examined the feature of hyperalgesia and used primary and secondary hyperalgesia to name 
evoked pain at the injury site and at the surrounding undamaged skin area, respectively 
(Figure 2.2). However, Hardy proposed different neural mechanisms for the two types of 
hyperalgesia. Firstly, he suggested that primary hyperalgesia was due to sensitisation of the 
peripheral nervous system (PNS), whereas secondary hyperalgesia was resulted mainly from 
sensitisation of the central nervous system (CNS) (Hardy, Wolff et al. 1950). Hardy’s view 
was developed and confirmed by later studies (Treede, Meyer et al. 1992). The terms primary 
and secondary hyperalgesia, continue to be used to describe such phenomena.  
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Figure 2. 2 Illustration of primary and secondary hyperalgesia areas in topical capsaicin 
model 
The innermost circle represents the site of the topical capsaicin application. 
 
 
2.1.3.2 Heat and mechanical hyperalgesia 
As researchers working in the field of hyperalgesia began to use different modalities of 
stimulation to explore the characteristics and mechanisms of primary and secondary 
hyperalgesia, heat and mechanical hyperalgesia were named accordingly, since these two 
types of stimulation were most commonly utilized by researchers. It was first described by 
Raja in 1984 (Raja, Campbell et al. 1984) and later by LaMotte (LaMotte, Shain et al. 1991) 
that primary hyperalgesia was characterized by a heightened responses to heat and mechanical 
stimuli, whereas secondary hyperalgesia only showed increased pain to mechanical stimuli. 
However, later studies demonstrated that heat hyperalgesia was also present in the area of 
secondary hyperalgesia in the topical capsaicin model (Yucel, Andersen et al. 2002).   
 
Furthermore, subcategories of mechanical hyperalgesia have also been discovered. In 1992, 
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Koltzenburg identified static and dynamic components of mechanical hyperalgesia, based on 
the method of delivering mechanical stimulation (Koltzenburg, Lundberg et al. 1992). Static 
hyperalgesia is induced with a mechanical device such as a pressure algometer, von Frey 
filaments or a safety pin at a single point, whereas dynamic hyperalgesia is induced by a 
moving stimulus, such as brush stroking across the skin surface (Kilo, Schmelz et al. 1994).  
 
According to the stimulation modality tested, punctate, stroking, pressure and impact 
hyperalgesia were classified (Kilo, Schmelz et al. 1994). Punctate hyperalgesia is assessed by 
poking the skin surface with a plastic filament or safety pin (Raja, Campbell et al. 1984). 
Stroking hyperalgesia is assessed by moving a brush across the skin (LaMotte, Shain et al. 
1991). Pressure hyperalgesia, similar to punctate hyperalgesia, is measured with a pressure 
algometer. Impact hyperalgesia is tested with a plastic cylinder or bullet shooting against the 
skin (Kilo, Schmelz et al. 1994). 
 
These subtypes of mechanical hyperalgesia manifest differently, according to the type of 
experiment models utilised. For example, stroking hyperalgesia is prominent in the topical 
capsaicin model, but almost absent in cold injury model. Furthermore, impact hyperalgesia is 
found in the cold injury model but absent in the capsaicin model (Kilo, Schmelz et al. 1994). 
 
2.1.4 Different types of cutaneous hyperalgesia and their 
mechanisms 
The knowledge of the neural mechanisms of hyperalgesia have been developed mainly based 
on studies using heat and capsaicin models in animal and human, as these two models have 
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been extensively studied. 
 
2.1.4.1 Primary hyperalgesia  
In his pioneering studies on hyperalgesia, Lewis attributed primary hyperalgesia to the 
sensitisation of the nociceptors by local release of the inflammatory factors from the damaged 
tissue (Lewis 1935). This view is supported by later studies conducted by Hardy and 
colleagues (Hardy, Wolff et al. 1950). 
 
Primary hyperalgesia, according to the stimulus modality, is characterized by sensitisation to 
both thermal and mechanical stimuli (Lewis 1935; Hardy, Wolff et al. 1950), therefore, both 
heat and mechanical hyperalgesia co-exist in the area of primary hyperalgesia. Thus its 
mechanisms should be discussed in terms of both of them. 
 
2.1.4.1.1 Peripheral neural mechanisms of heat hyperalgesia 
Studies have shown that sensitisation of A-fiber and C-fiber mechano-heat nociceptors 
(AMHs and CMHs) account for heat hyperalgesia (Reeh, Kocher et al. 1986) following 
stimuli such as heat and mechanical injury, inflammation, and various chemical stimulations. 
However, the action of nociceptor is different between hairy skin and glabrous skin. Both 
AMHs and CMHs develop sensitisation to heat stimuli in hairy skin (LaMotte, Thalhammer et 
al. 1982), whilst AMHs are sensitised after injury in glabrous skin only (Meyer and Campbell 
1981). Furthermore, preferential A-fiber blockade showed that the time course of heat 
hyperalgesia is not affected by the blockade in hairy skin whilst it is suppressed in a model of 
glabrous skin after the blockade (Meyer and Campbell 1981; LaMotte, Thalhammer et al. 
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1982). This suggests that CMHs may play a dominant role in hairy skin, however may not 
contribute to heat hyperalgesia in glabrous skin. 
 
2.1.4.1.2 Peripheral neural mechanisms of primary mechanical 
hyperalgesia 
Mechanical hyperalgesia, such as pressure, punctate and stroking hyperalgesia also develop 
after heat injury or capsaicin application. However, evidence of nociceptor sensitisation is 
contradictory (Treede, Meyer et al. 1992). Sensitisation of CMHs to mechanical stimuli has 
been found in both human (Torebjork and Hallin 1978) and cats (Bessou and Perl 1969) 
however, not in monkeys and rats (Treede, Meyer et al. 1992), whereas sensitisation of AMHs 
to mechanical stimulation has only been found in rats (Reeh, Bayer et al. 1987). In addition, 
neither AMHs nor CMHs have displayed sensitisation to von Frey filaments stimulation in the 
microneurography test in humans (Baumann, Simone et al. 1991; Handwerker, Forster et al. 
1991; LaMotte, Shain et al. 1991) or in monkeys (Baumann, Simone et al. 1991) following 
heat injury or capsaicin injection.  
 
To an extent, further studies resolve the contradiction of nociceptor sensitisation underlying 
mechanical hyperalgesia within the area of primary hyperalgesia. The novel CMiHi 
nociceptors (mechano-heat insensitive C nociceptors) and CH nociceptors (heat sensitive C 
nociceptors) became sensitized to pressure (Schmidt, Schmelz et al. 1995) and punctate 
stimuli after injection of mustard oil and capsaicin (Schmelz, Schmid et al. 2000). An increase 
of mechanoreceptive field of CMH nociceptors after capsaicin or mustard oil application has 
also been reported (Schmelz, Schmidt et al. 1994). These findings may account for the 
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sensitivity change to mechanical stimuli within the area of primary hyperalgesia.  
 
Importantly, evidence supporting nociceptor sensitisation to stroking stimuli has not been 
found within the region of primary hyperalgesia. Stroking hyperalgesia within the injury site 
may be due to central sensitisation. 
 
2.1.4.2 Secondary hyperalgesia  
Secondary hyperalgesia occurs in the uninjured region surrounding the injury site. Previously, 
it has been widely accepted that only mechanical hyperalgesia was present in this area 
(Treede, Meyer et al. 1992). However, recent studies have found that heat hyperalgesia also 
exists (Yucel, Andersen et al. 2002). Two early pioneers in the area, Lewis and Hardy, 
proposed different mechanisms underlying this phenomenon. Lewis suggested that a 
peripheral mechanism, involving the activation of primary afferent nociceptors by the release 
of substance from the activated nerve terminals, was responsible (Lewis 1935). Lewis 
proposed an unidentified peripheral nervous system called “nocifensor nerves” to support his 
view. However this hypothesis is rarely supported by later performed studies. Hardy, on the 
other hand, proposed that the spread of sensitisation within the central nerves system was the 
underlying mechanism (Hardy, Wolff et al. 1950). Hardy’s view, which was later referred as 
central sensitisation, has been supported by numerous studies in the last three decades and has 
become widely accepted as the mechanism for secondary hyperalgesia (Koltzenburg, 
Lundberg et al. 1992; Treede, Meyer et al. 1992; Kilo, Schmelz et al. 1994). 
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2.1.4.2.1 Peripheral mechanism of secondary hyperalgesia 
It was found in Lewis’s early research that a proximal nerve block interrupting peripheral 
input to the central nervous system did not prevent the development of hyperalgesia and flare. 
Lewis then concluded that the spread of secondary hyperalgesia was due to a peripheral 
mechanism.  He theorised a “nocifensor nerves” system (an unidentified peripheral nervous 
network) may account for these changes (Lewis 1935). A later study which identified 
electrical or chemical coupling between unmyelinated fibres in the periphery may support the 
existence of the nocifensor system (Meyer, Raja et al. 1985). However, no further evidence 
has been provided to support these findings.  
 
In order to explain the characteristic of secondary hyperalgesia with peripheral mechanisms, 
two pieces of key evidence need to be identified. Firstly, the size of receptive fields of 
nociceptor is required to be at least half the size of the secondary hyperalgesia. Secondly, the 
nociceptors are required to become sensitised in the area of secondary hyperalgesia (Treede, 
Meyer et al. 1992).  However, neither of these two findings was supported by further studies.  
It has been found that the mean size of a receptive field in both humans and moneys is 18 
mm² (Campbell, Raja et al. 1989). This is significantly smaller than half of the size of 
secondary hyperalgesia which is up to 550 mm² (LaMotte, Shain et al. 1991).  Furthermore, 
no sensitivity to mechanical stimuli (stroking or punctate) was found in CMiHi, CMHs, and 
AMHs nociceptors, or any other types of afferent fiber (LaMotte 1992; Schmelz, Schmidt et 
al. 1996). Therefore, secondary hyperalgesia cannot be readily explained by the peripheral 
mechanism alone. 
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2.1.4.2.2 Central mechanism of secondary hyperalgesia 
Hardy and coworkers conducted a serial of psychophysical experiments on hyperalgesia using 
electrical nerve stimulation and local anesthetics. They found that proximal nerve block near 
the torso slowed the spreading of secondary hyperalgesia instead of preventing its 
development, whereas distal nerve block, near the extremity, prevented hyperalgesia 
spreading to the blocked area. These findings led Hardy and coworkers to conclude that the 
spread of the secondary hyperalgesia must be likely due to the changes in the central nervous 
system (Hardy, Wolff et al. 1950).  
 
Evidence supporting central sensitization came from a series of electrophysiological 
experiments using animal hyperalgesia models. These findings included the heat injury model 
in monkeys showing the dorsal horn neurons to develop increased sensitivity to mechanical 
stimuli applied outside the injury site (Kenshalo, Leonard et al. 1982), decreasing mechanical 
thresholds reported in the receptive field of rat lamina I neurons (McMahon and Wall 1984) 
and sensitisation observed in the somatosensory cortex (Kayser and Guilbaud 1987) and 
spinothalamic tract (STT) neurons (Simone, Baumann et al. 1989; Simon, Sorkin et al. 1991) 
in animals under hyperalgesia state. Furthermore, following intradermal injections in 
monkeys, WDR and NS neuronal activity response was heightened due to both stroking and 
punctate stimuli (Simon, Sorkin et al. 1991) with changes also reported in the receptive field 
of central neurons, and an enlarged receptive field of STT neurons after burn injury 
(McMahon and Wall 1984). 
 
Mechanical injury within the receptive field of dorsal horn neurons of rats was found to cause 
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the expansion of the receptive field of these neurons (Laird and Cervero 1989). Application of 
mustard oil outside of the receptive field of dorsal horn neurons of rats also led to its 
expansion (Woolf and King 1990).  
 
More recently, studies in healthy human subjects using PET (Iadarola, Berman et al. 1998) 
and fMRI (Baron, Baron et al. 1999) demonstrated that under hyperalgesia state produced by 
capsaicin application, same amount of mechanical stimulations elicited an enhanced level of 
activity in the prefrontal cortex and somatosensory cortex. In another study, fMRI indicated 
different patterns of brain activation between thermal and mechanical hyperalgesia, which 
related to different psychophysical properties for these two types of hyperalgesia (Maihofner 
and Handwerker 2005). Another animal study using fMRI found that mechanical stimulation 
induced a decrease in blood oxygen levels dependent of signal intensity in periaqueductal 
grey (PAG), in capsaicin treated rats. This also demonstrates the roles of PAG in central 
sensitisation (Moylan Governo, Morris et al. 2006). 
 
2.1.5 Experimental cutaneous hyperalgesia in humans 
In a clinical setting, hyperalgesia can occur in both superficial and deep somatic tissue 
(Bonica 1992). Manifestations of hyperalgesia vary substantially between individuals, making 
it extremely difficult to study quantitatively. Inducing hyperalgesia in healthy human subjects 
under controlled experimental conditions provides the opportunity to study its underlying 
mechanisms and therapeutic effects of various analgesics.  
 
The following methods were employed by early researchers to induce hyperalgesia in healthy 
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participants (Hardy, Wolff et al. 1950): 
1. Ultraviolet light from a lamp applied over an area of skin. 
2. High intensity thermal radiation applied onto an area of blackened skin. 
3. Electrical stimulation on a small area of skin anaesthetized by procaine. 
4. Crushing a small area of skin by forceps. 
5. Injecting saline into the intraspinous ligament. 
 
Skin, due to its easy accessibility, is the main site for producing hyperalgesia. However, some 
of these methods mentioned above cause significant tissue damage and hence, not widely 
used.  For this reason, it is necessary to find a hyperalgesia model that resembles clinical pain 
conditions, yet with minimum tissue injury. Several models have been developed over the 
decades.  These include chemical models, thermal models and a combination of these. 
 
2.1.5.1 Chemical models 
2.1.5.1.1 Capsaicin model 
Topical application or intradermal injection of capsaicin, the pungent substance from chili 
peppers, can produce burning pain and distinct areas of both primary and secondary 
hyperalgesia without producing evident tissue injury (Simon, Baumann et al. 1989; LaMotte 
1992).  Due to this feature, capsaicin is one of the most commonly used models in the study 
of hyperalgesia.  
 
It is understood that capsaicin has a unique selectivity for unmyelinated C-fibres and thinly 
myelinated Aδ primary sensory neurones (Dray and Dickenson 1993). Topical application or 
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local injection of capsaicin into healthy human skin produces a concentration-dependent, 
burning sensation and flare response. For example, an intradermal injection of capsaicin (100 
µg capsaicin in 10µl vehicle) can produce punctate hyperalgesia for up to 24 hours, and 
stroking hyperalgesia for up to 6 hours (LaMotte, Shain et al. 1991). Within the area of 
application, mechanical and thermal hyperalgesia (primary hyperalgesia) are present. Around 
the area of application there is a region of secondary hyperalgesia, in which enhanced 
sensitivity to mechanical stimulation such as pinprick, is present (mechanical hyperalgesia) 
(Campbell, Bevan et al. 1993). These features of capsaicin-induced hyperalgesia serve as a 
criteria for measuring the analgesic efficacy of various interventions (Bonica 1992), such as 
Ketamine, alfentanil (Park, Max et al. 1995; Sethna, Liu et al. 1998), gabapentin (Iannetti, 
Zambreanu et al. 2005), and complementary therapies including chiropractic adjustment 
(Mohammadian, Gonsalves et al. 2004). 
  
Properties of both intradermal and topical application models have been investigated through 
numerous studies. Zheng et al. (2000) studied the time-course of capsaicin-induced 
hyperalgesia in different age groups and found that punctate hyperalgesia lasts for a longer 
duration in older people than in the young (Zheng, Gibson et al. 2000). A study regarding 
intradermal capsaicin model concluded that the reproducibility of this model over a period of 
time (at least one week interval) was acceptable for pharmacological profiling of novel anti-
nociceptive agents (Hughes, Macleod et al. 2002). However, the reproducibility of topical 
capsaicin model has not been studied yet.  
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2.1.5.1.2 Mustard oil 
Like capsaicin, topical application of mustard oil can produce burning pain as well as primary 
and secondary hyperalgesia (Reeh, Kocher et al. 1986; Koltzenburg, Lundberg et al. 1992), its 
sensory changes is comparable to capsaicin model but develop faster (Koltzenburg, Lundberg 
et al. 1992). It takes effect by stimulate CMHs and make them sensitized to heat but not to 
mechanical stimulation (Reeh, Kocher et al. 1986; Schmelz, Schmidt et al. 1996). 
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2.1.5.2 Thermal models 
2.1.5.2.1 Cold injury model 
Lewis (Lewis 1935) was the first to introduce cold injury to produce hyperalgesia. They used 
two different stimulations, namely, copper bar at -15oC and rod of compressed carbon dioxide 
(CO2) snow. The onset time of hyperalgesia for these two methods is approximately 20 
minutes and 20 hours, respectively.  
 
In 1994, Kilo et al. described an injury model in which the skin is briefly frozen to -28 oC to 
cause moderate pain. Itching or burning sensation lasts for about 2 hours after the inflicted 
injury. Heat pain threshold is lowed within the injury site; however no hyperalgesia presented 
in the first hour after injury. Sensory tests conducted 22 hours after the procedure of freezing 
found that punctate hyperalgesia, but not stroking hyperalgesia, developed around the injury 
site (area of secondary hyperalgesia), whilst pressure and impact hyperalgesia only presented 
in the area of primary hyperalgesia (Kilo, Schmelz et al. 1994). 
 
As revealed by differential nerve blocks, punctate hyperalgesia in this model is mediated via 
C fibers or thinly myelinated A-delta fibers, and impact hyperalgesia is most likely to be 
mediated by sensitized C fibers. Pressure hyperalgesia may be due to the involvement of 
sensitised nociceptor units (Kilo, Schmelz et al. 1994). 
 
2.1.5.2.2 Heat injury model 
Two different methods have been used to produce heat injury that include radiant heat (Hardy, 
Wolff et al. 1950; Raja, Campbell et al. 1984) and contact heat (LaMotte, Shain et al. 1991; 
Dirks, Petersen et al. 2003). 
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The temperature of heat stimulation varies between studies. In one study, heat stimulus of 49-
50 oC was applied for five to seven minutes. This caused blister and heat hyperalgesia within 
the injury site, which lasted for over 24 hours. Stroking and punctate hyperalgesia in the area 
of secondary hyperalgesia developed after the injury and lasted for up to 6 and 24 hours, 
respectively (Dahl, Brennum et al. 1993; Moiniche, Dahl et al. 1993). In another study, the 
skin was heated to 47 oC for seven minutes with a computer controlled thermode. Similar 
sensory changes were induced at 49 oC, however minimal blistering occurred in young 
volunteers (Petersen, Brennum et al. 1997).  During this study, it was found that heating the 
skin to 45 oC for three minutes caused mild to no pain with no spontaneous pain persisting 
after removal of the heat source from the skin. Stoking and punctate hyperalgesia in this 
model lasted for only a few minutes after the termination of the heat stimulation (Brennum, 
Dahl et al. 1994; Dirks, Petersen et al. 2003). 
 
It is generally understood that heat injury causes greater degree of hyperalgesia in hairy skin 
than in glabrous skin (LaMotte, Thalhammer et al. 1982). In hairy skin, suprathreshold heat 
stimuli activate CMH nociceptors (LaMotte, Thalhammer et al. 1982). AMHs nociceptors can 
only be activated by heat stimuli above 51 oC. It is believed that the heat allodynia by heat 
injury attributes to the lowering of activation threshold of CMH nociceptors, while heat 
hyperalgesia may be due to lowering of activation thresholds and increasing of suprathreshold 
response in both CMHs and AMHs nociceptors (LaMotte, Thalhammer et al. 1982; Brennum, 
Dahl et al. 1994). On the other hand, in the glabrous skin, heat hyperalgesia is  caused by 
sensitisation of AMHs nociceptors (Handwerker and Reeh 1991). 
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2.1.6 Heat/capsaicin model 
2.1.6.1 Introduction 
The heat/capsaicin model is a newly developed model by Petersen et al. (Petersen and 
Rowbotham 1999). This model involves the use of two different nociceptive stimuli, that 
include topical capsaicin and heat, which produces a longer lasting and stable hyperalgesia 
model when compared to using either method individually (Dirks, Petersen et al. 2003).  
 
When using the heat/capsaicin model, capsaicin cream of low concentration (0.075%) is 
applied topically to the medial aspect of the forearm for 30 minutes, immediately after heating 
the site to 45 oC for five minutes using a thermode. The sensitised skin is rekindled at 40 oC at 
40-45 minute intervals, four to fives times during the procedure, to maintain the area of 
secondary hyperalgesia (Petersen and Rowbotham 1999; Dirks, Fabricius et al. 2000; Petersen, 
Maloney et al. 2003; Frymoyer, Rowbotham et al. 2007). The area of punctate hyperalgesia is 
better maintained throughout rekindling than that of stroking hyperalgesia (Petersen and 
Rowbotham 1999; Dirks, Petersen et al. 2003).  
 
Rekindling is the key to marinating the area of secondary hyperalgesia. An area of secondary 
hyperalgesia will shrink markedly without the application of rekindling (Petersen and 
Rowbotham 1999; Dirks, Petersen et al. 2003). Previous studies have demonstrated that 
applied cooling will result in the secondary area to shrink, whereas reheating the sensitised 
skin will cause it to expand (LaMotte, Shain et al. 1991; Koltzenburg, Lundberg et al. 1992).  
Rekindling in combination with stimulation from capsaicin of a low concentration can 
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produce sufficient C-nociceptor input to partially counteract the natural reduction of the 
secondary hyperalgesia, thus achieving maintenance (Petersen and Rowbotham 1999). 
 
There have been various studies performed to determine the reproducibility of this model. To 
determine the within-day reproducibility, coefficients of variance were calculated by using 
area of secondary hyperalgesia of first and third rekindling. The between-day reproducibility 
was determined by calculating the coefficient of variance with data from two separate study 
days.  Results demonstrate that heat/capsaicin model has better within-day reproducibility 
(CV, 23%) on punctate hyperalgesia than either heat model (CV, 36%) or capsaicin model 
(CV, 36%) alone, but relatively poor within day reproducibility on stroking hyperalgesia than 
either of the stimulation alone. No significant difference was found in the size of area of 
punctate hyperalgesia between the two study days. However, it was determined that within-
day reproducibility is higher than the between-day reproducibility (Dirks, Petersen et al. 
2003). 
 
Gender differences of the heat/capsaicin model have also been explored.  Studies have shown 
that the area of punctate hyperalgesia is the same in both genders, while area of stroking 
hyperalgesia is larger in females than in males. No gender difference was found to exist in 
pain rating and heat pain thresholds. Overall, there are minimal gender differences in the 
heat/capsaicin model (Jensen and Petersen 2006). 
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2.1.6.2 Measurements 
Both mechanical and heat hyperalgesia can be assessed in this heat/capsaicin model. Area of 
secondary hyperalgesia was measured with both von Frey filaments and foam paintbrush 
along four linear paths arranged vertically and horizontally around the stimulation site 
(Petersen, Maloney et al. 2003). The heat pain detection threshold was measured using a 
computer-controlled thermode, whereby subjects indicate the threshold by pressing a mouse 
button (Mathiesen, Imbimbo et al. 2006). Subjects were also asked to rate pain sensation 
during the rekindling procedure.  The rating was then continuously recorded with an 
electronic VAS (Dirks, Fabricius et al. 2000). 
 
2.1.6.3 Application in the clinical trials for analgesics 
Since 1999, the heat/ capsaicin model has been used in 10 pharmaceutics studies (Table 2.1). 
The measurements include the area of punctate or stroking hyperalgesia, allodynia, heat pain 
thresholds, VAS rating to the rekindling (40 oC, 1 minute) and pain rating to long thermal 
stimulation (45 oC, 1 minute) (Petersen and Rowbotham 1999; Dirks, Petersen et al. 2003). 
Anti-hyperalgesia effects of various medications have been evaluated using these 
measurements. 
 
Table 2.1 (below) summarises the pharmaceutical studies that have used this model. Several 
types of analgesic medications were used including opioid, NMDA receptor antagonist, local 
anesthetics, anticonvulsants, COX-2 inhibitor, and others agents. Three studies showed that 
opioids, such as Remifentanil, Hydromorphone and morphine reduced both mechanical and 
heat hyperalgesia (Petersen, Jones et al. 2001; Duedahl, Dirks et al. 2005; Frymoyer, 
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Rowbotham et al. 2007). These results indicate their effect on both peripheral and central 
sensitisation. NMDA receptor antagonists, such as dextromethorphan and CHF3381, only 
reduced punctuate hyperalgesia but not heat hyperalgesia (Duedahl, Dirks et al. 2005; 
Mathiesen, Imbimbo et al. 2006), indicating their specific anti-central sensitisation effect. 
 
There was only one study that tested systemic lignocaine, a local anaesthetic agent. Results 
found that it reduced stroking hyperalgesia but not punctuate or heat hyperalgesia (Dirks, 
Fabricius et al. 2000). The effect of anti-hyperalgesia of anticonvulsants was not consistent 
amongst the studies. For example, oral gabapentin reduced both mechanical (stroking and 
punctuate hyperlagesia) and heat hyperalgesia (Dirks, Petersen et al. 2002), whereas oral 
lamotrigine had no effect over these two types of hyperalgesia (Petersen, Maloney et al. 2003).  
Other medications such as valdecoxib (COX-2 inhibitor) (Burns, Hill et al. 2006), adenosine 
(Dirks, Petersen et al. 2001) and magnesium (Mikkelsen, Dirks et al. 2001), although having 
NMDA receptor antagonist-like effect (Poleszak, Wlaz et al. 2007), showed no anti-
hyperalgesia function.  
 
In brief, this model provides a non-invasive, non-injury yet reliable and reproducible way to 
evaluate the efficacy of analgesic interventions. It is also possible to use this model to test the 
specific anti central or peripheral sensitization effects of medications and interventions. 
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Table 2. 1 Summary of the studies using heat/capsaicin model for testing anti-hyperalgesia effects of analgesics 
 
Paper No. Design Types of 
medications  
Intervention Medication 
time point 
Subject No. 
(total) 
Measurement  Result 
(compared to control) 
Area of stroking 
hyperalgesia  
Reduced 
Area of punctate 
hyperalgesia  
No effect 
Heat pain detection 
thresholds 
No effect 
Pain rating to long 
thermal stimulation 
(45˚C) 
No effect 
1 (Dirks, 
Fabricius et 
al. 2000). 
double 
blinded, 
randomise
d order of 
infusion, 
crossover, 
placebo 
controlled. 
local 
anaesthetic   
Systemic 
lidocaine 
(bolus 2 
mg/kg over 10 
minutes, 
followed by 
infusion 
3 mg/kg/h 
for 75 
minutes )  
immediately 
after the 
heat/capsaic
in model 
24 
Pain rating to 
rekindling (40˚C), 
No effect 
Area of  stroking 
hyperalgesia 
No effect 
Area of  punctate 
hyperalgesia 
No effect 
Heat pain detection 
thresholds 
No effect 
2 (Dirks, 
Petersen et 
al. 2001) 
double 
blinded, 
randomise
d, 
crossover, 
placebo 
controlled 
Antiarrhythmi
c agents, has 
anti-central 
sensitisation 
effect  
Systemic 
adenosine 
(intravenous 
60 µg/kg/min 
for 85 
minutes ) 
 
 
immediately 
after the 
heat/capsaic
in model 
25 
Pain rating to long 
thermal stimulation 
(45˚C), 
No effect 
Area of stroking 
hyperalgesia 
No effect 
Area of punctate 
hyperalgesia 
No effect 
Heat pain detection 
thresholds 
Reduced 
3.(Mikkelsen
, Dirks et al. 
2001) 
Double 
blinded, 
randomise
d, 
crossover, 
placebo 
controlled 
Has NMDA 
antagonist 
like effect  
 
Intravenous 
magnesium 
(bolus 2 
mg/kg over 10 
minutes, 
followed by 
infusion 
immediately 
after the 
heat/capsaic
in model 
25 
Pain rating to long Increased 
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thermal stimulation 
(45˚C) 
3 mg/kg/h for 
75 minutes)  
 Pain rating to 
rekindling (40˚C), 
No effect 
Area of stroking 
hyperalgesia 
Reduced 
Area of punctate 
hyperalgesia 
Reduced 
Heat pain detection 
thresholds 
Increased 
4.(Petersen, 
Jones et al. 
2001) 
Double 
blinded, 
randomise
d, 
crossover, 
placebo 
controlled 
opioid 
medication 
Intravenous 
Remifentanil 
(0.05 mg /kg/ 
min for  5 
minutes, 
followed by 
0.1 mg/ kg/ 
min for 35 
minutes) 
 
 
immediately 
after the 
heat/ 
capsaicin 
model 
14 
Pain rating to long 
thermal stimulation 
(45˚C), 
Reduced 
Area of stroking 
hyperalgesia 
Reduced 
Area of punctate 
hyperalgesia 
Reduced 
5. (Dirks, 
Petersen et 
al. 2002) 
Double 
blinded, 
randomise
d, 
crossover,  
placebo 
controlled 
anticonvulsant Oral 
gabapentin 
(1,200 mg) 
 
immediately 
after the 
heat/capsaic
in model 
25 
Heat pain detection 
thresholds 
Increased  
Area of stroking 
hyperalgesia 
No effect 
Area of punctate 
hyperalgesia 
No effect 
6. (Petersen, 
Maloney et 
al. 2003) 
Double 
blinded, 
randomise
d,crossove
r, placebo 
controlled 
anticonvulsant
s 
Oral 
Lamotrigine 
(400 mg), 
 
 
90 minute 
before and 
immediately 
after the 
heat/capsaic
in model 
13 
Pain rating to long 
thermal stimulation 
(45˚C) 
No effect 
Area of stroking 
hyperalgesia 
Reduced   opioid Oral 
hydromorpho
ne (8 mg), 
immediately 
after the 
heat/capsaic
 
Area of punctate Reduced 
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hyperalgesia  
 
in model 
Pain rating  to long 
thermal stimulation 
(45˚C) 
Reduced 
Area of stroking 
hyperalgesia 
Reduced 
Area of punctate 
hyperalgesia 
Reduced 
  opioid Intravenous 
Remifentanil 
(0.05 mg /kg/ 
min for  10 
minutes, 
followed by 
0.1 mg/ kg/ 
min for 25 
minutes),   
 
immediately 
after the 
heat/capsaic
in model 
 
Pain rating to long 
thermal stimulation 
(45˚C) 
Reduced 
Area of punctate 
hyperalgesia  
Reduced 
Heat pain detection 
thresholds 
No effect 
7. (Duedahl, 
Dirks et al. 
2005) 
Double 
blinded, 
randomise
d placebo 
controlled, 
crossover 
NMDA 
receptor 
antagonist 
Intravenous 
dextromethor
phan, 0.5 
mg/kg, 
 
 
 
after 1st 
rekindling 
and baseline 
24 
Pain rating of long 
thermal stimulation 
(45˚C) 
No effect 
Area of stroking 
hyperalgesia 
No effect 
Area of punctate 
hyperalgesia  
No effect 
Hot/cold pain 
threshold 
No effect 
8. (Burns, 
Hill et al. 
2006) 
Double 
blinded, 
randomise
d, placebo 
controlled, 
crossover 
COX-2 
inhibitor 
Oral 
valdecoxib 
(40 mg), 
 
2 hours 
before the 
heat/capsaic
in model 
20 
Pain rating to long 
thermal stimulation 
(45˚C) 
No effect 
9. 
(Mathiesen, 
Randomis
ed, 
NMDA 
receptor 
Oral 
CHF3381 
after first 
rekindle 
27 Area of punctate 
hyperalgesia  
Reduced 
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Heat pain detection 
threshold 
No effect Imbimbo et 
al. 2006) 
double-
blind, 
crossover, 
placebo 
controlled 
antagonist (500 mg), 
 
Pain rating to long 
thermal stimulation 
(45˚C) 
No effect 
Area stroking 
hyperalgesia  
Reduced 
Heat pain detection 
threshold 
No effect 
  anticonvulsant Oral 
gabapentin 
(1,200 mg),   
after first 
rekindle 
 
 
Pain rating to long 
thermal stimulation 
(45˚C) 
No effect 
Area of stroking 
hyperalgesia  
Reduced 
Area of punctate 
hyperalgesia  
Reduced 
10. 
(Frymoyer, 
Rowbotham 
et al. 2007) 
randomize
ddouble-
blind, 
placebo-
controlled, 
crossover 
NMDA 
receptor 
antagonist and 
opioid 
medication 
Oral 
dextromethor
phan (30 mg) 
and morphine 
(30 mg) 
combination 
 
immediately 
after the 
heat/capsaic
in model 
22 
Pain rating of long 
thermal stimulation 
(45˚C) 
Reduced 
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2.2 Acupuncture and hyperalgesia  
2.2.1 Introduction 
Previous acupuncture studies have mainly focused on pain threshold, which has limited 
clinical significance. Central sensitisation is an important characteristic of clinical pain 
however, cannot be tested using the non-injury pain model. To solve this problem, 
hyperalgesia animal models were introduced into acupuncture studies. Models such as 
Complete Freud’s Adjuvant (CFA), Chronic Constrictive Injury (CCI) and Irritable Bowel 
Syndrome (IBS) mimic painful, clinical conditions for a period of time, often lasting several 
days to months. These models can provide researchers with the opportunity to test 
medications and other interventions in a more clinically orientated setting, therefore 
producing more clinically significant results. 
 
There are two major types of animal models used in acupuncture studies: inflammatory and 
neuropathic models, each with different neurological mechanisms and clinical significance.  
Inflammation models, including those induced by CFA, carrageenan and formalin, mimic 
inflammatory pain conditions, such as arthritic pain.  
 
Neuropathic models, including CCI, Spinal Nerve Ligation (SNL) and Inferior Caudal 
Trunk Resection (ICTR) models, aim to reproduce clinical neuropathic pain conditions, 
such as sciatica and trigeminal neuralgia.  Several other models have also been used, 
including a cancer pain model that reproduces pain symptoms caused by cancer, and an 
incision model to replicate post-operative pain, and IBS model that mimics the irritable 
bowel syndrome.  
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Most of these models produce thermal and mechanical hyperalgesia, which are cardinal 
features of human hyperalgesia models and clinical pain conditions. Therefore, by 
measuring hyperalgesia, it is possible to assess the analgesic efficacy of novel interventions. 
 
2.2.2 Aim 
The aims of the review were to:   
1) Identify the animal models used, 
2) Assess the effect of acupuncture on hyperalgesia in animal pain models, 
3) Identify the optimal acupuncture parameters for anti-hyperalgesia effect 
 
2.2.3 Searching strategy 
“Acupuncture AND hyperalgesia” or “acupuncture AND allodynia” or “electroacupuncture 
AND hyperalgesia” or “electroacupuncture AND allodynia” in text word were terms used to 
search the major databases: PubMed, Proquest and CINHAL. There were no limits placed 
on publication date, subjects or publication types. Studies published up to October 2007 
were included. 
 
Studies that tested the effect of acupuncture on hyperalgesia, such as paw withdrawal 
latency to thermal or mechanical stimuli, were included. Included studies must have had at 
least one control group. Studies on animals or humans were included. Acupuncture in the 
studies was required to be invasive, with no drugs injected into the acupoint. Case studies, 
review and studies that did not include a valid acupuncture group were excluded.  
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As shown in Figure 2.3, the search generated 55 papers, of which 32 were relevant. All of 
these studies were animal (rat) studies and used electroacupuncture. Twenty-three papers 
were excluded according to selection criteria: nine of these did not assess hyperalgesia, five 
did not use acupuncture, five used bee venom and laser acupuncture, three were case studies 
and one was a review. Included and excluded studies are listed in Tables 2.2 and 2.3, 
respectively. 
 
 
Figure 2. 3 A flowchart illustrating the process of study selection 
 
 
55 
46 
41 
9 excluded for not testing hyperalgesia 
5 excluded for not using acupuncture 
5 excluded for using bee venom and laser 
36 
33 
3 excluded due to case study 
1 excluded due to review 
32 
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Table 2. 2 Titles of the included studies 
 
Paper No. Title and reference 
1 Electroacupuncture combined with indomethacin enhances antihyperalgesia in 
inflammatory rats (Zhang, Lao et al. 2004) 
2 Excitatory amino acid receptor antagonists and electroacupuncture synergistically 
inhibit carrageenan-induced behavioral hyperalgesia and spinal Fos expression in 
rats (Zhang, Ji et al. 2002) 
3 Electro-acupuncture attenuates behavioral hyperalgesia and selectively reduces 
spinal Fos protein expression in rats with persistent inflammation (Lao, Zhang et al. 
2001) 
4 Involvement of opioid receptors in electroacupuncture-produced anti-hyperalgesia 
in rats with peripheral inflammation (Zhang, Lao et al. 2004) 
5 Electro-acupuncture relieves chronic visceral hyperalgesia in rats (Cui, Li et al. 
2005) 
6 Ketamine potentiates the effect of electroacupuncture on mechanical allodynia in a 
rat model of neuropathic pain (Huang, Li et al. 2004) 
7 A parametric study of electroacupuncture on persistent hyperalgesia and Fos 
protein expression in rats (Lao, Zhang et al. 2004) 
8 Attenuation of mechanical but not thermal hyperalgesia by electroacupuncture with 
the involvement of opioids in rat model of chronic inflammatory pain (Huang, Hu 
et al. 2004) 
9 A minimal stress model for the assessment of electroacupuncture  analgesia in rats 
under halothane (Wen, Yeh et al. 2007) 
10 Anti-hyperalgesic effect of electroacupuncture in a model of post-incisional pain in 
rats (Oliveira and Prado 2000) 
11 Corticosterone mediates electroacupuncture-produced anti-edema in a rat model of 
inflammation (Li, Zhang et al. 2007) 
12 Corticotropin-releasing factor and interleukin-1β are involved in the 
electroacupuncture-induced analgesic ffect on inflammatory pain elicited by 
carrageenan (Sekido, Ishimaru et al. 2004) 
13 Differences of electroacupuncture-induced analgesic effect in normal and 
inflammatory 
conditions in rats (Sekido, Ishimaru et al. 2003) 
14 Disruption of glial function enhances electroacupuncture analgesia in arthritic rats 
(Sun, Chen et al. 2006) 
15 Down- regulation of GFR -1 expression by antisense oligodeoxynucleotide 
attenuates electroacupuncture analgesia on heat hyperalgesia in a rat model of 
neuropathic pain (Dong, Ma et al. 2006) 
16 Effects of electroacupuncture on the mechanical allodynia in the rat model of 
neuropathic pain (Hwang, Min et al. 2002) 
17 Effects of pertussis toxin on electroacupuncture-produced anti-hyperalgesia in 
inflamed rats (Liu, Zhang et al. 2005) 
18 Electroacupuncture (EA) modulates the expression of NMDA receptors in primary 
sensory neurons in relation to hyperalgesia in rats (Wang, Zhang et al. 2006) 
19 Electro-acupuncture attenuates stress-induced defecation in rats with chronic 
visceral hypersensitivity via serotonergic pathway (Tian, Bian et al. 2006) 
20 Electroacupuncture combined with MK-801 prolongs anti-hyperalgesia in rats with 
peripheral inflammation (Zhang, Wang et al. 2005) 
21 Electroacupuncture inhibits inflammatory edema and hyperalgesia through 
regulation of cyclooxygenase synthesis in both peripheral and central nociceptive 
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sites (Lee, Jang et al. 2006) 
23 Electroacupuncture suppresses spinal expression of neurokinin-1 receptors induced 
by persistent inflammation in rats (Zhang, Liu et al. 2005) 
25 Involvement of nociceptin/orphanin FQ and its receptor in electroacupuncture-
produced anti-hyperalgesia in rats with peripheral inflammation (Fu, Wang et al. 
2006) 
26 Is functional state of spinal microglia involved in the anti-allodynic and anti-
hyperalgesic effects of electroacupuncture in rat model of monoarthritis? (Shan, Qi-
Liang et al. 2007) 
27 Kynurenic acid enhances electroacupuncture analgesia in normal and carrageenan-
injected rats (Zhang, Ji et al. 2003) 
28 Mu opioid receptor-containing neurons mediate electroacupuncture-produced anti-
hyperalgesia in rats with hind paw inflammation (Zhang, Wang et al. 2005) 
29 Stage-dependent analgesia of electro-acupuncture in a mouse model of cutaneous 
cancer pain (Mao-Ying, Cui et al. 2006) 
30 Involvement of peripheral opioid mechanisms in electroacupuncture analgesia 
(Zhang, Yu et al. 2005) 
31 The anti-inflammatory effects of 2 Hz electroacupuncture with different intensities 
on acute carrageenan-induced inflammation in the rat paw (Lee, Choi et al. 2005) 
32 Effects of electroacupuncture on the pain threshold and NMDA R1 mRNA in DRG 
on neuropathic pain rats (Chen, Yang et al. 2003) 
34 Effect of electroacupuncture on GDNF positive cell immunoreactivity in local 
dermal tissue of the inflammatory pain focus in the rat of adjuvant arthritis (Liu, Li 
et al. 2006=) 
35 Effect of varying frequency and duration of electroacupuncture stimulation on 
carrageenan-induced hyperalgesia (Taguchi and Taguchi 2007) 
Note: Paper No. 22, 24, 33 were excluded 
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Table 2. 3 Excluded studies and reasons for exclusion 
 
Excluded paper Reason for exclusion 
(Dai and Xu 1993) Hyperalgesia not tested  
(Hamba 1988) Hyperalgesia not tested 
(Kong, Fufa et al. 2005) Hyperalgesia not tested 
(Dickhaus, Pauser et al. 1978) Hyperalgesia not tested 
(Clark, Yang et al. 1986) Hyperalgesia not tested 
(Raevskaia 1992) Hyperalgesia not tested 
(Omana, Olvera et al. 1994) Hyperalgesia not tested 
(Wang, Zhu et al. 1998) Hyperalgesia not tested 
(Cha, Choi et al. 2006) Hyperalgesia not tested 
(Gracely, Dubner et al. 1983) Acupuncture not used 
(Liu, Li et al. 2006) Acupuncture not used 
(Fu, Zhu et al. 2007) Acupuncture not used 
(Ma, Xie et al. 2003) Acupuncture not used 
(Dong, Wang et al. 2006) Acupuncture not used 
(Kwon, Lee et al. 2001) Bee venom 
(Kwon, Lee et al. 2002) Bee venom 
(Roh, Kwon et al. 2004) Bee venom 
(Giuliani, Fernandez et al. 2004) Laser acupuncture 
(Zhu, Li et al. 1990) Laser acupuncture 
(Zanon, Garetto et al. 2004) Case study  
(Biedermann, Lapeer et al. 1986) Case study 
(Luo 1996) Case study 
(Vinik 2005) Review 
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The design of the study is summarised in Table 2.4.  Listed are the sham control, 
randomisation and blinding details of the included studies. 
 
Table 2. 4 Summary of study design 
 
Design Paper No. Number of 
study 
Sham acupuncture 
was used  
1, 2, 3, 4, 5, 7, 8, 10, 
11, 14, 16, 17, 18, 20, 
23, 25, 26, 27, 28, 29, 
30, 34, 35 
23 
Randomisation was 
used  
3, 4, 6, 7, 8, 15, 17, 
18, 20, 23, 25, 28, 29, 
30, 34 
15 
Blinding (assessor) 1, 3, 4, 5, 7, 14, 15, 
17, 19, 20, 23, 26, 27, 
28 
14 
Sham, randomisation 
and blinding 
3, 7, 17, 20, 23, 28 6 
 
2.2.4 Animal models 
Animal pain models used in acupuncture studies are listed in Table 2.5, which include 
inflammatory, neuropathic and cancer pain models and visceral hyperalgesia (Dai, Kondo et 
al. 2001; Hwang, Min et al. 2002; Huang, Hu et al. 2004; Sekido, Ishimaru et al. 2004; Lee, 
Choi et al. 2005). The most commonly used models were for inflammation, such as CFA 
and carrageenan models.   Other models including neuropathic, IBS and cancer models are 
not often used. 
 
 51 
Table 2. 5 Types of animal models used in acupuncture studies
Outcome measures  Model site 
Type Name No. of study 
Type  Usage No. Injury site Usage No. 
PWL to radiant heat 14 Plantar surface of one hind paw 12 
Response Latency to hot plate test 1 Left tibio-tarsal joint 1 
Mechanical withdraw threshold to 
von Frey filaments 
3 Unilateral ankle articular cavity 1 CFA 16 
Foot-bend score 2 Left malleolus articular cavity 2 
PWL to radiant heat 2 
Response latency to hot plate test 2 Carrageenan 7 
PPT using analgesy-meter 3 
Plantar surface of one hind paw 7 
formalin 1 
Weighted pain score 
(behavioral hyperalgesia) 
1 Plantar surface of left hind paw 1 
 
Inflammati
on 
incision 1 
Mechanical withdraw threshold to 
von Frey filaments 
1 1cm longitudinal, through skin 
and fascia of the plantar region 
of heel 
1 
CCI 2 PWL to radiant heat 2 Left sciatic nerve 2 
SNL 1 Mechanical withdraw threshold to 
von Frey filaments 
1 L5-L6 1 Neuropathi
c 
ICTR  1 Mechanical allodynia to von Frey filaments 
1 Between S3 and S4 of right 
superior caudal trunk 
1 
AWR to CRD 2 
EMG to CRD 1 
PTP to CRD 1 
Visceral 
Hyperalges
ia 
IBS 2 
Fecal pellet output to WAS 1 
Colorectal 2 
Cancer 
pain 
Cutaneous 
cancer pain 1 
Response latency to hot plate test 1 Plantar region of the unilateral 
hind paw 
1 
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2.2.4.1 Inflammation models 
Three different chemicals have been used to produce the inflammation model. These 
include CFA, carrageenan and formalin models. All three are used to model human arthritis 
in studies to evaluate efficacy of various anti-inflammation medications. 
 
Unlike an acute pain model, which uses heat or electrical stimulation to create transient 
noxious stimuli in normal animals, these inflammation models utilise chemical agents to 
produce a persistent, local inflammation state, lasting for days to weeks, thus mimicking 
sub-acute and chronic pain conditions. These models not only produce local tissue 
inflammation but also central sensitisation, which is an important feature of chronic pain. 
 
2.2.4.1.1 CFA 
CFA model is the most frequently used model in acupuncture studies and appeared in 16 
out of 32 included papers. The Complete Freund’s adjuvant (CFA), which is named after an 
American immunologist, Jules T. Freund (1890-1960), was originally used as 
immunopotentiator for boosting immune system. It is made by emulsifying an inactivated 
pathogenic agent of tuberculosis (mycobacterium tuberculosis) in mineral oil. 
 
When injected subcutaneously or intraperitoneally, CFA induces painful reactions in 
animals (Zhang, R. Lao et al. 2002) (Zhang, Ji et al. 2002; Zhang, Lao et al. 2004). 
However, due to its severe toxicity, it is forbidden to be used in human subjects. To produce 
the hyperalgesia state in a rat, a small amounts of CFA solution (0.05 or 0.08ml, suspended 
in 1:1 oil/saline emulsion, containing 40 or 50 µg Mycobacterium tuberculosis) is 
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subcutaneously injected into the plantar surface of one hind paw, or injected into the joint 
cavity (Sun, Chen et al. 2006), using a 25-gauge hypodermal needle. In some studies, before 
the injection, the animals were briefly anesthetised with chlorohydrate (Huang, Hu et al. 
2004) or isoflurane (Fu, Wang et al. 2006; Sun, Chen et al. 2006). 
 
Inflammation induced by the local injection of CFA manifests as redness, edema and 
hyperalgesia of the local tissue. These conditions become evident within 2 hours after the 
injection and maximize during 6 to 24 hours. Manifestations then generally disappear after 
2 weeks. 
 
Outcome measures of the CFA model are the Paw Withdrawal Latency (PWL), Response 
Latency (hot plate test) and mechanical withdrawal threshold using von Frey filaments and 
Foot-bend score. 
 
2.2.4.1.2 Carrageenan 
Another commonly used inflammation model is carrageenan model. Carrageenan, a 
polysaccharide extracted from seaweed, has been used as food additive for centuries. When 
injected subcutaneously, it can cause local swelling and pain, thus being used to produce 
animal models of inflammation. 
 
Carrageenan-produced hyperalgesia is of a similar magnitude to CFA. However, its 
duration is much shorter. The inflammatory hyperalgesia appears within 1 hour and lasts for 
about 24 hours (Ren and Dubner 1999). 
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The carrageenan model is produced by subcutaneously injecting 0.1 ml of carrageenan 
solution into the plantar surface of the hind paw, using a 26-gauge needle. In some studies, 
rats are anaesthetised during administration of the injection (Sekido, Ishimaru et al. 2003; 
Sekido, Ishimaru et al. 2004; Taguchi and Taguchi 2007). Measurements used in this 
include PWL, mechanical withdrawal threshold using Analgesy-meter and Response 
Latency to hot plate tests. 
 
2.2.4.1.3 Formalin 
The formalin model was firstly used in cats by Frankstein and later modified by O’Keefe 
(Dubuisson and Dennis 1977). This model is produced by intraplantar injection of 50 µl 
diluted formalin (5%) via a 26-gauge needle. The injection produces a distinct biphasic 
behavioural changes and heightened activity of dorsal horn nociceptive neurons (Hogan 
2002). 
 
Compared with CFA and carrageenan models, formalin model is short lived for one hour 
only.  However, it has two distinct behavior phases with different underlying neurological 
mechanisms. The first phase is observed during the initial 5 minutes after injection whereby, 
the rats lift their injected paw to prevent it from touching the surface of the cage. During the 
following phase, which last for about 40 minutes, rats began to use the paw to bear weight, 
however constantly shaking and licking. Only behavioral hyperalgesia is feasible to be 
measured in this model using weighted pain score. Mechanical/heat hyperalgesia or 
allodynia are not usually tested. 
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2.2.4.2 Neuropathic pain model 
There are three types of neuropathic pain models used in the selected studies: Chronic 
Constrictive Injury (CCI) model, Spinal Nerve Ligation (SNL) model and Inferior Caudal 
Trunk Resection (ICTR) model. 
 
2.2.4.2.1 Chronic Constrictive Injury (CCI) model 
Two studies used the model of Chronic Constrictive Injury (CCI) to evaluate the effect of 
EA.   This method is described by Bernett and Xie (Bennett and Xie 1988). Essentially, the 
sciatic nerve is exposed at the level of middle of the thigh via blunt dissection through 
biceps femoris. The sciatic nerve is loosely tied with four 4-0 chromic gut sutures. 
Hyperalgesia to noxious radiant heat stimulation on the injured limb appears on the second 
day after the operation and last for approximately two months. Allodynia, and possibly, 
spontaneous pain also present.  However, due to the limitation of this model it is difficult to 
properly measure the spontaneous pain based on the behavioral observation (Bennett and 
Xie 1988). It is understood that hyperalgesia and allodynia peak around 10 to 14 days after 
operation (Hogan 2002). However, the tightness of the ligature, the operator factor and the 
degree of the injury of the fascicles in the same nerve are the major variants influencing the 
consistency of this model (Hogan 2002). Measurement used on this model includes PWL. 
 
2.2.4.2.2 Spinal Nerve Ligation (SNL) model 
One study used this model following the procedure described by Kim and Chung (Kim and 
Chung 1992). Rats are anesthetised with 10% chlorohydrate and the dorsal vertebral 
columns of Lumbar 5 (L5) to L6 spinal nerves are exposed. Tight ligation of these nerves is 
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made distally to the dorsal root ganglion with 4-0 silk sutures. Animals are then allowed to 
recover for 5 days. Hyperalgesia and allodynia develop in the affected hind foot shortly 
after the ligation and last for about 4 months. Behavioral signs of spontaneous pain are also 
present (Wang and Wang 2003). 
 
Compared to the CCI model, this model achieves better consistency by choosing a relatively 
fixed location and applying complete ligation. However, the model does require more 
extensive surgical procedures (Wang and Wang 2003). The measurement used includes 
mechanical withdrawal threshold. 
 
2.2.4.2.3 ICTR (inferior caudal trunk resection) model 
This model is described by Na and colleagues et al (Na, Han et al. 1994). Under sodium 
pentobarbital anaesthesia, the right superior caudal trunk is transected between the Sacrum 
3 (S3) and S4 spinal nerves, which innervate the tail. This model produces cold or thermal 
hyperalgesia and mechanical allodynia in the tail within a day after operation. These 
changes can last for several weeks. 
 
In this model, thermal and mechanical stimulation can be easily applied to the tail, and blind 
behaviour assessment is possible due to a lack of deformity of the tail by the surgery. 
Measurement used in this model includes tail response frequency. 
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2.2.4.3 Other models 
2.2.4.3.1 Irritable Bowel Syndrome (IBS) model 
The Irritable Bowel Syndrome (IBS) model was first developed by Al-chaer et al. in 2000 
(Al-Chaer, Kawasaki et al. 2000).  This model mimics IBS symptoms in humans by 
applying repetitive colorectal distention (CRD) in male neonatal Sprague-Dawley rats. 
When these rats become adults, they develop chronic visceral hypersensitivity, which is 
characterised by hyperalgesia and allodynia to CRD in abdominal and colorectal areas.  
 
In this model (Cui, Li et al. 2005; Tian, Bian et al. 2006), neonatal rats (8 days old) receive 
mechanical colon distention on a daily basis until they are 21 days old. An inflatable silica 
balloon (length 20.0 mm; diameter 3.0/2.0 mm) is inserted into the descending colon via the 
rectum. The balloon is distended with 2 ml air, exerting 60 mm Hg pressure on the colon, as 
measured by a sphygmomanometer. After one minute duration, the balloon is deflated and 
withdrawn from the colon. The stimulation is repeated twice, at 30 minutes intervals within 
one hour. After the colon distention treatment, the rat is fed until adulthood, which is 
generally six weeks old. 
 
Measurements used to test this model include an Abdominal Withdrawal Reflex (AWR) 
score, Pain Threshold Pressure (PTP), Electromyogram (EMG) and Water Avoidance Stress 
(WAS) test. 
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2.2.4.3.2 Incision model  
Brennan et al. (1996), developed the paw incision model in 1996 (Brennan, Vandermeulen 
et al. 1996) In this model, under halothane anaesthesia, a 1-cm cut is made through the skin 
and fascia of the plantar region using a surgical blade. The incision starts 0.5 cm from the 
proximal edge of the heel. The plantaris is elevated with its origin and insertion left intact. 
The skin is stitched with two 5-0 nylon sutures after hemostasis. The animal is then placed 
in the cage for recovery. 
 
This model produces reliable and quantifiable mechanical hyperalgesia around the wound 
for several days. The measurement used is mechanical withdrawal threshold to von Frey 
filaments. 
 
2.2.4.3.3 Cancer pain model 
This model is recently developed by Sasamura et al. (Sasamura, Nakamura et al. 2002). The 
B16-BL6 melanoma cells are inoculated into plantar surface of the hind paw, and moderate 
hyperalgesia appears on day 7 to 10 and becomes marked at day 14 after inoculation. 
Measurements used include PWL and hot plate test. 
 
2.2.5 Measurements  
2.2.5.1 Measurement of spontaneous pain 
Spontaneous pain is one of the cardinal features of chronic pain, and is likely to be present 
in some pain models such as CCI model (Bennett and Xie 1988). For example, in the CCI 
model, researchers assumed the behavior of sudden lifting the affected hind paw and 
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protecting it can be a sign of spontaneous pain. However, it can also be a result from some 
undetected simulation like a slight shift of weight (Bennett and Xie 1988). In principle, 
researchers have to rely on indirect observation of the animal behaviors such as autotomy 
(gnaw claw tips) and sudden lifting and holding the injured hind paw in guarding position, 
to infer the existence of spontaneous pain, which can be imprecise and sometimes 
inappropriate. Therefore, the reliability of current measurements of spontaneous pain, which 
heavily rely on observation of the animal behavior, is limited.  
 
It is interesting to note that none of the selected acupuncture studies in this review reported 
or measured spontaneous pain. 
 
2.2.5.2 Measurements of hyperalgesia 
Table 2.6 summarises the measurements used in different animal models and their 
equivalence in human.  
 
In human studies, hyperalgesia is always classified as primary hyperalgesia (occurring at 
the site of injury and characterised by hyperalgesia by both thermal and mechanical stimuli) 
and secondary hyperalgesia (around the injury site, characterised by hyperalgesia to 
mechanical stimuli). While in animal studies, hyperalgesia state is usually defined 
according to the behavioral response to different types of stimuli (thermal or mechanical). 
Researchers use PWL as the test for thermal hyperalgesia, and algesiometry as the test for 
mechanical hyperalgesia. Therefore, the thermal hyperalgesia in inflammation animal 
model is possibly equivalent to primary hyperalgesia in human model, and mechanical 
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hyperalgesia is equivalent to secondary hyperalgesia. For the neuropathic model, the test 
site is remote from the injury site, thus both thermal and mechanical hyperalgesia can be 
understood as being equivalent to secondary hyperalgesia in human. 
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Table 2. 6 Tests used in different animal model 
 
Test Types of 
measurements 
Human equivalence Model  Model site Test site 
Paw withdrawal latency Thermal hyperalgesia Primary hyperalgesia  CFA Plantar surface of hind paw Plantar surface of hind 
paw 
 Thermal hyperalgesia  Primary hyperalgesia  Articular cavity between the 
tibiofibular and tarsus bone 
Plantar surface of hind 
paw 
 Thermal hyperalgesia Primary hyperalgesia  Left tibio-tarsal joint Plantar surface of hind 
paw 
 Thermal hyperalgesia  Primary hyperalgesia CAR Plantar surface of hind paw Plantar surface of hind 
paw 
 Thermal hyperalgesia Secondary hyperalgesia  CCI Left sciatic nerve Plantar surface of hind 
paw 
 Thermal hyperalgesia  Primary hyperalgesia Cancer Plantar region of the unilateral hind 
paw 
Plantar surface of hind 
paw 
Hot plate test  
(Response Latency) 
Thermal hyperalgesia  Primary hyperalgesia CFA Plantar surface of hind paw Plantar surface of hind 
paw 
 Thermal hyperalgesia Primary hyperalgesia CAR Plantar surface of hind paw Plantar surface of hind 
paw 
Mechanical withdraw 
threshold 
Mechanical 
hyperalgesia  
Primary and secondary 
hyperalgesia 
CFA Plantar surface of hind paw Plantar surface of hind 
paw 
 Mechanical 
hyperalgesia  
Secondary hyperalgesia SNL L5-L6 Plantar surface of hind 
paw 
 Mechanical 
hyperalgesia  
Secondary hyperalgesia Incision 1cm longitudinal, through skin and 
fascia of the plantar region of heel 
Mid-plantar right hind 
paw 
Foot-bend score Behavior 
hyperalgesia 
Primary hyperalgesia CFA Left malleolus’ articular cavity Ankle joint 
Analgesy-meter Mechanical 
hyperalgesia 
Secondary hyperalgesia CAR Plantar surface of hind paw Dorsal surface of the 
hind paw 
Weighted pain score Mechanical 
hyperalgesia 
Primary and secondary 
hyperalgesia 
Formali
n 
Plantar surface of hind paw N/A 
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Tail response frequency Mechanical allodynia Secondary hyperalgesia ICTR Between S3 and S4 of right superior 
caudal trunk 
The sensitive spot on the 
tail 
AWR test Visceral hyperalgesia N/A IBS Colorectal area Colorectal area 
EMG test Visceral hyperalgesia N/A IBS Colorectal area Colorectal area 
Water-avoidance stress Visceral hyperalgesia N/A IBS Colorectal area N/A 
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2.2.5.2.1 Paw withdrawal latency (PWL) 
 
This test is first described by Hargreaves et al. (Hargreaves, Dubner et al. 1988). It determines 
the hyperalgesia state of the affected paw to noxious thermal stimulus. The Paw Thermal 
Stimulator System (UCSD, San Diego) (Lao, Zhang et al. 2004; Zhang, Lao et al. 2004; Li, 
Zhang et al. 2007) or equivalent (Fu, Wang et al. 2006) is used. Rats are placed on a glass 
surface enclosed in a plastic chamber and are allow acclimatise for 30 minutes before the test. 
To deliver the thermal stimulation, a projector lamp bulb (50w) controlled by a timer is 
focused on the plantar surface of each hind paw underneath the glass surface. The latency is 
automatically determined by the timer to the nearest 0.1 s when the paw is withdrawn. The 
intensity of the lamp is adjusted to derive a baseline of 10 s (Lao, Zhang et al. 2004; Li, 
Zhang et al. 2007) or 20 s (Wang, Zhang et al. 2006) in naive animal. To prevent tissue 
damage, a 20 s cut-off is used. 
 
Mean latency is achieved by averaging results from four tests with 5-minutes intervals (Zhang, 
Liu et al. 2005). 
 
2.2.5.2.2 Response Latency 
 
The hot plate test is used to determine the thermal hyperalgesia. Rats are placed on a hot plate 
of 52℃, the latency time is recorded when the rats lift its paws or jump. A 60-s cut-off is used 
to prevent tissue damage. The thermal hyperalgesia latency is determined by averaging results 
from three tests (Huang, Hu et al. 2004). 
 
2.2.5.2.3 Mechanical withdrawal threshold to von Frey filaments 
 
This test uses a serial of von Frey filaments ranging from 1 to 26 g to determine the paw 
withdrawal threshold. The individual rat is placed onto a wire mesh floor enclosed in a 
Plexiglas chamber, which enables the researchers to apply the von Frey filaments to the 
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plantar surface of one paw through the hole of the wire floor. After a period of acclimatisation, 
the von Frey filaments are applied in ascending order. If the stimulation of a filament does not 
elicit a valid response by completely lifting the stimulated paw from the floor within five 
repeated stimulations, the next filament with a higher bending force is applied. The bending 
force of the filament that elicits the lifting response is recorded as the withdrawal force. The 
paw withdrawal threshold is either defined as the average results of three measurements 
(Huang, Hu et al. 2004), or as the force of a particular filament that produce valid response 
more than twice out of five applications (Sun, Chen et al. 2006; Shan, Qi-Liang et al. 2007). 
 
2.2.5.2.4 Foot-bend score 
 
This measure is used in the model when CFA is injected into the tibio-tarsal joint (Wang, 
Zhang et al. 2006) or malleolus joint (Liu, Li et al. 2006=). The hyperalgesia is defined as the 
score obtained in flexion test or extension test with 15 minutes interval between them. The 
flexion or extension score (1 or 0) is given according to the response, such as squeaking or 
withdrawing leg, of the animals to flexion or extension manipulation of the hind paw. Each 
manipulation is applied 5 times at 5-s interval (Wang, Zhang et al. 2006). 
 
2.2.5.2.5 Analgesy-meter 
 
Analgesy-meter (Ugo Basile) is used to evaluate the nociceptive threshold. Rats are restrained 
in a jacket whilst pressure is incrementally applied to the dorsal surface of the hind paw. Paw 
Pressure Threshold (PPT) is defined as the pressure that elicits paw withdrawal response. The 
mean PPT is the average of the result of two consecutive measurements with a 2-minutes 
interval. A cut-off of 250g is used to prevent tissue damage. 
 
2.2.5.2.6 Weighted pain score 
 
This assessment is used in the formalin test to evaluate pain based on the behavioral response. 
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Three prominent pain-induced behaviors that include favouring, elevation and licking or 
biting of the paw, are given weights of 1, 2 and 3, respectively, for a period of one hour 
(weighted every 5 minutes, 12 times). The pain score is calculated by multiplying these 
weights with the number of each behaviors presented (Abbott, Franklin et al. 1995). 
 
2.2.5.2.7 Tail response frequency (Mechanical allodynia) 
 
The Tail response frequency is evaluated using a von Frey filament with the bending force of 
2.0g. During the test, the rat is restrained in a plastic holder with its’ tail laid on a plate.  The 
area of allodynia is determined by stroking different areas on the tail with the von Frey 
filament. Once the sensitive area is spotted, the von Frey filament is applied to the most 
sensitive spot for ten times at 10-20s intervals. A valid response is defined as an abrupt tail 
movement of more than 0.5 cm to the gentle poking of the filament. The degree of response, 
which attribute to the mechanical allodynia, is expressed as the percentage of valid response 
out of ten stimulations (Hwang, Min et al. 2002). 
 
2.2.5.2.8 Abdominal withdrawal reflex (AWR) score 
 
After light anaesthesia with halothane, a deflated balloon is inserted into the descending colon. 
The rat is then placed into a clear plastic chamber (20×8×8cm) on a platform, and allowed to 
wake up and adapted for 20-30 minutes. Colorectal Distention (CRD) is achieved by inflating 
the balloon to a designated pressure (20, 40, 60, 80 mmHg) for 10s.  The pressure is applied 
in an ascending order at 4-minutes intervals.  Abdominal Withdrawal Reflex (AWR) is 
evaluated based on the observation of the response to a certain grade. The score is assigned 
according to the scale described by Al-Chaer et al. 
 
2.2.5.2.9 EMG 
 
Under pentobarbital anaesthesia (40/mg/kg, intraperitoneal), EMG of rectus abdominis is 
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recorded by electrodes placed on them bilaterally. The signal is amplified and fed into 
computer for analyse. The CRD is applied in the same manner as the AWR test. During the 
complete test, the body temperature is kept at approximtely 37℃ by a servo-controlled heat 
blanket. 
 
2.2.5.2.10 Pain threshold pressure (PTP) 
 
To determine the pain threshold pressure (PTP), pressure is increased by 5 mmHg for 
duration of 30s. The pressure that elicits pain behavior, such as obvious contraction of 
abdominal wall, is defined as PTP. The maximum pressure of 80 mmHg is applied to avoid 
tissue damage. 
 
2.2.5.2.11 Water-avoidance stress (WAS) 
 
This test is used in the IBS model. In this test, rat is placed on a platform (8×6×6cm) fixed in 
the middle of a water tank. The tank is filled with water 7cm deep and within 1 cm on top of 
the platform. The rat stays on the block for 1 hour between 10:00AM and 13:00PM. The fecal 
pellet output is countered every 15 minutes for 1 hour. 
 
2.2.6 Mechanism of animal models 
 
2.2.6.1 Inflammation models 
 
2.2.6.1.1 CFA model 
 
Systemic application of CFA leads to inflammation of multiple joints eyes, nose, ears and 
penis.  It also causes lymph node enlargement and liver dysfunction. These changes are 
thought to be T-cell mediated delayed-type hypersensitivity reactions (Pearson and Wood 
1959).  
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Injected locally, CFA leads to local inflammation and produces an algogenic substance, such 
as prostaglandins, bradykinin and substance P. These chemicals sensitise the peripheral 
sensory fibers, causing spontaneous Aδ and C-fiber activity and an increased responsiveness 
of ipsilateral nociceptive lamina I projection neurons (Stein, Millan et al. 1988). 
 
2.2.6.1.2 Carrageenan model 
 
Local injection of carrageenan causes inflammation and edema. Evidence suggests that 
carrageenan injection alters the C-fiber responsiveness to thermal as well as mechanical 
stimuli (Handwerker, Anton et al. 1987).  Furthermore, the recording from the nociceptive 
neurons in the ventrobasal thalamus, following carrageenan injection, showed decrease in the 
thermal threshold of these neurons and increased responsiveness to thermal stimulation 
(Benoist, Kayser et al. 1984). 
 
2.2.6.1.3 Formalin model 
 
The two-phase pain-induced behaviors seen in a formalin model have different neurological 
mechanism underlying each phase. The first phase, which lasts for approximately 5 minutes, 
results from direct activation of primary afferent fibers of both low-threshold 
mechanoreceptive and nociceptive at the injection site. The secondary phase, which lasts for 
about 40 minutes, is more complex and less understood. It is generally accepted that this 
phase attributes to the increased activity in the spinal dorsal horn neurons, being initiated by 
the peripheral afferent input during the first phase (Ren and Dubner 1999; Hogan 2002). 
 
2.2.6.2 Neuropathic pain model 
 
Neuropathic pain models such as CCI, SNL and ICTR model share similar neurological 
mechanisms. 
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Injury to the peripheral nerve system causes functional changes in the somatosensory neurons 
in both peripheral and central nervous system (Porreca, Ossipov et al. 2002; Bennett 2005). 
Neuropathic pain involves two pathological changes in the nervous system: spontaneous 
discharge in nociceptors evoked by nerve injury; and central sensitisation initiated and 
maintained by ongoing discharge from C nociceptors (Bennett 2005).  
 
Several mechanisms were discovered to explain the ongoing discharge in nociceptors and 
low-threshold mechanoreceptors. Firstly, several afferent axons begin to discharge 
spontaneously and ectopically. This is understood to be caused by oscillations in the neurons 
membrane potential (Devor and Seltzer 1999). Secondly, intact afferent neurons traveling in a 
nerve (C fibers) adjacent to the degenerating nerve, discharges spontaneously which may be 
due to the peripheral input that maintain central sensitisation (Bennett 2005). Thirdly, 
sensitised nociceptors may produce ongoing discharge however, no tangible evidence 
supports this hypothesis (Cline, Ochoa et al. 1989; Bennett 2005). Forthly, tumor necrosis 
factor-α (TNF-α) may also contribute to the ongoing ectopic discharge, as anti-TNF-α 
neutralising antibodies can reduce neuropathic pain in CCI and PSL models and exposing 
nerve fiber to TNF-α can elicit neuropathic pain (Sorkin and Doom 2000; Sommer, 
Lindenlaub et al. 2001). 
 
Central nervous system also plays an important role in the neuropathic pain. It is now clear 
that central sensitisation is triggered by the release of glutamate from the C fiber terminals 
that acts on glutaminergic synapses of the NMDA type (Bennett 2005). Another important 
change in the spinal dorsal horn is disinhibition, which inhibits neurons that exert negative 
feedback control over the message sent to the brain. Evidence showed anatomical changes in 
this negative feedback system that are significantly decreased in the CCI model (Sugimoto, 
Bennett et al. 1990). Later, studies have been found to suggest that GABAergic inhibition is 
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substantially decreased in the models of neuropathic pain (Moore, Kohno et al. 2002). 
 
2.2.6.3 Other models 
 
2.2.6.3.1 Incision model 
 
In the incision model, mechanical hyperalgesia develops after the operation. The initiative 
afferent input of mechanical hyperalgesia from the incision area (plantar region starting 0.5 
cm from the proximal edge of the heel) is transmitted by both sural and tibial nerves. 
Resection of the tibial nerve blocks the mechanical withdrawal response in the medial 
proximal side of the rat foot, while the resection of both sural and tibeal nerves blocked the 
mechanical withdrawal response in the lateral proximal side of the rat foot (Brennan, 
Vandermeulen et al. 1996).  
 
In this model, probing the incision site and a site about 10 mm distal to the incision site one 
can detect decreased withdrawal thresholds, suggesting that mechanical hyperalgesia presents 
in the wounded and surrounding uninjured areas. Hyperalgesia, at the intact area around the 
incision, is considered as secondary hyperalgesia  (Brennan, Vandermeulen et al. 1996). 
 
2.2.6.3.2 IBS 
 
The nociceptive neural circuits undertake significant development in the neonatal stage, thus 
become very susceptible to plasticity. Noxious stimulation in this stage produces permanent 
alteration in afferent pathways (Al-Chaer, Kawasaki et al. 2000). The IBS model is a result of 
the neonatal colon irritation which causes permanent plasticity change in the central nervous 
system in the adult. On the contrary, if colon irritation is applied in adults, it does not produce 
the permanent state of central sensitisation (Cui, Li et al. 2005).  
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2.2.7 The effect of EA on hyperalgesia in different animal model 
 
All the included studies used electro-acupuncture as intervention. No manual acupuncture was 
used. This could be due to the reason that electro-acupuncture delivers consistent stimulation 
with accurate intensity and frequency.  
 
2.2.7.1 Immediate effect of EA 
 
2.2.7.1.1 Single application of EA 
 
Compared with sham or no treatment, single EA treatment significantly reduced both 
mechanical (PPT, MWT) and thermal (PWL, hot plate test) hyperalgesia in inflammatory, 
neuropathic, IBS and cancer models.  
 
For the single application, the most commonly used models are CFA and carrageenan models.  
Both high (100 Hz) and low (2 Hz) frequencies were used. Only distal acupoints (away from 
the injection site, in the same limb) were used, and stimulation was given bilaterally, 
ipsilaterally or contralaterally. Commencing time for EA treatment varied from minutes to 
days, and EA showed its effect usually within one hour and the effect lasted up to 20 hours. 
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Table 2. 7 A summary of the immediate effect of single EA application in different studies 
No
. 
Model Frequen
cy 
Curren
t 
Pulse Duratio
n 
Acupoint  Time 
point 
(EA ) 
Tests Effect time 
9 Formali
n 
4 Hz, 
10/20 v,  
 0.5 ms 
square 
pulse 
30 min ST36, 
5mm 
below 
ST36, 
contralater
al to 
formalin(l
eft) 
end 10 
min 
before 
formalin 
Weigh
ted 
pain 
score 
Both 10, 
20V: 20-60 
min (second 
phase) 
,compared 
with no 
treatment 
2 Car A DS of 60 
and 2 Hz 
1-2-3 
mA  
10min 
each 
n/a 30 min ST36, 
UB60,  
Contralate
ral 
3h post 
carrageena
n 
PWL 10, 20, 30 
min after 
EA begin, 
10 min after 
EA end, 
compared 
with NS 
control 
12 Car 3 Hz 
 
1-2-3 
mA for 
20 min 
each 
0.1ms 60 min  ST36, 
5mm from 
ST 36, 
ipsilateral 
3h after 
carrageena
n  
PPT At least 20 h 
after EA 
end, 
compared to 
no treatment 
13 Car 3 Hz 
 
1-2-3 
mA for 
20 min 
each 
0.1ms 60 min  ST36, 
5mm from 
ST 36, 
ipsilateral 
3h after 
carrageena
n  
PPT At least 20 h 
after EA 
end, 
compared 
with non 
treatment  
21 Car 2, 15, 120 
Hz 
1-2-3 
mA 10 
min for 
each 
 
 30 min ST36, 
SP6, 
bilateral 
immediate 
after 
injection 
Hot 
plate 
test 
At least 30 
min to 120 
min after 
EA end, 
compared 
with no 
treatment 
27 Car A DS 60 
and 2 Hz,  
1-2-3 
mA 10 
min each 
 30 min ST36, 
UB60, 
contralater
al 
3h post 
carrageena
n injection 
PWL 10, 20, 30, 
40 min after 
EA start, 
compared 
with sham 
31 Car 2 Hz,  0.5, 1 or 
3 mA 
 30 min  ST36, 
SP6, 
bilateral 
immediate
ly after 
carrageena
n injection 
Hot 
plate 
test 
At least 0 
min to 3h 
after EA 
end, 
compared 
with non 
treatment 
35 Car 3, 15 or 100 
Hz,  
1-2-3 
mA for 3 
biphasic 
square, 
for 1, 15 ST36, 3h after PPT 1min EA: 
  
72 
Hz, 0.5-
1-1.5 
mA for 
15, 100 
Hz 
0.1 ms  or 60 
min 
5mm from 
ST36, 
ipsilateral   
carrageena
n 
no effect for 
all FQ, 
compared 
with  no 
treatment 
  
   
    15min EA: 
only 
3Hz :45min, 
105min 
after EA 
end, 
compared 
with  no 
treatment 
  
   
    60min EA: 
only 3Hz: at 
least 20 h 
after EA 
end,  
compared 
with  no 
treatment 
MWT 15 min after 
EA start,  
compared 
with  no 
treatment 
8 CFA 100 Hz 0.5-1-
1.5 mA  
for 10 
min 
each 
0.2 ms 30 min ST36, 
SP6, 
bilateral 
48 h after 
CFA 
Hot 
plate 
test 
No effect,  
compared 
with  no 
treatment 
14 CFA A 100 
and 2 Hz 
 0.2 ms 30 min GB30, 
GB34, 
ipsilateral 
48h after 
CFA 
injection 
PWL 45 min after 
EA end, 
compared 
with sham 
        MWT 45 min after 
EA end, 
compared 
with sham 
25 CFA A DS 60 
and 2 Hz, 
0.6 ms 
pulse width 
less than 
1 mA 
bidirecti
onal 
asymme
tric 
pulse 
30 min GB30, 
GB34, 
unilateral 
72 h after 
CFA 
PWL 10, 20, 40, 
60 min after 
EA start, 
compared 
with sham 
30 CFA 30 Hz, 2 mA, 0.1 ms 
pulse 
width 
30 min  GB30, 10 
mm below 
GB30, 
ipsilateral 
5 day after 
CFA 
injection 
PWL 30 min to 3h 
after EA 
end, 
compared 
with non 
treatment 
and vehicle 
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10 Incision 4 Hz,  to 
derive 
muscle 
contrac
tion 
n/a 15 min ST36, 
SP6, 
ipsilateral 
2h after 
incision 
MWT At least 0-
30 min after 
EA end, 
compared 
with no 
treatment 
16 ICTR 2 Hz 0.07 0.3 30 min  S13, 3 
mm off 
S13, 
unilateral 
21 day 
after 
operation. 
MWT 
(tail) 
15 to 45 min 
after EA 
start, 
compared 
with before 
EA 
19 IBS 2 Hz,  0.3 mA contin
uous 
wave 
30 min  ST36, 
SP6, 
bilateral 
after IBS AWR 
score, 
PTP 
Effective, 
compared 
with non 
treatment,  
time point 
not given 
29 Cutaneo
us 
cancer 
pain 
A DS 100 
and 4 Hz 
1 mA, 0.6 ms 
pulse 
width, 
bidirecti
onal 
asymme
tric 
pulse 
30 min ST36, 
BL60, 
unilateral 
Day 8 and 
20 after 
inoculatio
n 
Hot 
plate 
test 
Day 8: 0, 
15, 30 min 
after EA 
end, no 
effect on 50 
min after 
EA end 
Day 20: no 
effect, 
compared 
with sham 
and vehicle 
 
 
 
2.2.7.1.2 Carrageenan 
 
In this model, EA was applied immediately after the injection or three hours post injection.  
EA reduced both mechanical and thermal hyperalgesia and produced a lasting effect. For 
example, a single treatment of acupuncture applied immediately after carrageenan injection 
produced a lasting alleviation of the latency in the hot plate test for 30 minutes to 3 hours after 
the cessation of EA treatment (Lee, Choi et al. 2005; Lee, Jang et al. 2006). A 60-minute EA 
intervention (3 hours after carrageenan injection) at 3 Hz significantly increased the PPT for 
at least 20 hours. However, EA at 5 or 15Hz did not produce any significant effect. Thirty 
minutes EA intervention of alternating frequency of 2 to 60 Hz significantly increased PWL 
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at 10, 20 and 30 minutes during the treatment and 10 minutes post treatment (Zhang, Ji et al. 
2002; Sekido, Ishimaru et al. 2003; Zhang, Ji et al. 2003; Sekido, Ishimaru et al. 2004; 
Taguchi and Taguchi 2007). 
 
2.2.7.1.3 CFA 
 
In the CFA model, EA was usually applied at 2 to 5 days post injection. EA with different 
parameters produce different effects at the same time point after injection of CFA. For 
example, at 48 hours post CFA, EA with alternating frequency of 2 and100 Hz at GB30 and 
GB 34 elevates mechanical hyperalgesia (MWT) 45 minutes after the end of treatment, while 
EA of 100 Hz at ST36 and SP6 elevates MWT at only 15 minutes during the treatment 
(Sasamura, Nakamura et al. 2002; Huang, Hu et al. 2004; Sun, Chen et al. 2006). This 
suggests that the anti-hyperalgesia effect of EA is parameter dependent.  
 
Interestingly, in an additional study, EA successfully increases MWT (mechanical 
hyperalgesia) but fails to elevate the PWL (thermal hyperalgesia) by single or repetitive 
treatment (Huang, Hu et al. 2004). However, this result contradicts with other completed 
studies. 
 
In conclusion, EA applied 3 days and 5 days after CFA injection produces significant 
alleviation of PWL for 30 minutes and 3 hours respectively (Zhang, Yu et al. 2005; Fu, Wang 
et al. 2006) 
 
2.2.7.1.4 Incision 
 
In this model, 15 minutes EA treatment increases MWT for at least 30 minutes after the 
cessation of the treatment (Oliveira and Prado 2000). 
 
2.2.7.1.5 Formalin 
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One study used this model reported thirty minutes of EA application that finished 10 minutes 
before the formalin injection significantly reduced the formalin-induced hyperalgesia 
(weighted pain score) during the first 60 minutes. It is notable that EA at 20V produce similar 
effect as morphine (2 mg/kg, given 40 minutes before formalin injection) (Wen, Yeh et al. 
2007). 
 
2.2.7.1.6 ICTR model (inferior caudal trunk resection) 
 
EA applied 21 hours after the operation increases the MWT in the rat tail at 15 minutes during 
the treatment and 15 minutes post treatment. This effect was similar to the effect of morphine 
(1.5 mg/kg). Furthermore, there was no synergetic effect of EA combined with morphine was 
observed in this study (Hwang, Min et al. 2002). 
 
2.2.7.1.7 IBS and Cancer 
 
Single EA treatment alleviates hyperalgesia in both models including IBS and Cancer, 
however, EA shows little effect when applied in the late stage of the cutaneous cancer model.  
 
2.2.7.1.8 Two sessions of EA 
 
In order to achieve maximum effect, EA was given twice, once immediately after the CFA 
injection and the other 2 hours after the injection. Several studies utilise this procedure. 
According to different parameters, EA significantly increases thermal hyperalgesia (PWL) at 
10 minutes to several days after the treatment (Lao, Zhang et al. 2004; Zhang, Lao et al. 2004). 
Table 2.8 summarises the immediate effect of two sessions of EA application in different 
studies. 
 
Table 2. 8 Effect of two sessions of EA treatments 
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No. Model Frequency Current Pulse Duration Acupoint  Time 
point 
Tests Effect 
time 
point 
1 CFA 10 or 100 
Hz 
3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL 10 or 
100Hz: 
10 min 
after EA 
end (2.5h 
post-
CFA), 
compared 
with 
vehicle 
and sham 
3 CFA 10 Hz 3v 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 10 
min and 
120 h 
after EA 
end (2.5h 
post-
CFA), 
compared 
with 
sham 
4 CFA 10 or 100 
Hz 
3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 10 
min after 
EA end 
(2.5h 
post-
CFA), 
compared 
with 
sham 
7 CFA 2Hz 2 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
  10Hz 1 mA 2 ms 20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5 
and 5 h 
post 
CFA, 
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compared 
with 
sham 
   1 mA 1 ms 20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   1 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   2 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h 
post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h, 
1d, 5d, 
7d post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
10 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   3 mA 0.1 
ms 
30 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
  50Hz 1 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
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   2 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h 
post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h 
post 
CFA, 
compared 
with 
sham 
  100Hz 1 mA 2 ms 20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h 
post 
CFA, 
compared 
with 
sham 
   1 mA 1 ms 20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   1 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   2 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h 
post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5h, 
5h, 1 d 
post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
10 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 5h, 
1d, 5d 
post 
CFA, 
compared 
with 
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sham 
   3 mA 0.1 
ms 
30 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
  10Hz 3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 2.5 
and 24 h 
120h, 
168h post 
CFA, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
TE5, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
   3 mA 0.1 
ms 
20 min 
twice 
Opposite 
aspect of 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL No effect 
at any 
time 
point, 
compared 
with 
sham 
11 CFA 10 Hz 3 mA 0.1 
ms 
20 min 
twice 
GB30, 
Huantiao, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 10 
min after 
EA end 
(2.5h 
post-
CFA) , 
compared 
with 
sham 
17 CFA 10 Hz 3 mA 0.1 
ms 
20 min 
twice 
GB30, 
bilaterally 
immediate 
after and 
2h after 
injection 
PWL At 10 
min after 
EA end 
(2.5h 
post-
CFA) , 
compared 
with 
sham and 
no 
treatment 
20 CFA 10 or 100 3 mA 0.1 20 min GB30, immediate PWL At 10 
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Hz ms twice bilateral after and 
2h after 
injection 
min after 
EA end 
(2.5h 
post-
CFA) , 
compared 
with 
sham 
23 CFA 10 Hz 3 mA 0.1 ms  20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 10 
min after 
EA end 
(2.5h 
post-
CFA) , 
compared 
with 
sham 
28 CFA 10 Hz 3 mA, 0.1 ms  20 min 
twice 
GB30, 
bilateral 
immediate 
after and 
2h after 
injection 
PWL At 10 
min after 
EA end 
(2.5h 
post-
CFA), 
compared 
with 
sham 
 
Two sessions of 20 minutes EA at 10 Hz and 3 mA produces an anti-hyperalgesia effect that 
lasts for 7 days, while the same treatment with a lower intensity of 2 mA only produces a 
transient effect that lasts for 10 minutes. At an intensity of 1 mA, no significant effect is 
achieved. Similar results are observed at 100 Hz but not at 50 Hz, which produce transient 
effect even at a high intensity (3 mA) (Lao, Zhang et al. 2004). This suggests that there could 
be a optimal combination among frequency, intensity, and wave width (Lao, Zhang et al. 
2004). 
 
In the two-session protocol, EA was always delivered bilaterally. Results suggest there is 
evidence that bilateral EA is achieves a better anti-hyperalgesia effect rather than unilateral 
EA (Lao, Zhang et al. 2004). GB30, which was distal from the model site, was the only 
acupoint being used. Although TE5 was also used to test the point specification of EA 
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intervention, it did not produce any anti-hyperalgesia effect. 
 
From these results it is difficult to establish which one is more effective, either the single 
treatment or repeated treatments, as the two treatments were not compared directly in a single 
study.  
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2.2.7.2 Cumulative effect of EA 
 
In general, repetitive application of EA produces cumulative anti-hyperalgesia effect in 
inflammatory as well as neuropathic models. Both mechanical (MWT) and thermal (PWL) 
hyperalgesia was significantly reduced after EA intervention. Some studies followed up the 
effect after the end of EA treatments and found that EA showed increased lasting effect. 
 
High frequency (100 Hz), low frequency (2 Hz) and alternating frequency (2 to 100 Hz) were 
used experimentally. Stimulation duration was 20 or 30 minutes on all occasions. The whole 
treatments consisted of 2 to 14 sessions given every day or every other day. Bilateral, 
ipsilateral or contralateral distal (away from the injection site, within the same limb) acupoints 
were used in the studies. 
 
Table 2.9 is the summary of the effect of cumulative effect of repetitive EA application in 
different studies. 
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Table 2. 9 Effect of repetitive EA treatment 
 
No. Model Frequency Current Pulse Duration Acupoint  Time point Tests Effect time Session 
times 
8 CFA 100 Hz 0.5-1-1.5 
mA  for 
10 min 
each 
0.2 ms 30 min ST36, SP6, 
bilateral 
day 3 and 6 
for 4 weeks 
MW
T 
At 3 to 4 week 
during EA. No 
follow up, compared 
with no treatment 
8 in 28 day 
34 CFA A DS 16 
and 4 Hz 
0.5-1-
1.5v, 
each for 
10 min 
N/A 30 min GB30, 
GB34, 
ipsilateral 
on left 
Non-
acupoint: 5 
mm left to 
GB30, 
GB34 with 
stimulation 
Contralatera
l: right 
GB30, 
GB34 with 
stimulation 
every other 
day on 
from day 1 
to day 13 
after CFA 
Foot 
bend 
score 
Point: day 9-11 (5th  
to 6th EA) 
Contra point: day 8-
12 (5th to 6th EA) 
Non point: day 8, 9, 
11 (5th to 6th EA) , 
compared with sham 
7 in 13 day 
PWL 5d to 8d after EA, 
compared with sham 
and no treatment 
18 CFA A DS 16 
and 4 Hz 
0.5-1-1.5 
v for 10 
min each 
 30 min GB30, 
GB34, 
ipsilateral 
once a day 
form 1st 
day after 
CFA 
injection, 
14 days 
Foot 
bend 
score 
5d to 8d after EA, 
compared with sham 
and no treatment 
14 in 14day 
23 CFA 10 Hz 3 mA 0.1 ms  20 min GB30, 4 
mm off 
GB30, 
ipsilateral 
immediate 
after, 2h 
after, and 
twice on 
day 2 after 
CFA 
injection 
PWL 1-2d during EA. No 
follow up, compared 
with sham 
2 in 2 day 
26 CFA Alternating 
100 and 2 
Hz 
1-2-3 
mA 10 
min for 
each 
0.2 ms 
square 
wave 
30min GB30, 
GB34, 
ipsilateral 
pre CFA, 1 
to 4 day 
post CFA, 
5 
treatments 
MW
T 
PWL 
2-5 during EA (3rd to 
5th EA). Last for 3-4 
d after EA end, 
compared with sham 
5 in 5 day 
        Hot 
plate 
 
6-8 day during EA 
(4th to 5th EA). Peak 
at 4th EA and 
decrease thereafter , 
compared with sham 
 
6 SNL 2 Hz 0.5-1-1.5 
mA for 
10 min 
each 
0.6 ms 30 min ST36, SP6, 
bilateral 
5 d after 
SNL, on 
day 3 and 6 
for 4 weeks 
MW
T 
At 2 to 4 week 
during the EA 
treatment. No follow 
up, compared with 
vehicle 
8 in 28 day 
32 CCI A DS 1-2-3v 
for 
5,10,15 
min 
 30 min GB30, 
GB34, 
ipsilateral 
Everyday 
from the 
first after 
operation 
for 14 days 
PWL Day 7, 10, 14 during 
EA. Peak at 14d. No 
follow up, compared 
with no treatment 
14 in 14 
day 
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15 CCI Alternating 
60 and 2 Hz   
less than 
1 mA, 12 
V 
 30 min GB30, 
GB34 
contralateral 
once every 
day from 
7th day 
after 
operation, 
11 
treatments 
PWL Appear 4 day EA 
start (3rd EA) peak 
by the end of 20 day 
(11th EA). No follow 
up, compared with 
no treatment 
11 in 20 
day 
29 Cutane
ous 
cancer 
pain 
Alternating 
DS 100 and 
4 Hz 
1 mA, 0.6 ms 
pulse 
width, 
bidirect
ional 
asymm
etric 
pulse 
30 min ST36, 
BL60, 
ipsilatera 
every other 
day, day 8-
16 after 
inoculation, 
5 
treatments 
PWL 4-8 day during EA 
(3rd to 5th EA). Peak 
at 4th EA and 
decrease thereafter, 
compared with sham 
and no treatment 
5 in 8 day 
5 IBS Alternating 
DS 100 and 
4 Hz 
1 mA  30 min ST36, ST37, 
bilateral 
once every 
other day 
for 13 days, 
7 
treatments 
AW
R, 
EM
G 
Appear 2-4d after 
EA start (1st to 2nd 
EA), peak at 8-12d, 
last 5 d after EA end 
(EA end at 13 d), 
compared with 
before EA 
7 in 13d 
 
2.2.7.2.1 Cumulative effect in CFA model 
 
Several studies utilised the CFA model to evaluate EA anti-hyperalgesia effect. The protocol 
of EA treatments varies from study to study. The frequencies of the acupuncture treatment 
vary among studies, it ranged from twice a week for one month (Huang, Hu et al. 2004), , 
daily or alternate day for about 14 days, to twice daily for 2 days. For most of the included 
studies, EA treatment started during the first day after the injection of CFA. One study 
initiated the first treatment 30 minute prior to the CFA injection (Shan, Qi-Liang et al. 2007). 
Different parameters of EA were used in these studies. 
 
Due to the variety of the EA protocol, comparability among studies is limited. Therefore, it is 
difficult to verify which protocol produced the most significant results. However, the general 
finding is that repetitive EA treatment produces cumulative and lasting effect. A study 
showed that the cumulative effect could last for 3-4 days after the cessation of EA treatment 
(Shan, Qi-Liang et al. 2007). Another study continued to apply EA after the PWL and foot 
bend score return to the baseline. In these studies, no change in these two measurements 
occurred despite continuous EA application. This suggests that EA has ability to restore 
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function back to baseline (Wang, Zhang et al. 2006). 
 
2.2.7.2.2 Cumulative effect in CCI model 
 
In CCI model, EA is applied either on the first day (Chen, Yang et al. 2003) after the 
performed operation or one week later (Dong, Ma et al. 2006).  Both studies achieved 
cumulative effect from their specific procedure.  The EA effect peaked by the end of the study, 
however no follow up observation is carried out.  Therefore, it is difficult to establish how 
long this cumulative effect lasted for after the cessation of the EA treatment. 
 
2.2.7.2.3 Cumulative effect in SNL model 
 
In the SNL model, EA (applied 5 days after the operation, twice a week for 4 weeks) 
increased MWT at 2 to 4 weeks after the commencement of treatment. However, due to a lack 
of follow up observation, the duration of the beneficial effect of EA is not known (Huang, Li 
et al. 2004). 
 
2.2.7.2.4 Cumulative effect in IBS model 
 
EA treatment was applied once every other day for 13 days. The anti-hyperalgesia effect 
appeared 2-4 days after EA started, peaked at 8-12 days, and lasted for 5 days after EA 
treatment ended (Cui, Li et al. 2005). 
 
2.2.7.2.5 Cumulative effect in Cancer model  
 
Five treatments were applied for 8 days after the inoculation. The anti-hyperalgesia effect 
(PWL and hot plate test) appeared at 3rd to 4th treatment and than peaked at 4th treatment and 
decreased thereafter despite the treatment continued (Mao-Ying, Cui et al. 2006). 
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2.2.8 Interactions with medications 
 
More than half of the included papers studied the interaction between EA and drugs. The 
results either suggest a possible analgesic mechanism occurring from EA, or provided 
evidence for EA’s potential in drug-reduction. 
 
A few lines of evidence support the involvement of spinal and peripheral opioid receptors in 
EA anti-hyperalgesic effect. Firstly, opioid receptor antagonists, CTOP (µ opioid receptor 
antagonist) and NTI (δ opioid receptor antagonist, naltrindole hydrochloride), inhibited the 
anti-hyperalgesic effect of EA in a dose-dependent manner (Zhang, Lao et al. 2004). Secondly, 
co-application of EA with sub-effective doses of morphine enhanced the anti-hyperalgesia of 
EA (Zhang, Lao et al. 2004). Thirdly, intraplantar injection of opioid antagonist naloxone 
methiodide blocked EA’s anti-hyperalgesia (Zhang, Yu et al. 2005). 
 
Other studies also showed that co-application of EA with sub-effective does analgesia such as 
INDO (Zhang, Lao et al. 2004), AP5, DNQX (Zhang, Ji et al. 2002) and morphine (Zhang, 
Lao et al. 2004) additively or synergistically enhanced EA’s effects. These results provide 
support that EA has the potential to reduce the dosage of certain analgesia which may have 
serious side effects. 
 
2.2.9 The effect of sham EA on hyperalgesia 
 
Several types of sham acupuncture were used in the studies (Table 2.10). Most of the studies 
used the invasive sham acupuncture in which acupuncture needles were inserted into the same 
acupoint as in the real acupuncture but without electrical stimulation. Some researchers used 
invasive as well as non invasive sham acupuncture, such as taping the needles on the 
acupoints (Lao, Zhang et al. 2004; Tian, Bian et al. 2006). There were sham methods 
delivering electrical stimulation to non-acupoint several mm off the acupoint (Oliveira and 
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Prado 2000) or acupoint in the abdominal (Hwang, Min et al. 2002) or acupoint contralateral 
to the inflamed limb (Liu, Li et al. 2006=). Sham acupuncture was not significantly 
differently from the no treatment group, and did not produce any significant anti-hyperalgesia 
effect when compared with real EA.  
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Table 2. 10 Summary of the types of sham acupuncture   
 
No. Mode Sham method Duration Measure Results 
1 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
Negativ
e  
2 Carrageena
n 
Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min for once, 3h post 
carrageenan 
PWL to 
radiant heat 
Negativ
e 
3 CFA Non-
invasive 
Invasive 
Non-invasive: 
taped on the 
G30, 
Invasive: 
insertion 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
Negativ
e 
4 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
Negativ
e 
5 IBS Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min, once every other 
day for 13 days, 7 
treatments 
AWR to 
CRD, EMG 
to CRD 
Negativ
e 
6 SNL  N/A 5 d after SNL,  30 min, for 
once or on day 3 and 6 for 
4 weeks 
MWT to 
von Frey 
filaments 
Negativ
e 
7 CFA Non-
invasive 
Invasive 
Non-invasive: 
taped on the 
GB30, 
Invasive: 
insertion 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
Negativ
e 
8 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min 
single: 48 h after CFA 
repetitive: day 3 and 6 for 
4 weeks 
PWL to hot 
plate test, 
MWT to 
von Frey 
filaments 
Negativ
e 
9 Formalin  N/A 30 min for once, end 10 
min before formalin 
Weight pain 
score 
Negativ
e 
10 Incision Invasive EA at 5mm 
lateral to sp6 in 
operated paw  
15 min, 2h after incision MWT to 
von Frey 
filaments 
Negativ
e 
11 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
Negativ
e 
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12 Carrageena
n 
 N/A 3h after carrageenan, 60 
min for once 
PPT using 
analgesy-
meter 
Negativ
e 
13 Carrageena
n 
 N/A 3h after carrageenan, 60 
min for once 
PPT using 
analgesy-
meter 
Negativ
e 
14 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
48h after CFA injection, 
30 min for once 
PWL to 
radiant heat 
PWT to von 
Frey 
filaments 
Negativ
e 
15 CCI  N/A 30 min, once every day 
from 7th day after 
operation, 11 treatments 
PWL to 
radiant heat 
 
Negativ
e 
16 ICTR Invasive Non-acupoint in 
abdominal area, 
with stimulation 
30 min for once, 21 day 
after operation. 
Mechanical 
allodynia to 
von Frey 
filaments 
Negativ
e 
17 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat 
 
Negativ
e 
18 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min, once a day form 1st 
day after CFA injection, 14 
days 
PWL to 
radiant heat, 
Foot-bend 
score 
 
Negativ
e 
19 IBS  N/A 30 min for once, after IBS PTP and 
AWR to 
colon 
stimulation, 
fecal pellet 
output to 
WAS 
Negativ
e 
20 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat, 
 
Negativ
e 
21 Carrageena
n 
 N/A 30 min, immediate after 
injection 
PWL to hot 
plate test 
Negativ
e 
23 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min/each, immediate 
after, 2h after, and twice 
on day 2 after CFA 
injection 
PWL to 
radiant heat, 
 
Negativ
e 
25 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min, 72 h after CFA PWL to 
radiant heat, 
 
Negativ
e 
26 CFA Invasive Needle insertion 
at acupoints 
without 
30min/day, pre CFA, 1 to 
4 day post CFA, 5 
treatments 
PWT to von 
Frey 
filaments, 
Negativ
e 
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stimulation PWL to 
radiant heat 
27 Carrageena
n 
Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min, 3 h post 
carrageenan injection 
PWL to 
radiant heat, 
 
Negativ
e 
28 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
20 min for twice, 
immediate after and 2h 
post-CFA injection 
PWL to 
radiant heat, 
 
Negativ
e 
29 Cutaneous 
cancer pain 
Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min/day, every other 
day, day 8-16 after 
inoculation, 5 treatments 
PWL to 
radiant heat, 
Response 
latency to 
hot plate test 
 
Negativ
e 
30 CFA Invasive Needle insertion 
at acupoints 
without 
stimulation 
30 min once, 5 day after 
CFA injection 
PWL to 
radiant heat, 
 
Negativ
e 
31 Carrageena
n 
 N/A 30 min for once, 
immediately after 
carrageenan injection 
Response 
latency to 
hot plate test 
Negativ
e 
32 CCI  N/A 30 min/day, everyday from 
the first after operation for 
14 days 
PWL to 
radiant heat, 
Negativ
e 
34 CFA Invasive Non-acupoint: 5 
mm left to 
GB30, GB34 
with stimulation 
Contralateral: 
right GB30, 
GB34 with 
stimulation 
30 min/day, every other 
day on from day 1 to day 
13 after CFA 
Ankle joints 
dorsiflexion  
pain test 
 
Negativ
e 
35 Carrageena
n 
Invasive Needle insertion 
at acupoints 
without 
stimulation 
for 1, 15 or 60 min, 3h 
after carrageenan 
PPT using 
analgesy-
meter 
Negativ
e 
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2.2.10 Discussion 
 
2.2.10.1 Ideal EA parameters  
 
The majority of the studies used an inflammation model to assess the anti-hyperalgesia effects 
of EA. The use of the neuropathic model and other models, such as IBS model and cancer 
pain model, was limited to one or two studies for each type. Thus, the result of EA effect in 
the inflammation model is more conclusive than that of the neuropathic models.  It is 
recommended that future studies should consider the use neuropathic models.  
 
Both immediate effect from a single EA treatment and cumulative effect from a series of EA 
treatment were assessed in these studies. In general, single treatment of EA produces anti-
hyperalgesia effect that last for hours to days; and repetitive EA treatments produce 
cumulative effect that last for days after the cessation of the treatment. There is also evidence 
suggest the restoring effect of EA (Wang, Zhang et al. 2006).  
 
Whilst EA generally produces anti-hyperalgesia effects, its’ capacity depends on the 
parameter of the EA application which include duration of treatment, pulse frequency, pulse 
intensity, pulse wave length, and acupoint.  
 
It was shown with fixed parameters that EA with high frequency (100 Hz) produces short 
lasing (within 1 day) but high potent anti-hyperalgesia effects, whilst low frequency (10 Hz) 
shows prolonged (1 to 7 days) but less potent effect on PWL (Lao, Zhang et al. 2004).  
 
Generally, EA with low frequency (2 or 10 Hz) produces better anti-edema effects than high 
frequency 100 Hz effects (Zhang, Lao et al. 2004; Lee, Jang et al. 2006).  However, the anti-
edema effect of high frequency is contradictory. One study showed that 100 Hz did not 
produce any anti-edema effect (Zhang, Lao et al. 2004), whilst another demonstrated that 120 
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Hz produced significant anti-edema effects.  This may be due to the variation in other 
parameters. 
 
Data also suggested that the anti-hyperalgesia effect is intensity dependent. Higher intensity 
(3 mA) produced the most potent anti-hyperalgesic effect compared to lower intensity (1 or 2 
mA) (Lao, Zhang et al. 2004). 
 
Treatment duration is another important parameter. Results suggest that longer duration is not 
necessarily more effective. It was found in the CFA model that two 20-minute EA treatments 
produce the best result when compared to two 10-minute and two 30-minute EA treatments, at 
either high or low frequency (Lao, Zhang et al. 2004). Whilst in the carrageenan model, 60-
minute EA treatment produced better result than the 15-minute treatment. The influence of 
treatment duration on the anti-hyperalgesia effect may depend on which models are used 
(Taguchi and Taguchi 2007). 
 
There is evidence to suggest that increasing pulse width has the similar anti-hyperalgesic 
effect as increasing frequency. However, this effect has not been systematically studied (Lao, 
Zhang et al. 2004). Pulse width ranging from 0.1 to 2 ms was adopted by most studies (Sekido, 
Ishimaru et al. 2003; Huang, Hu et al. 2004; Lao, Zhang et al. 2004; Zhang, Lao et al. 2004; 
Taguchi and Taguchi 2007). 
 
Taken together, no single optimal EA combination was found. The optimal EA profile varied 
according to different models. One study identified that 10 Hz EA, with a intensity of 3 mA, 
and pulse width of 0.1 ms for 20 minutes, was the ideal combination for the CFA model (Lao, 
Zhang et al. 2004). The other study demonstrated 3 Hz EA  for 60 minutes was the optimal 
combination for carrageenan-induced hyperalgesia (Taguchi and Taguchi 2007).  
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2.2.10.2 Implication for human studies 
 
Currently, there is no literature available on human studies assessing anti-hyperalgesic effect 
of acupuncture. It is worth mentioning, outcome measures of hyperalgesia differ between 
studies in animals and humans. Thus, the result from animal studies cannot be directly applied 
to humans. Nevertheless, reviewing animal studies on this topic has provided valuable 
information for the future direction of human studies. 
 
Based on the evidence of animal studies, and the assumption of the human equivalent of the 
measurements, it can be inferred that EA may have the anti-hyperalgesia effect in human 
hyperalgesia model as well. 
 
Although the models and outcome measures of hyperalgesia differ in animals to humans.  
Thus, a range of parameters including response to both thermal and mechanical should be 
tested. EA should be used as none of the selected study used manual acupuncture. EA effects 
can be tested immediately after the treatment. The intensity of stimulation should be high with 
either high or low frequency. Additionally, EA on the same side of the injury is important.  
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Chapter 3 Methodology 
 
3.1 Overall design 
 
In order to answer the research aims of this project, two steps need to be taken. First is to 
identify a reliable hyperalgesia model and second is to test the anti-hyperalgesia effect of 
acupuncture on the model.  
 
In the literature review section, two promising hyperalgesia models have been identified, one 
is topical capsaicin model, and another is the heat/capsaicin model. The capsaicin model is 
validated, low-cost, and easy-to-use. It does not require an instrument to produce heat 
stimulation and also allows the researchers to assess spontaneous pain, heat and mechanical 
hyperalgesia.  However, despite its popularity, its reproducibility over a period of one month 
was not investigated by any studies. On the other hand, the reproducibility of the 
heat/capsaicin model is acceptable (Dirks, Petersen et al. 2003), but the device to produce this 
model was not available in this department at the time of the initial design. Furthermore, it is 
a model only used to test mechanical hyperalgesia but not other parameters, such as 
spontaneous pain. To tackle the dilemma, we decided to test the reproducibility of topical 
capsaicin model to find out whether it was suitable for this project.  
 
Thus, the whole project consists of two experiments. In experiment one, we designed a two-
session protocol to compare the key parameters of the topical capsaicin model over one month 
interval. If the results from this experiment indicated that the reproducibility was acceptable, 
we would use this model to test the anti-hyperalgesia effect of acupuncture. Otherwise, we 
would use the heat/capsaicin model for the second experiment.  
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3.2 HREC approvals 
 
Both experiments was reviewed and approved by the Human Research Ethic Committee of 
RMIT University (Reference No. 13/07) (Appendix 01), of which the principles were in 
accordance with the “National Statement on Ethical Conduct in Research Involving Humans 
1999” issued by National Health and Medical Research Council. Both experiments were 
conducted at the clinical research laboratory of RMIT Chinese Medicine Research Group, 
Bundoora West Campus. The laboratory was a quiet, well-lit and temperature controlled (20 – 
22 ˚C) room. 
 
3.3 Subjects 
 
Subjects were recruited from the local community via advertisements (Appendix 02, 03) 
posted on the RMIT Bundoora west campus. Volunteers who responded to the advertisement 
were screened according to the following inclusion and exclusion criteria 
 
Inclusion criteria: 
1) Aged between 18 and 40 years old healthy volunteers; 
2) Agree to make themselves available for the period of the study; 
3) Provide a written consent for participation.  
Exclusion criteria: 
Volunteers who take one or more of the following medications were excluded: 
1) Analgesics (Medication for relieving pain) 
2) Anti-inflammatory agents (Medication for reducing inflammation) 
3) Anti-anxiety agents (Medication for reducing anxiety) 
4) Anti-depressants (Medication for reducing depression) 
5) Anti-psychotic agents (Medication for psychosis) 
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Volunteers who have one or more of the following conditions were excluded: 
01) Stoke 
02) Epilepsy 
03) Diabetes 
04) Severe Alcoholism 
05) Peripheral Vascular Disease 
06) Peripheral Neuropathy 
07) Psychosis 
08) Heart disease 
09) Impaired circulation in hands or feet 
10) Wearing a cardiac pacemaker 
11) Pregnancy 
12) Have metal implant 
13) A history of chronic pain 
14) Having any types of pain currently 
15) Allergies to chilli pepper or adhesive paper 
 
For Experiment two, an additional item, volunteers did not have acupuncture treatment in the 
past one year, was added. 
 
Included subjects were given Plain Language Statement (Appendix 04, 05) and verbal 
explanation regarding any questions about the experiment. Subjects were notified that they 
were free to withdraw at any time. A signed consent form (Appendix 07) was obtained from 
each subject prior to the commencement of the experiments.  
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3.4 Hyperalgesia model 
 
3.4.1 Topical capsaicin model 
 
1 mg/ml capsaicin solution was prepared by dissolving capsaicin powder (sigma) in 50% 
ethanol 50% distilled water. 0.1 ml of the solution was absorbed onto a patch of filter paper 
(2×2 cm²). The patch was applied to the middle of the forearm, and then covered with a piece 
of transparent dressing (3×3 cm²) to prevent evaporation (Zheng, Gibson et al. 2000). After 50 
minutes, the capsaicin patch was removed, and the site was cleaned with alcohol swabs. 
    
Previous studies show that topical application of capsaicin can reliably induce pain at a 
concentration between 1 mg/ml and 10 mg/ml (Helme and McKernan 1985; Green and 
Flammer 1988), and produce mechanical hyperalgesia at a minimum concentration of 0.1 
mg/ml (Morris, Cruwys et al. 1997; Morris, Cruwys et al. 1998). 
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3.4.2 Heat/capsaicin model 
 
To produce the heat/capsaicin model, moderate thermal stimulation (45˚C) was given for five 
minutes in the middle of the non-dominant forearm. Capsaicin cream (Zotrix HP cream, 
0.075% capsaicin) was then applied topically to the heated area for 30 minutes to achieve 
further sensitisation. The sensitised area was rekindled at 40˚C for 5 minutes periodically 
throughout the session to maintain the status of mechanical hyperalgesia (Petersen and 
Rowbotham 1999; Dirks, Petersen et al. 2003).  
 
The thermal stimulation is delivered by the Medoc TSA 2001 (Medoc, Ramat Yishai, Israel) 
(Photo 3.1) with a computer controlled thermode with a surface area of 3×3 cm² (Photo 3.2). 
 
 
Photo 3. 1 TSA 2001 
 
 
 
                       
Photo 3. 2 A 3×3 cm² thermode 
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3.5 Measurements 
 
Table 3.1 lists the outcome measures used in Experiment 1 and Experiment 2, MPT and 
stimulus-response function were only used in Experiment 1, while HPT and pain rating to 
long thermal stimulation were only used in Experiment 2. The area of secondary hyperalgesia 
was measured in both experiments.  
 
Table 3. 1 Outcome measures used in experiment 1 and 2 
 
Measurements Experiment 1 Experiment 2 
Mechanical pain threshold (MPT) Yes No 
Stimulus-response function Yes No 
Area of secondary hyperalgesia Yes Yes 
Heat pain threshold (HPT) No Yes 
Pain rating to long thermal stimulation No Yes 
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3.5.1 Mechanical pain threshold (MPT) 
 
MPT and stimulus-response function to mechanical stimulation were tested with a series of 
von Frey filaments (Stoelting, USA) (Photo 3.3) at different stages of Experiment 1. Von Frey 
filaments are the standard tool widely used for measuring mechanical sensitivity in both 
healthy subjects and patients with pain. 
 
 
Photo 3. 3 A set of von Frey filaments 
 
 
The MPT was measured according to the guideline below: 
1) Hold the end of the filament bar with the dominant hand while the wrist was support by a 
soft cushion 2-5 cm above the test surface; 
2) Apply the filament perpendicularly to the test surface; 
3) On contact with the test surface, increase force gradually by pushing the bar of the 
applicator till the filament starts to bend. At this point, the bearing force is the designed force 
of that particular filament. 
 
To determine the MPT, we tested the skin of volar aspect of the non-dominant forearm of the 
subject using a pseudo-double random staircase method. Subject was asked to close their eyes 
and report whether a stimulus was painful or not. The least force that evokes sharp pain on 
50% of occasions was recorded as the MPT. Stimuli were applied at an interval of 30 seconds 
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and each lasted for 3 seconds. Within one test session, stimuli were not to be applied on the 
same point. 
 
After determining the area of secondary hyperalgesia, we then measured MPT with von Frey 
filaments using the method described as above. The measurement was conducted twice in 
each session of the experiment. MPT was measured within the areas of primary and secondary 
hyperalgesia, and on the non-capsaicin side.  Data was recorded on a pain threshold recording 
sheet (Appendix 08) 
 
3.5.2 Stimulus-response function 
 
In Experiment 1, five von Frey monofilaments (4.93, 5.07, 5.46, 6.10, and 6.45 log10 mgforce) 
were used to test the stimulus-response function.  
 
These five filaments were applied randomly to avoid any order effects. The random order was 
generated using Excel. They were applied twice on the skin of volar aspect of the capsaicin 
and non-capsaicin sides. Each filament was applied for 3 seconds with a 10-second interval 
during which subjects were asked to rate the stimulus on a modified 100-mm VAS (where 
0=no sensation, 50mm= just painful, 100mm= worst pain possible) (Appendix 10). The mean 
VAS ratings to the repeated stimuli were then computed and used for statistical analyses.  
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3.5.3 Area of secondary hyperalgesia 
 
The area of secondary hyperalgesia was measured by applying a von Frey filament (4.93) at a 
point 8 cm away from the center of the capsaicin area and then moving towards the center at 
approximately 1 cm intervals every 2 seconds. Subjects were provided with a written 
instruction about skin hypersensitivity (Appendix 09) and asked to report when the filament 
caused a definite increase in the magnitude of pricking sensation or pain. This point was 
marked on the skin using a colored fiber-tipped pen and this process was repeated in a pattern 
of eight radial lines from the center of the capsaicin site (Figure 3.1). The resulting eight 
points were connected to define the outline of secondary hyperalgesia, which was then 
transferred onto a transparent plastic sheet. 
 
 
Figure 3. 1 Illustration of measurement for the area of secondary hyperalgesia 
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The area of secondary hyperalgesia was then measured with a Digital Planimeter (Planix, 
Tamaya & Company Ltd., Japan) (Photo 3.4).  
 
 
Photo 3. 4 Digital planimeter 
 
3.5.4 Heat pain threshold (HPT) 
 
HPT is the lowest temperature that the subjects perceived as painful. In Experiment 2 it was 
measured on the forearm of both capsaicin and non-capsaicin sides using a 3×3 cm² thermode 
(Medoc TSA 2001). The test used was a modified Limits test with four continuous heat 
stimulations. The baseline temperature of the thermode was 32˚C. After the test began, it 
increased at a rate of 1˚C/s. Subjects indicated when the pain threshold (the point they began 
to feel the stimulation became painful) was reached by pressing the Yes mouse button. The 
temperature was automatically recorded by the computer and the thermode temperature 
immediately returned to baseline. The cut-off temperature was set at 50˚C. The next 
stimulation was given 4 to 6 seconds after the restoration of the baseline. The HPT was 
calculated as the average of 4 measurements.                           
 
3.5.5 Painfulness of the long thermal stimulation 
 
In Experiment 2, painfulness to the long thermal stimulation (40˚C, 1 minute) was measured 
during baseline measurement and in the first minute during each rekindling, using a modified 
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VAS (Appendix 11). Subjects were instructed to rate their sensation at 5, 10, 15, 25, 35, 45 
and 55 seconds to the stimulation.   
 
3.6 Method of randomisation and double-blinding 
 
Randomisation and blinding were used in Experiment 2. Before the acupuncture intervention, 
subjects drew a sealed envelope which contained a random number, indicating the assignment 
to either REA or SEA group. The random number sequence was generated with Microsoft 
Excel (Microsoft Office, Windows version) by an independent investigator who was involved 
in neither acupuncture intervention nor testing. The acupuncturist was the only person who 
knew the group assignment, and was blinded from the outcome measures. The investigator 
who performs the test was blinded from the group assignment and the process of the 
acupuncture intervention. During the acupuncture treatment, subjects lay on a treatment bed 
in supine posture and their vision to the site of the acupuncture was blocked. By the end of the 
treatment they were informed not to disclose any information about the nature of their 
treatment to the investigator who performed tests on them. During the data analysis stage, an 
independent investigator conducted the data analysis. 
 
3.7 Acupuncture interventions 
 
In Experiment two, the non-invasive sham electro-acupuncture was employed. 
 
Acupuncture needles were eight 0.3×40 mm sterile single-use needles with guide tube (Huato, 
Suzhou Medical Appliance Company, China) 
 
3.7.1 Selection of acupoints 
 
Four acupoints on both sides were selected: Zusanli (ST36) and Fenglong (ST40), Hegu (LI4) 
and Shousanli (LI10). These points were commonly used for pain treatment (Chen 1994). The 
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following methods were used for locating these acupoints: 
 
ST36: “With a flexed knee or in a supine position, ask the patient put the thumb on the middle 
of the patella with the remaining four fingers closed together and placed on the lateral side of 
the patella. The point is located at the tip of the middle finger. Alterative method: the point is 
located in the fossa one finger breadth lateral to the anterior margin of the tibia, and 3 inches 
inferior to Dubi (ST35).” Page 68 (Chen 1994) 
 
ST40: “The point is located at the midpoint between the inferior margin of the patella and 
skin crease of the ankle joint, 1.5 inches lateral to the anterior margin of the tibia, and 
between the tibia and fibula; or 8 inches above the lateral malleolus and one finger’s breadth 
lateral to TiaoKuo (ST38).” Page 73 (Chen 1994) 
 
LI4: “The point is located on the dorsum of the hand, between the first and second 
metacarpals at the midpoint of the radial margin of the second metacarpal bone. Alternative 
method: ask the patient to adduct the thumb and the index finger; the point is located at the 
highest spot of the first and second metacarpal muscles.” Page 37-38 (Chen 1994) 
 
LI10: “With the elbow flexed, the point is located on the radial side of the elbow on the line 
between Quchi (LI11) and Yangxi (LI5), and 2 inches below Quchi (LI11); or clenching the 
hand firmly and flexing the elbow, the point is located in the fosa of the brachioradialis 
muscle.” Page 20 (Chen 1994) 
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3.7.2 REA 
 
Needles were inserted into acupoints to a depth of 15-25 mm, and were manipulated to 
achieve De Qi sensations (described as soreness, numbness, or distension at the needling site). 
A bipolar electrical acupuncture stimulator (MEE 501, Australia) (photo 3.5) was connected 
to the eight acupoints on both sides of the body using four pairs of electrodes. The parameter 
for REA was dense-disperse (D-D) mode with alternating frequency between 5 and 15 Hz. 
The intensity was initially set to a strong but comfortable level with visible muscle 
contraction; and was further adjusted twice during the treatment to cater for the subject’s 
tolerance. The duration of EA treatment was 25 minutes. 
 
Photo 3. 5 A modified electrical acupuncture stimulator (MEE 501, Australia) 
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3.7.3 SEA 
 
Non-invasive sham was used in this trial. First, an empty plastic guide tube was tapped at 
each acupoint to produce the discernible sensation; then bent needles with adhesive bandage 
(Photo 3.6) were taped to the dermal surface of each acupoint; and was connected to a mock 
electrical acupuncture stimulator without delivering electrical stimulation. The stimulator was 
placed within the subject’s sight, showing a continuously flashing light. The acupuncturist 
adjusted the stimulator twice. The treatment duration was 25 minutes during which bended 
needles were  pressed to the skin three times to produce some discernible sensation. De Qi 
sensation was not intended to be produced during SEA. 
 
Table 3.2 is a detailed comparison of REA and SEA procedure.   
 
Photo 3. 6 sham acupuncture 
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Table 3. 2 A comparison of REA and SEA 
 
 REA SEA 
Posture of 
subjects 
Supine Supine 
Acupoints Zusanli (ST36) and Fenglong 
(ST 40), Hegu (LI4) and 
Shousanli (LI10) on both sides 
of the body 
Zusanli (ST36) and Fenglong 
(ST40), Hegu (LI4) and 
Shousanli (LI10) on both sides 
of the body 
Insertion 15-25 mm No insertion, tapped on 
acupoint 
De Qi Yes No 
Duration 25 minutes 25 minutes 
Schedule for 
adjusting the 
stimulation  
Every 10 minutes Every 10 minutes 
Parameter dense-disperse, 5-15 Hz N/A 
Intensity  Adjust to strong but 
comfortable level with muscle 
contraction 
N/A 
EA stimulator Connected to the needles via 
alligator clips, delivering 
electrical pulse 
Connected to the needles via 
alligator clips, without 
electrical stimulation, only 
showing flashing light within 
subject’s eyesight 
 
3.8 Statistical analysis and sample size 
 
3.8.1. Statistical analysis  
 
For Experiment 1, ratings to von Frey filaments stimulation and the size of the area of 
secondary hyperalgesia were analyzed with two-way Analysis of Variance (ANOVA) with two 
repeated measures to test the effects of time and session. Mechanical pain threshold was 
analyzed with non-parametric Friedman tests. The responses within each group to topical 
application of capsaicin were correlated via Pearson’s correlation coefficient. SPSS software 
(Windows Version 16.0) was used.  
 
For Experiment 2, data were summarized as means and standard deviations (SD) in the tables 
and means and standard error of mean (SEM) or percentage in the figures. The experiment 
was a two way (time point and intervention group) with one repeated measure (time point) 
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design. Two-way ANOVA was used to analyze the effect of intervention on the size of 
secondary hyperalgesia area, heat pain threshold and VAS rating to long thermal stimulation. 
A p-value of 0.05 (P<0.05) was considered statistically significant. Independent-samples T 
test was used to compare the age difference between groups. For the categorical data such as 
gender, hand dominance, sham procedure credibility and acupuncture perception, the chi-
squared test was used. 
 
In both experiments, a p-value of 0.05 was considered statistically significant. 
 
Data analysis was conducted by an independent researcher who was blinded to the group 
assignment and tests. All of the statistical analyses were conducted using the Statistical 
Package for the Social Sciences (SPSS, Windows Version 16.0).  
 
3.8.2. Sample size and power calculation  
 
For Experiment 1, since no similar experiment was published, the sample size was estimated 
based on a study (Hughes, Macleod et al. 2002) in which 12 subjects were recruited to assess 
the reproducibility of intradermal capsaicin model.  
 
For Experiment 2, as this is the first study assessing the anti-hyperalgesia effect in human 
subject, no previous data was available for the sample size calculation. The  sample size was 
calculated based on the data from a drug study (Petersen, Jones et al. 2001) using 
heat/capsaicin model. In this study, the mean area of secondary hyperalgesia reduced from 
142 ± 60 cm² to 34 ± 17 cm² during the drugs infusion, with a sample size of 14 subjects. 
Based on an online sample size calculator (http://home.clara.net/sisa/samsize.htm), the 
recommended sample size was 29 per group to achieve 80% power. 
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By the end of the Experiment 2, post-hoc power analysis and sample size calculations were 
done using G*Power (Version 3.0.10). 
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Chapter 4 Experiment 1: the reproducibility of 
hyperalgesia in the topical capsaicin model 
 
4.1 Introduction 
 
In order to evaluate the effect of EA on hyperalgesia in human subjects, we need a 
hyperalgesia model that can be reliably reproduced on the same subject over a period of time. 
Capsaicin is the most commonly used hyperalgesia due to its unique features. It can be 
applied either topically or intradermally. It is found that the intradermal capsaicin injection 
produces relatively reliable areas of allodynia and hyperalgesia within a subject over a period 
of one hour (Hughes, Macleod et al. 2002). However intradermal injection of capsaicin also 
elicits severe pain that cannot be accepted by all subjects. Therefore, we chose topical 
capsaicin model for the current research.  The topical capsaicin model has been widely used 
in hyperalgesia research for decades.  However, its reproducibility has not been examined 
systematically. This pilot study aimed to evaluate the between-session, within-subject 
reproducibility of this hyperalgesia model over a period of one month. Mechanical 
hyperalgesia will be assessed as it is an indication of central sensitisation and could be used to 
test the central effect of acupuncture. 
 
4.2 Aims 
 
The aim of this pilot study was to examine the reproducibility of several key parameters of 
this model, including the area of mechanical hyperalgesia, mechanical pain threshold, ratings 
to sub- and supra-threshold mechanical stimulation and rating to spontaneous pain in healthy 
volunteers at one month interval.  
 
4.3 Design  
 
This experiment is a two-session trial conducted on 12 healthy volunteers (7 male, 5 female). 
In each session, capsaicin solution (0.1 ml, 1mg/ml) was applied topically onto the non-
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dominant forearm for 45 minutes. A series of tests were carried out to determine the time-
course of the hyperalgesia in these subjects. The two sessions were separated by an interval of 
one month. The data from the two sessions was compared to determine the reproducibility of 
this model.  
 
4.3.1 Procedure 
 
Table 4.1 demonstrates the detailed procedure of the experiment.  
 
Before the experiment, subjects were instructed not to drink coffee on the day of the 
experiment. On the day of the experiment, the eligible subjects were first asked to be 
familiarised with the procedure and tests of the experiment. A series of tests was then 
conducted, including measuring mechanical pain threshold and stimulus response function to 
mechanical stimulation. Refer to “Methods” chapter for detailed description of these tests. 
Immediately after the baseline measurements, a capsaicin patch (1×1 cm²) saturated with 
capsaicin solution (0.1 ml, 1mg/ml) was applied topically onto the skin in the middle of the 
non-dominant forearm. Forty-five minutes later the patch was removed and residue capsaicin 
was cleaned. After a 10-minute rest, the subjects went through the first session of post-
capsaicin measurements. Sixty minutes after the removal of the capsaicin patch, the second 
session of post-capsaicin measurement was conducted. The whole session took approximately 
three hours, and was repeated one month later. 
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Table 4. 1 Procedure and time points of the experiment 
Time point Step 
-20 min 
Preparation: eligible subjects were familiarised with the 
procedure and instruments of the study. The consent form 
was signed before the commencement of the trial. 
-15 min 
Pre-capsaicin (baseline) measurements: 
(1) mechanical pain threshold  
(2) stimulus-response function (VAS) 
0-45 min 
Application of the capsaicin patch immediately after the 
baseline measurements. 
45 min Remove the capsaicin patch 
45-55 min Rest 
55-75 min 
post-capsaicin measurement 1:  
(1) area of the secondary hyperalgesia;  
(2) mechanical pain threshold within the secondary 
hyperalgesia area primary hyperalgesia area; 
(3) stimulus-response function (VAS) within the secondary 
hyperalgesia area. 
75-115 min Rest 
115-135 min 
post-capsaicin measurements 2:  
(1) area of the secondary hyperalgesia;  
(2) mechanical pain threshold within the secondary 
hyperalgesia area primary hyperalgesia area; 
(4) stimulus-response function (VAS) within the secondary 
hyperalgesia area. 
 
 
Please refer to Methodology (Chapter 3) for detailed description regarding screening of 
subjects, producing the topical capsaicin model, outcome measurements, and statistical 
methods. 
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4.4 Results  
 
4.4.1 General information of subject 
 
The experiment was conducted from July to October 2007. In total, 12 subjects were recruited 
based on the inclusion and exclusion criteria. All subjects signed the consent form (Appendix 
07) before starting the experiment and completed the two-session trial. No side effects were 
reported. 
 
The average age of subjects was 30.50 ± 4.72 (Mean ± SD), ranging from 25 to 38 years. 
There were 7 male and 5 female, all of whom were right-handed.  
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4.4.2 Development of hyperalgesia sensitisation 
 
After the topical capsaicin application, hyperalgesia developed in both sessions.  
 
Table 4.2 shows the area of mechanical hyperalgesia in the two sessions. Immediately after 
capsaicin application, the mean area was 33 cm² in session one and 29 cm² in session two, and 
dropped significantly to 25 cm² and 22 cm² immediately and one hour after the removal of 
capsaicin patch, respectively (time effect: F (1, 11) = 57.978; p < 0.001). There was no main 
effect of sessions (F (1, 11) = 0.363, p = 0.199) (Figure 4.1). 
 
Table 4. 2 Area of secondary hyperalgesia in session one and two 
 
Session No.  
(n = 12) 
Post-capsaicin 1  
(immediately after capsaicin) 
(Mean ± SD) 
Post-capsaicin 2  
(one hour after capsaicin) 
(Mean ± SD) 
1 33 ± 12 cm² 25 ± 10 cm² 
2 29 ± 6 cm² 22 ± 8 cm² 
 
 
 
Figure 4. 1 Area of secondary hyperalgesia to a von Frey filament in first and second 
session 
Data are expressed as mean ± S.E.M. post-capsaicin 1 = immediately after 
capsaicin; post-capsaicin 2 = one hour after capsaicin 
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Table 4.3 and figure 4.3 show the VAS rating to von Frey filaments stimulation during each 
session. Rating to five von Frey filaments increased as the pressure increased (significant bar 
effect: session 1, F (4, 44) = 71.998, p < 0.001; session 2, F (4, 44) = 88.202, p < 0.001). The 
overall rating of each bar increased significantly after capsaicin application (time effect: 
session 1, F (2, 22) = 10.658, p = 0.001; session 2, F (2, 22) = 18.222, p < 0.001), 
demonstrating a left-shift phenomenon.  Before capsaicin, stimulation delivered with Bars 4 
and 5 were considered to be painful. After capsaicin, Bar 3 was also considered painful. 
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Table 4. 3 VAS rating to von Frey filaments stimulation in session one and two 
Session No. Stage Von Frey bar VAS rating (Mean±SD) 
Bar 1 1.7 ± 1.4 
Bar 2 2.1 ± 1.8 
Bar 3 3.1 ± 1.5 
Bar 4 5.4 ± 0.8 
Pre-capsaicin 
(Before capsaicin) 
Bar 5 7.1 ± 1.2 
Bar 1 3.7 ± 2.2 
Bar 2 3.5 ± 1.5 
Bar 3 5.0 ± 2.3 
Bar 4 6.9 ± 1.1 
Post-capsaicin 1 
(Immediately after 
capsaicin) 
Bar 5 8.0 ± 1.1 
Bar 1 3.4 ± 2.6 
Bar 2 3.6 ± 2.6 
Bar 3 5.0 ± 2.4 
Bar 4 6.8 ± 1.3 
1 
Post-capsaicin 2  
(One hour after 
capsaicin) 
Bar 5 7.7 ± 1.2 
Bar 1 1.2 ± 1.1 
Bar 2 1.6 ± 1.1 
Bar 3 2.4 ± 1.3 
Bar 4 5.9 ± 1.7 
Pre-capsaicin 
(Before capsaicin) 
Bar 5 7.3 ± 1.4 
Bar 1 4.0 ± 2.1 
Bar 2 4.4 ± 2.0 
Bar 3 4.8 ± 2.4 
Bar 4 7.1 ± 1.4 
Post-capsaicin 1 
(Immediately after 
capsaicin) 
Bar 5 8.5 ± 0.9 
Bar 1 3.5 ± 2.5 
Bar 2 3.9 ± 2.2 
Bar 3 4.7 ± 2.5 
Bar 4 6.8 ± 1.4 
2 
Post-capsaicin 2  
(One hour after 
capsaicin) 
Bar 5 8.3 ± 1.0 
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Figure 4. 2 VAS rating to von Frey filaments in session one (upper panel) and two (lower 
panel), before, immediately after and one hour after capsaicin.  
 
On the non-capsaicin side, rating to five von Frey filaments also increased as the pressure 
increased (significant bar effect: session 1, F (4, 44) = 85.334, p < 0.001; session 2, F (4, 44) 
= 135.954, p < 0.001), indicating the subjects differentiated the sensation induced by different 
bars successfully. Time effect was not significant (time effect: session 1, F (2, 22) = 0.429, p 
= 0.657; session 2, F (2, 22) = 0.883, p = 0.428), indicating hyperalgesia was not induced on 
the non-capsaicin side.    
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Table 4.4 and Figure 4.4 show the mechanical pain thresholds in primary and secondary 
hyperalgesia area in both sessions. There was a significant decrease in the mechanical pain 
threshold after the application of capsaicin in both sessions within the areas of primary 
hyperalgesia and secondary hyperalgesia, respectively. The pain threshold was measured as 
actual forces (gram/cm²) and then each converted into a log10 scale measurement. 
Friedman’s non-parametric ANOVA was used to assess for the differences among different 
stages. Friedman’s test produced a chi-squared value, which was assessed for statistical 
significance via a p-value. 
 
Table 4. 4 Mechanical pain threshold in session one and two in primary and secondary 
hyperalgesia area  
 Pre-capsaicin Post-capsaicin 1 Post-capsaicin 2 
Friedman 
test 
χ² (dƒ) 
p-value 
Session 1 
PT (capsaicin side, 
primary 
hyperalgesia area) 
(mean ± SD) 
5.77 ± 0.26 4.98 ± 0.34 5.04 ± 0.30 18.766(2) <0.001 
PT (capsaicin side, 
secondary 
hyperalgesia area) 
(mean ± SD) 
5.77 ± 0.26 4.86 ± 0.34 4.86 ± 0.43 18.426(2) <0.001 
PT (non-capsaicin 
side) (mean ± SD) 5.70 ± 0.33 5.60 ± 0.42 5.49 ± 0.52 4.526(2) 0.104 
Session 2 
PT (capsaicin side, 
primary 
hyperalgesia area) 
(mean ± SD) 
5.85 ± 0.12 5.14 ± 0.39 5.16 ± 0.39 16.650(2) <0.001 
PT (capsaicin side, 
secondary 
hyperalgesia area) 
(mean ± SD) 
5.85 ± 0.12 4.99 ± 0.30 5.04 ± 0.44 17.149(2) <0.001 
PT (non-capsaicin 
side) (mean ± SD) 5.85 ± 0.12 5.75 ± 0.23 5.59 ± 0.34 4.222(2) 0.121 
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Figure 4. 3 Mechanical pain thresholds to von Frey filaments within the primary and 
secondary hyperalgesia in both secessions 
Data are expressed as mean ± S.E.M. 
Pre-capsaicin = before capsaicin; post-capsaicin 1 = immediately after 
capsaicin; post-capsaicin 2 = one hour after capsaicin; 
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4.4.3 Reproducibility of area of secondary hyperalgesia area 
 
As shown in the Table 4.5, the area of secondary hyperalgesia in the two sessions showed 
significant correlation immediately after the removal of capsaicin, but not one hour after. 
 
Table 4. 5 Correlation of hyperalgesia area in session one and two 
 
Stage Sample size Pearson Correlation p-value 
Post-capsaicin 1 12 0.643  0.024* 
Post-capsaicin 2 12 0.456 0.136 
*Correlation is significant at the 0.05 level (2-tailed) 
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4.4.4 Reproducibility of the pain threshold 
 
Table 4.6 shows the correlation of pain threshold of both sessions in each stage of the 
experiment. There was no significant correlation detected on the non-capsaicin (right) side. 
On the capsaicin (left) side, correlation was significant in the final stage of the experiment, 
which was one hour after the removal of capsaicin. 
 
Table 4. 6 Correlation of mechanical pain threshold measured in session one and two 
**Correlation is significant at the 0.01 level (2-tailed) 
 *Correlation is significant at the 0.05 level (2-tailed) 
 
Pre-capsaicin: baseline 
Measurements Sample size Pearson Correlation p-value 
Pain threshold on the non-capsaicin side 12 0.234 0.464 
Pain threshold on the capsaicin side 12 -0.133 0.680 
Post-capsaicin 1: immediately after capsaicin 
Measurements Sample size Pearson Correlation p-value 
Pain threshold on the non-capsaicin side 12 0.017 0.959 
Pain threshold in the primary 
hyperalgesia area 
12 0.553 0.062 
Pain threshold in the secondary 
hyperalgesia area 
12 0.429 0.164 
Post-capsaicin 2: one hour after capsaicin 
Measurements Sample size Pearson Correlation p-value 
Pain threshold on the non-capsaicin side 12 0.531 0.076 
Pain threshold in the primary 
hyperalgesia area 
12 0.745   0.005** 
Pain threshold in the secondary 
hyperalgesia area 
12 0.644  0.024* 
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4.4.5 Reproducibility of the VAS rating 
 
Tables 4.7 and 4.8 show the correlation of VAS ratings to mechanical stimulation applied on 
both sides. On the non-capsaicin side, there was moderate, non significant correlation at 
baseline, with one significant correlation (p < 0.05); the correlation became more obvious 
immediately and one hour after the capsaicin, three out of five rating were found to be 
significantly correlated (p < 0.05 and p < 0.01).  
 
Similarly, correlation on the capsaicin side was moderate and significant at the baseline stage 
(two bars, p < 0.05 and p < 0.01), and improved after capsaicin. Four out five rating were 
found significantly correlated immediately after capsaicin (p < .05 and p < 0.01), and all five 
rating correlated significantly one hour after capsaicin removal (p < 0.01). 
 
In general, the number of significant correlations increased from baseline to immediately after 
capsaicin and one hour after capsaicin on both sides of the forearm. However, the number of 
significant correlations obtained was more on the capsaicin side compared to the non- 
capsaicin side. 
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Table 4. 7 Correlations of VAS rating side in session one and two on the non-capsaicin  
 
Pre-capsaicin: baseline 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.546 0.066 
VAS rating 2 12 0.660  0.020* 
VAS rating 3 12 0.503 0.096 
VAS rating 4 12 0.360 0.250 
VAS rating 5 12 0.431 0.162 
Post-capsaicin: immediately after capsaicin 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.517 0.085 
VAS rating 2 12 0.782   0.003** 
VAS rating 3 12 0.659  0.020* 
VAS rating 4 12 0.774   0.003** 
VAS rating 5 12 0.459 0.133 
Post-capsaicin: one hour after capsaicin 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.737   0.006** 
VAS rating 2 12 0.758 0.04* 
VAS rating 3 12 0.328 0.298 
VAS rating 4 12 0.429 0.164 
VAS rating 5 12 0.707  0.010* 
**Correlation is significant at the 0.01 level (2-tailed) 
 *Correlation is significant at the 0.05 level (2-tailed) 
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Table 4. 8 Correlations of VAS rating in session one and two on the capsaicin side  
 
Pre-capsaicin: baseline 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.248 0.437 
VAS rating 2 12 0.692  0.013* 
VAS rating 3 12 0.396 0.202 
VAS rating 4 12 0.551 0.064 
VAS rating 5 12 0.786   0.002** 
Post-capsaicin: immediately after capsaicin 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.673  0.017* 
VAS rating 2 12 0.654  0.021* 
VAS rating 3 12 0.847   0.001** 
VAS rating 4 12 0.567 0.055 
VAS rating 5 12 0.731   0.007** 
Post-capsaicin: one hour after capsaicin 
Measurements Sample size Pearson Correlation p-value 
VAS rating 1 12 0.888 < 0.001** 
VAS rating 2 12 0.881 < 0.001** 
VAS rating 3 12 0.797   0.002** 
VAS rating 4 12 0.840   0.001** 
VAS rating 5 12 0.865 < 0.001** 
**Correlation is significant at the 0.01 level (2-tailed) 
 *Correlation is significant at the 0.05 level (2-tailed) 
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4.5 Conclusion 
 
Topical capsaicin application (0.1 ml, 1 mg/ml, 1×1cm²) successfully induced hyperalgesia in 
both sessions. The significant change in the area of secondary punctate hyperalgesia, 
mechanical pain threshold and VAS rating to von Frey filaments stimulation indicated the 
development of skin sensitivity. On the non-capsaicin side, VAS rating and pain threshold 
remains unchanged, indicating capsaicin did not sensitise the skin on the opposite of the body. 
 
The statistical analysis showed that the correlations of area of secondary hyperalgesia and 
mechanical pain threshold between the two sessions were poor, suggesting between-day 
within-subject reproducibility was poor to justify their use in the acupuncture study. However, 
the VAS rating on the capsaicin side of the two sessions was found correlated with each other, 
especially after the capsaicin sensitisation. This suggests that VAS rating might be a reliable 
measurement for the evaluation of intervention. However, these results alone does not justify 
the use of topical capsaicin model in evaluating the acupuncture effect on hyperalgesia, as the 
primary outcome measure, which is the hyperalgesia area, was not reliable for the evaluation 
of acupuncture’s effect on central sensitisation. 
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Chapter 5: Experiment 2-the anti-hyperalgesia effect of 
EA in healthy humans  
 
5.1 Introduction 
 
Experiment 1 demonstrated that hyperalgesia induced by using the topical capsaicin model 
was reduced over time. Furthermore, its between-day reproducibility of area of secondary 
hyperalgesia and mechanical pain threshold were poor. These two weaknesses do not allow us 
to evaluate the effect of acupuncture on the same subject over a period of one month. In this 
experiment a more stable model called heat/capsaicin model was used to assess the effect of 
electroacupuncture (EA) on hyperalgesia as compared to a sham procedure. This was made 
possible after the purchase of the heat simulator Medoc TSA 2001 (Refer to Methodology, 
Chapter 3) by the Chinese Medicine Division. The heat/capsaicin model has been successfully 
used in a number of drug studies to assess their anti-hyperalgesia effect (Refer to Review 
Chapter 2). In previous drug studies, cross-over designs were widely used. However, in the 
acupuncture study, it is not appropriate to use this design as subjects can easily distinguish the 
difference between real and sham electroacupuncture.  
 
5.2 Aims 
 
The primary aim of this experiment was: 
1. To compare the effect of real electroacupuncture (REA) and sham electroacupuncture (SEA) 
on mechanical hyperalgesia in a heat/capsaicin model. 
 
The secondary aim was: 
2. To compare the effect of REA and SEA on Heat Pain Threshold (HPT), and pain rating on 
the capsaicin-treated and untreated (contralateral) sides of the body. 
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5.3 Design 
 
The current experiment is a one-session, double-blind, randomised, sham acupuncture -
controlled study in healthy human subjects.  
 
Twenty young volunteers who responded to the advertisements were screened according to 
the inclusion and exclusion criteria. All eligible volunteers who signed the consent form 
(Appendix 07) before participating in the experiment were recruited. 
 
5.3.1 Procedure 
 
Table 5.1 illustrates the detailed procedure used in the experiment.  Full experimental 
procedure details were explained to subjects. Subjects were familiarised with the HPT test and 
the use of VAS. During the baseline (pre-capsaicin) measurement, HPT in both forearms, and 
rating to the long thermal stimulation (40˚C for 1 minute) was measured. Following this, 
hyperalgesia was produced on the non-dominant forearm of subject, referred to as capsaicin 
side,and dominant forearm, referred to as non-capsaicin side, by heating an area of 3×3 cm² to 
45ºC in the middle of the forearm for 5 minutes, followed by the application of a thick layer 
of capsaicin cream (0.075%) in the sensitised site for 30 minutes. Subjects were allowed to 
rest for 35 minutes following the removal of the capsaicin cream. The sensitised area was then 
rekindled with heat stimulation at 40˚C for 5 minutes. Subjects was asked to rate the 
stimulation every 10 seconds during the first minute. The area of the secondary hyperalgesia 
was measured with a von Frey filament immediately after the rekindling and the previous 
measurements at baseline (pre-capsaicin) were repeated. Subjects were then randomly 
allocated to receive a 25-minute intervention of either REA or SEA delivered by an 
acupuncturist who was blinded to the group allocation.  Forty minutes after the first 
rekindling, the second rekindling was given and the same measurements were taken. The third 
rekindling was given 40 minutes after the second rekindling, and no measurements were taken 
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after this rekindling. The last rekindling was given 40 minutes after the third one, and the 
previous measurements (area of hyperalgesia, HPT) were repeated. The whole session took 
about four and half hours. 
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Table 5. 1 Procedure and time points of the experiment 
 
Time point Procedure 
-30 min Explain the procedure to the subjects; subjects completed the forms 
and tasks to familiarize themselves with the tests.  
-15 min Locate and mark the heat/capsaicin site 
Baseline (pre-capsaicin) measurement 
Measure Heat Pain Threshold (HPT) on the non-capsaicin side 
Measure HPT on the capsaicin side -10 min 
Subjects rate the long thermal stimulation (40˚C, 1 min) applied to the 
capsaicin side using VAS. 
0 min Apply thermal stimulation (45˚C) on the capsaicin side for 5 min to 
sensitised the skin 
5 min Application of topical capsaicin cream for 30 min 
35 min Remove capsaicin cream 
35-70 min Rest 1 
70-75 min Rekindle (rekindling 1) the sensitised area (40˚C for 5 min), and 
subjects rate the first minute using VAS 
Measurement 1 (rekindling 1) 
Measure Area of the secondary hyperalgesia 
Measure HPT on the non-capsaicin side 
Measure HPT on the capsaicin side 
Intervention 
75-120 min 
Real or sham EA 
120-125 min Rekindle (rekindling 2) the sensitised area (40˚C for 5 min) 
Measurement 2 (rekindling 2) 
Area of the secondary hyperalgesia 
Measure HPT on the non-capsaicin side 
Measure HPT on the capsaicin side 
125-165 min 
Rest 2 
165-170 min Rekindle (rekindling 3) the sensitized area (40˚C for 5 min) 
170-210 min Rest 3 
210-215 min Rekindle (rekindling 4) the sensitised area (40˚C for 5 min), and 
subjects rated the first minute of the stimulation using VAS 
Measurement 3 (rekindling 4) 
Area of the secondary hyperalgesia 
Measure HPT on the non-capsaicin side 
215-230 min 
Measure HPT on the capsaicin side 
230 min Subjects completed Acupuncture treatment questionnaire.  
 
Please refer to methodology chapter 3 for a detailed description of subject screening, 
producing of the heat/capsaicin model, outcome measurements, and statistical method.  
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5.4 Results 
 
5.4.1 General information on the subjects 
 
The experiment was conducted from April to July in 2008. A total 20 subjects were recruited 
according to the inclusion and exclusion criteria. All 20 subjects completed the experiment, 
and no serious side effects were reported. 
 
Of the 20 subjects, 12 were male, and 8 were female. The average age was 24.90 ± 4.12 
(Mean ± SD), ranging from 18 to 32. One subject was left handed, the rest were right handed. 
Table 5.2 shows the demographic data of the subjects. No significant difference in age, gender 
or hand dominance were found between the two groups. 
 
Table 5. 2 Demographic data of subjects 
 
 EA (n=10) SEA (n=10) Statistical tests p-value  
Age (Mean ± 
SD) 
23.20 ± 4.02 26.60 ± 3.63 t-value = 1.985 0.063* 
Gender (Male : 
Female) 
6 : 4 6 : 4 χ² (df=1) > 0.000 ª 1.000* 
Hand 
dominance 
(Right : Left) 
10 : 0 9 : 1 χ² (df=1) = 1.053 b 0.305* 
χ²: chi-square value 
ª 2 cells (50.0%) have expected count less than 5. The minimum expected count is 4.00 
b
 2 cells (50.0%) have expected count less than 5. The minimum expected count is 0.50  
* The significance level for the above chi-square calculations was at p < 0.05 
 
5.4.2 Heat/capsaicin sensitisation 
 
All subjects developed mechanical and thermal hyperalgesia, following heat/capsaicin 
sensitisation (Table 5.3). The area of secondary hyperalgesia was 57.29 ± 19.24 cm² in the 
REA group and 57.96 ± 21.00 cm² in the SEA group.  
 
The first VAS rating (at the 5th second) increased from 2.00 ± 1.83 to 6.34 ± 1.22 in the SEA 
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group and from 2.29 ± 2.02 to 6.47 ± 1.95 in the REA group. However, rating to heat 
stimulation reduced progressively over the next 55 seconds (Figure 5.1). There was a 
significant change within the 1-minute measurement (time effect: F (5, 14) = 2.284, p = 0.01). 
For this reason, only the rating to the first 5 seconds was used for future analysis.  
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Figure 5. 1 VAS rating to long thermal stimulation in rekindling 1 in REA and SEA group 
Data are expressed as mean ± S.E.M 
VAS 1 = rating at the 5th second, VAS 2 = rating at the 15th second, VAS 3 = 
rating at the 25th second, VAS 4 = rating at the 35th second, VAS 5 = rating at 
the 45th second, VAS 6 = rating at the 55th second 
 
HPT was also slightly reduced from 41.96 ± 3.30 to 41.53 ± 1.97 in the SEA group (t = 0.553, 
p = 0.593) and from 42.84 ± 3.23 to 42.54 ± 2.08 in REA group (t = 0.451, p = 0.663) on the 
capsaicin side. One the non-capsaicin side, HPT changed from 43.90 ± 3.26 to 43.30 ± 2.65 in 
the SEA group (t = 0.991, p = 0.348), and from 44.25 ± 3.29 to 43.72 ± 2.66 in the REA 
group (t = 0.782, p =0. 454). However, there was no time effect for these changes.  
  
5.4.3 Comparison of pre-treatment data between groups 
 
As shown in Table 5.3, there was no significant difference between two groups in pre-
capsaicin and rekindling in 1 stage, in terms of HPT, VAS rating to long thermal stimulation 
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and the area of secondary hyperalgesia. 
 
Table 5. 3 A comparison of the baseline (pre-capsaicin) and pre-acupuncture (Rekindling 
1) values of all measurements between REA and SEA group 
 
Stage Measurement (Mean ± SD) n df t-value p-value 
SEA: 44.25±3.29 10 HPT non-capsaicin 
side  REA: 43.90±3.26 10 18 -0.239 0.814 
SEA: 41.96±3.29 10 
pre-capsaicin 
 HPT capsaicin side  
REA: 42.84±3.23 10 18 -0.603 0.554 
SEA: 43.30±2.65 10 HPT non-capsaicin 
side REA: 43.72±2.66 10 18 -0.353 0.728 
SEA: 41.53±1.97 10 
rekindling 1 
 HPT capsaicin side 
REA: 42.54±2.08 10 18 -1.114 0.280 
SEA: 2.00±1.83 10 VAS 1  
REA: 2.29±2.02 10 18 -0.336 0.740 
SEA: 1.90±1.70 10 VAS 2  
REA: 2.37±2.12 10 18 -0.547 0.591 
SEA: 1.82±1.57 10 VAS 3  
REA: 2.38±2.16 10 
18 
-0.664 0.515 
SEA: 1.97±1.68 10 VAS 4  
REA: 2.04±1.71 10 18 -0.092 0.927 
SEA: 2.11±1.84 10 VAS 5 
REA: 2.07±1.90 10 18 0.048 0.962 
SEA: 2.12±1.80 10 
pre-capsaicin 
VAS 6  
REA: 1.99±1.99 10 
18 0.153 
 
0.880 
 
SEA: 6.34±1.21 10 VAS 1  
REA: 6.47±1.95 10 18 -0.179 0.860 
SEA: 5.83±1.24 10 VAS 2  
REA: 5.84±1.45 10 
18 
-0.017 0.987 
SEA: 5.90±1.11 10 VAS 3  
REA: 5.60±1.87 10 
18 0.435 0.668 
SEA: 5.76±1.25 10 VAS 4  
REA: 5.19±2.72 10 
18 0.602 
 
 0.555 
SEA: 5.43±1.02 10 VAS 5 
REA: 5.12±2.88 10 
18 0.321 0.752 
SEA: 5.47±1.34 10 VAS 6  
REA: 4.82±2.92 10 
18 0.639 0.531 
SEA:57.96±21.00 10 
Rekindling 1 
Area of mechanical 
hyperalgesia 
 
REA:57.29±19.24 10 
18 0.074 
 
0.942 
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5.4.4 The effect of EA on the area of secondary hyperalgesia 
 
Table 5.4 shows data corresponding to the area of secondary hyperalgesia at each point of 
measurement. The pre-treatment area of hyperalgesia was 57.96 ± 21.00 cm² in the SEA 
group, and 57.29 ± 19.24 cm² in REA group. Ninety minutes post intervention, the area 
decreased significantly by 30% in REA group and 24% in the SEA group (Figure 5.2). Two-
way ANOVA shows there was a statistical significant time effect (F (2, 36) = 10.209, p < 
0.001) but no treatment group by time interaction (F (2, 36) = 2.146, p = 0.988), indicating 
both REA and SEA reduced the area of secondary hyperalgesia in a similar manner. 
 
Table 5. 4 Area of secondary hyperalgesia at each point of measurement 
 
Group n Stage Area of secondary hyperalgesia (Mean ± 
SD) 
Rekindling 1  57.96 ± 21.00 
Rekindling 2 
 
49.24 ± 16.05 Sham EA 10 
Rekindling 4 
 
39.07 ± 14.06 
Rekindling 1 57.29 ± 19.24 
Rekindling 2 47.26 ± 24.69 EA 10 
Rekindling 4 37.72 ± 18.65 
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Figure 5. 2 Effect of REA and SEA on the area of secondary hyperalgesia immediately
  (rekindling 2) and 90 minutes (rekindling 4) after intervention. 
Data are expressed as mean ± S.E.M 
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5.4.5 The effect of EA on the heat pain threshold 
 
Table 5.5 shows the effect of acupuncture on heat pain threshold in both REA and SEA 
groups. HPT increased to or above the baseline (pre-capsaicin) values in both groups after the 
intervention (rekindling 2). After rekindling 4, there was a reduction in the HPT in SEA group, 
while the HPT in REA group remained relatively unchanged.  A two-way ANOVA showed 
that after rekindling 1, there was a statistically significant time effect (F (2, 36) = 4.342, p = 
0.02) but no significant group by time interaction (F (2, 36) = 2.569, p = 0.091), indicating the 
changes in HPT changed in both REA and SEA were similar (Figure 5.3).  
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Table 5. 5 HPT during baseline (pre-capsaicin) and each rekindling 
 
Group n Stage  HPT (Mean ± SD) 
Pre-capsaicin 41.96 ± 3.30 
Rekindling 1 41.53 ± 1.97 
Rekindling 2 42.50 ± 2.30 
SEA 10 
Rekindling 4 41.18 ± 2.50 
Pre-capsaicin 42.84 ± 3.23 
Rekindling 1 42.54 ± 2.08 
Rekindling 2 42.93 ± 1.35 
REA 10 
Rekindling 4 42.84 ± 1.72 
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Figure 5. 3 Effect of REA and SEA on the heat pain threshold on capsaicin side 
Data are expressed as mean ± S.E.M  
 
On the non-capsaicin side, two-way ANOVA showed, after rekindling 1, there was no 
statistically significant time effect (F (2, 36) = 1.308, p = 0.283) and group by time interaction 
(F (2, 36) = 0.339, p = 0.715), indicating HPT in both REA and SEA on non-capsaicin side 
remained stable (Figure 5.4). 
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Figure 5. 4 Heat pain thresholds on non-capsaicin side 
Data are expressed as mean ± S.E.M  
 
5.4.6 The effect of EA on the pain rating to long thermal 
stimulation 
 
Figure 5.5 shows the effect of acupuncture on the first pain rating assessed at the 5th second of 
the 1 minute thermal stimulation. The pain at this point was the strongest during the one 
minute test; the sensation would gradually decrease due to adaptation. Compared to the 
baseline (pre-capsaicin), pain rating increased significantly (p < 0.01) after the heat/capsaicin 
sensitisation. 
 
After rekindling 1, two-way ANOVA showed there was a statistically significant time effect (F 
(2, 36) = 26.994, p < 0.001) but no significant treatment group by time interaction (F (2, 36) = 
2.256, p = 0.119), indicating both REA and SEA significantly reduced the VAS rating to long 
thermal stimulation in a similar manner. 
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Figure 5. 5 Effect of acupuncture on pain rating to long thermal stimulation. 
Data are expressed as mean ± S.E.M  
 
Table 5. 6 First pain rating (at the 5th second) during baseline (pre-capsaicin) and each 
rekindling 
 
Group n Measurement Stage VAS rating (Mean ± SD) 
Pre-capsaicin 2.00 ±1.83 
Rekindling 1 6.34 ± 1.22 
Rekindling 2 4.20 ± 2.10 
SEA 10 VAS1 
Rekindling 4 5.48 ± 1.17 
Pre-capsaicin 2.29 ± 2.02 
Rekindling 1 6.47 ± 1.95 
Rekindling 2 2.75 ± 1.65 
REA 10 VAS1 
Rekindling 4 4.29 ± 2.59 
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5.4.7 Credibility of sham acupuncture  
 
At the end of the experiment, a questionnaire was used to assess the credibility of sham 
acupuncture. All 20 subjects completed this questionnaire (appendix 12). There was no 
difference between the REA and SEA groups on the subject guessing which group they were 
assigned to, indicating the blinding procedure was successful (Table 5.7). 
 
Table 5. 7 Subject’s perception of treatment 
 
Subject’s answer Frequency of answer in each group (number) Statistical test 
 REA (n) SEA (n) χ² (dƒ) p-value** 
I had Real 
acupuncture  
7 5 
I had placebo/sham 
acupuncture 
1 2 
Don’t know 2 3 
0.867* (2) 0.648 
* 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.5. 
** Significance for the above chi-square calculations at p<0.05. 
dƒ: degrees of freedom. 
χ²: chi-square value 
 
5.4.8 Perception of acupuncture stimulation and side effects 
 
At the end of the experiment, a questionnaire (Appendix 12) was used to assess subjects’ 
perception of acupuncture stimulation (Table 5.8). Four choices were given: no pain, slight 
pain, moderate pain and severe pain.  
 
None of the subjects reported experiencing severe pain during the intervention. The majority 
of REA groups (70%) reported slight pain compared to only 30% in the SEA groups. While 
60% of SEA groups considered the intervention to be painless, only one subject (10%) in the 
REA group rated it so. Moderate pain was experienced by 20% of subjects in the REA group 
and 10% in the SEA group. Although there was a trend to show group difference in the 
perception of acupuncture stimulation, it was not significant (p = 0.064).  
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None of the subjects reported any side effects such as nausea or dizziness during or after the 
procedure. 
 
 
Table 5. 8 Rating to acupuncture stimulation 
 
 Rating to acupuncture stimulation   
 No pain; n (%) Slight/mild 
pain; n (%) 
Moderate 
pain; n (%) 
Severe pain; 
n (%) χ² (dƒ) p-value** 
EA (n=10, 
100%) 
1(10%) 7(70%) 2(20%) 0 
Sham EA 
(n=10, 
100%) 
6(60%) 3(30%) 1(10%) 0 
5.505* 
(2) 
0.064 
* 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.5 
** Significance for the above chi-square calculations at p<0.05. 
dƒ: degrees of freedom 
χ²: chi-square value 
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5.4.9 Post-hoc power analysis and sample size calculations 
 
The current study was underpowered. Table 5.9 shows the effective power of the statistical 
tests with the existing sample size and required sample size for 80% power for comparison of 
REA and SEA.  
Table 5. 9 Post-hoc power analyses and required sample size for comparison of REA and 
SEA 
 
Measureme
nts 
SEA 
(Mean ± SD) 
REA 
(Mean ± SD) 
Effect 
size Power 
Sample size per group 
to achieve  80% 
power  
VAS rating 
(first 5th 
second) 
4.20 ± 2.10 2.75 ± 1.65 0.177 37% 28 
HPT 42.50 ± 2.30 42.93 ± 1.35 0.23 8% 303 
Area of 
secondary 
hyperalgesia 
39.07 ± 14.06 37.72 ± 18.65 0.08 0.05% 2351 
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5.5 Summary 
 
In this experiment, capsaicin combined with repeated heat stimulation successfully produced 
mechanical and heat hyperalgesia state in both REA and SEA groups. The area of secondary 
hyperalgesia, HPT, and VAS rating before acupuncture was comparable between the two 
groups. Thus, the randomisation procedure was successful.  
 
After REA or SEA intervention, area of secondary hyperalgesia was significantly reduced in 
both groups, however, no statistically significant difference was detected between them.  
There were some fluctuations in the HPT and rating to heat stimulation during the experiment, 
however no group difference was detected.  
 
In general, hyperalgesia was reduced in both REA and SEA groups to a similar degree.  
Potential factors underlying these findings are discussed in Chapter Six.  
  
144 
Chapter 6 Discussion and conclusion 
 
6.1 Summary of results 
  
The main purpose of the current project was to use a validated hyperalgesia model to assess 
the anti-hyperalgesia effect of acupuncture and compare it with a sham procedure. 
 
In the first part of the literature review, hyperalgesia was reviewed and two promising 
candidates of hyperalgesia model were identified, i.e., topical capsaicin model and 
heat/capsaicin model. In the second part, the review focused on the animal studies which 
assessed the anti-hyperalgesia effect of acupuncture. It is concluded that electroacupuncture 
reduces hyperalgesia in both inflammatory and neuropathic models. No human studies were 
identified. 
 
The literature review was followed by two experiments in healthy humans. In Experiment 1, 
we examined the reproducibility of the topical capsaicin model on 12 healthy subjects. This 
experiment is the first study examining its reproducibility of this model over a period of one 
month. It was found that in the same subject the between-day reproducibility of the area of 
secondary hyperalgesia and the mechanical pain threshold was poor, thus not appropriate for 
the evaluation of anti-hyperalgesia effect of acupuncture.  
 
Experiment 2 is the first human study to examine the anti-hyperalgesia effect of acupuncture. 
We used the heat/capsaicin model to compare the effect of REA with SEA. It was found that 
REA and SEA significantly reduced both the area of secondary punctate hyperalgesia and the 
VAS rating compared to thermal stimulation.  However, there was no statistically significant 
difference between the two groups.  
 
6.2 Strengths of the study 
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The entire project follows a logical design.  Firstly, the parameters of acupuncture used in 
animal research of hyperalgesia were identified. Then, the reproducibility of a hyperalgesia 
model was assessed. Finally, a validated model was used to evaluate the anti-hyperalgesia 
effect of acupuncture on humans.  
 
Both mechanical and thermal hyperalgesia were assessed with well-accepted methods. Where 
possible, each type of hyperalgesia was assessed with two methods of measurements. For 
instance, mechanical hyperalgesia was assessed with the area of mechanical hyperalgesia, 
mechanical pain threshold, and VAS rating to suprathreshold stimulation. All of these 
methods have been used in other hyperalgesia studies (Park, Max et al. 1995; Zheng, Gibson 
et al. 2000). For heat hyperalgesia, both HPT and rating to long thermal stimulation were 
adopted. These measures have been used to examine the anti-hyperalgesia effects of 
analgesics (Burns, Hill et al. 2006; Frymoyer, Rowbotham et al. 2007; Mattia and Coluzzi 
2007).  
 
To control the placebo effect, acupuncture naïve and pain free healthy subjects were recruited 
and randomly allocated to either the REA or SEA groups. We used a validated, non-invasive 
sham procedure that has been used in both animal (Lao, Zhang et al. 2004) and human (Feng 
2007) studies. This model successfully blinds subjects from the nature of the treatment they 
receive, as shown by the acupuncture credibility questionnaire.  
 
Acupuncture intervention was carried out by a registered acupuncturist, and the evaluator was 
blinded from treatment allocation. This blinding procedure ensures that the performance bias 
of both subjects and investigator was well-controlled. Before starting the experiment, subjects 
were also given an oral explanation and training session, so as to be familiar with the 
experimental procedure. 
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To minimise the impact of room temperature on pain perception (Pertovaara, Kauppila et al. 
1996), both experiments were conducted in a temperature-controlled room (20-22 degrees 
Celsius). 
 
6.3 Limitations 
 
The major limitation of this study is the relatively small sample size and a lack of a non-
treatment group. As this experiment is the first study assessing the anti-hyperalgesia effect of 
acupuncture in healthy human, it was difficult to determine the proper sample size. The 
calculation of the sample size in this study was based on the data reported in a previous drug 
study using the heat/capsaicin model (Petersen, Jones et al. 2001). According to the 
calculation, a total number of 58 subjects were needed with 29 subjects in each group. 
However, only 20 subjects with 10 in each group participated in the experiment.  
 
Several factors limited the recruitment of participants. Firstly, subjects were required to be 
acupuncture naïve. Secondly, subjects were required to remain in the lab for 4 to 5 hour 
duration. Thirdly, the experiment involved possible needling, thus the potential of induced 
pain.  It was understood that this aspect may have intimidated a group of people who were 
initially interested in participating in the study. Finally, the student conducting the research of 
this project was due to complete the thesis, thus there was insufficient time for further rounds 
of recruitment. As a result, the relatively small sample size limited the power of the statistical 
analysis.  
 
The small number of participants may have impacted on conclusions drawn regarding heat 
hyperalgesia, as the study had only one third of the required sample of 56 subjects, indicated 
by our post-hoc sample size calculation. However, it is understood that this should not impact 
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on the outcome of the area of mechanical hyperalgesia. The sample size required for detecting 
one eighth of a standard deviation difference with 80% power is 4702 in total.  
 
Although other researchers have shown that hyperalgesia is stable in the heat/capsaicin model, 
without a third non-treatment group in the current study, we cannot be sure that the area of 
mechanical hyperalgesia will not naturally reduce, as seen in Experiment 1. Furthermore we 
did not include a second measure of mechanical hyperalgesia in Experiment 2 making it even 
harder to know its resolution. 
 
In Experiment 1, we found that rating to suprathreshold mechanical stimulation was a reliable 
measurement. However, due to the time limit during Experiment 2, this outcome measure was 
not taken. In addition, the area of secondary hyperalgesia is the recommended method and has 
been successfully used in other studies for evaluation of the anti-hyperalgesia effect of various 
medications (refer to review chapter 2). Suprathreshold mechanical stimulation was not used 
in preliminary studies testing the heat/capsaicin model.(Petersen and Rowbotham 1999; Dirks, 
Petersen et al. 2003), however it does have an application to determine hyperalgesia and could 
be used in future studies. Results suggest that it may be important to include a 2nd measure of 
mechanical hyperalgesia.   
 
There is also a limitation in the HPT measurement due to the modified Method of Limits test 
having four measurements. This produced relatively less sensitive results when compared 
with an alternative test, Staircase tests.  However, the Limits test had also been used in other 
drug studies using the heat/capsaicin model (Petersen, Maloney et al. 2003; Burns, Hill et al. 
2006; Frymoyer, Rowbotham et al. 2007). Furthermore, due to the time limit between various 
measurements and rekindling of hyperalgesia, the Limits test (approximately 8 minutes) was 
the only choice we had within the given time for measurements (20 minutes) of the 
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heat/capsaicin model. Staircase tests require considerable time, approximately 20 minutes, to 
complete.  Thus, due to the time constraints, this test was not appropriate to be used in this 
model. 
 
6.4 Interpretation of the findings 
 
In the 32 animal studies reviewed, 32 studies employed the use of SEA and REA, however 
REA is found to be consistently better than SEA.  Furthermore, no universal optimum EA 
parameter was identified from the review. Two studies identified different optimum EA 
parameters using different animal models (Lao, Zhang et al. 2004; Taguchi and Taguchi 
2007). It is concluded that it may be likely that there is a set of optimum EA parameters for 
specific hyperalgesia model. 
 
In Lao’s study, an optimum parameter for EA stimulation, 10 Hz, 3 mA, 0.1 ms, 20 minutes, 
was found (Lao, Zhang et al. 2004). In the present study, we used a similar parameter in order 
to achieve optimum results. However, there were not any group differences to be observed.  
 
This result, though was not what we expect to find, was not surprising. In the clinical studies 
conducted, the effect of REA compared with SEA was also controversial. For instance, in one 
osteoarthritis study, both EA and manual acupuncture was significantly superior to non-
penetrating sham acupuncture in relieving osteoarthritic knee pain (Jubb, Tukmachi et al. 
2008). However, in a migraine study, sham acupuncture had a similar effect when compared 
with manual acupuncture (Alecrim-Andrade, Maciel-Junior et al. 2008). A review has shown 
that the evidence supporting acupuncture in treating chronic pain when compared with sham 
acupuncture is inconclusive (Itoh and Kitakoji 2007). It is also possible that the magnitude of 
hyperalgesia in the heat/capsaicin model was not strong enough to detect the difference 
between REA and SEA. The average VAS rating to thermal stimulation was approximate 6.5 
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immediately after the establishment of the model in both groups. This rating is a relatively 
low given in a modified 0-10 VAS scale 5 is defined as just painful and 10 as worst pain 
possible. Lastly, the EA parameter may also account for the insignificant result, as only low 
frequency were used. In the inflammatory animal model it was found that EA with high 
frequency (100 Hz) produces shorter lasting, within 1 day, but high potent anti-hyperalgesia 
effects, whilst low frequency, 10 Hz, showed prolonged anti-hyperalgesia effects, 
approximately 1 to 7 days, but less potent effect on PWL (Lao, Zhang et al. 2004). 
 
Experiment 2 found that HPT on the non-capsaicin side was not affected by either REA or 
SEA. This result is contradictory to Feng’s finding (Feng 2007) in which EA (2 /100 Hz 
alternating) significantly increased the pain threshold to single electrical stimulation mostly at 
the site of EA stimulation. This discrepancy may be due to the difference in the nature of 
stimulation (heat vs. electrical) or EA frequency. Furthermore, as previous evidence suggests, 
compared with non-invasive sham, EA with high frequency (120 Hz) significantly increases 
heat pain tolerance threshold (Berlin, Bartlett et al. 1975), whilst EA with low frequency (2.5 
Hz) does not significantly increase heat pain threshold or heat pain tolerance threshold 
(Stewart, Thomson et al. 1977).   
 
An additional explanation is the possible time effect.  In Feng’s study, the anti-temporal 
summation effect of EA became more evident post 24 hours.  The current model only lasted 
for 4 hours, thus does not allow sufficient time for assessment of the time profile of 
acupuncture.  
 
The results from experiment 2 are contradictory to the finding in the animal studies.  The 
animal studies demonstrated that acupuncture always outperformed sham acupuncture and 
furthermore, the non-invasive sham procedure consistently showed no anti-hyperalgesia effect. 
This discrepancy may be due to several factors. Firstly, the magnitude of hyperalgesia in 
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animal model is much higher compared with the human model. It is possible that at this level 
of severity, the sham procedure is unable to produce any significant non-specific effect. 
Secondly, the intensity of EA stimulation is stronger than that used in the human studies. It is 
clear from the animal studies that the higher the intensity, the stronger the effect of EA. 
Thirdly, level of expectancy may also play a significant role. There is evidence suggesting 
that expectancy contributes positively to the clinical outcome in patients with low back pain 
treated with acupuncture (Kalauokalani, Cherkin et al. 2001). It is unlikely that animals have 
any expectancy from the treatment, thus do not develop any expectancy-related placebo effect. 
However, the level of expectancy was not assessed in the current study.    
 
6.5 Implication for future study 
 
In future studies, the suitability of the heat/capsaicin mode requires to be adjusted for 
acupuncture studies. The time intervals between outcome measures, rekindling and 
acupuncture treatments may need to be re-arranged so that more measures can be included. 
Furthermore, a hyperalgesia model that lasts for more than 24 hours would be ideal, such as a 
burn injury (Pedersen 2000). 
 
The current study shows a trend that REA may be better than SEA in reducing VAS rating to 
sub-threshold thermal stimulation. The potential disparity in acupuncture effect on mechanical 
and heat hyperalgesia may have indicated it has a different impact on peripheral and central 
sensitisation. In future studies, EA’s effect on the response to sub-threshold and supra-
threshold thermal or mechanical stimulation should be tested. 
 
Further studies to determine a possible impact of different EA parameters could provide 
significant understanding to support clinical application of EA.  Such studies to establish the 
level of frequency on anti-hyperalgesic effect using alternating frequencies, such as 2/100 Hz, 
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could be useful, as this parameter has been shown to be effective in reducing temporal 
summation (Feng 2007).  Furthermore, subjects’ expectancy for acupuncture should also be 
assessed in healthy human studies to determine its impact.  
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Appendix 2 Advertisement for the experiment one 
 
 
School of Health Sciences 
The Chinese Medicine Research Group 
 
Make a contribution to acupuncture research 
Volunteer needed! 
 
Are you eligible for the research? 
 
If you are between 18-40 years old, healthy and do not have pain currently, we welcome you to this 
experiment.  
 
What is this research about? 
 
We want to find out whether electro-acupuncture can reduce tenderness, called hyperalgesia, a very 
important feature of chronic pain, in healthy humans. 
 
What will you be asked to do? 
 
We will place a patch saturated with chili pepper solution, called capsaicin, on one of your forearms 
for about 45 minutes. The application will induce mild to moderate hot or burning sensation, and 
induce temporary tenderness on your forearm. This sensation will peak within one hour of 
application, and gradually reduce to no pain within the next three to four hours.  
 
We then use nylon filaments to test your pain threshold and your rating to mechanical stimuli 
applied around the area of the capsaicin application. The stimulation from the nylon filaments may 
cause transient pain of a few seconds. You are required to evaluate the sensation produced by these 
mechanical stimuli, whether it is painful or not, and how strong it is. Then the tests will be repeated 
once in the following one hour. In one month, you will be asked to come back and the procedure 
will be repeated. 
 
How long does this experiment take? 
 
The whole experiment consists of two sessions with one month interval, and each takes about three 
hours. Totally, the experiment takes about six hours. 
 
Although your participation in the study might not benefit you directly, it will help us advance our 
knowledge of the mechanism of electro-acupuncture and lead us to better clinical applications for 
pain management. 
 
Will you get paid for taking part in the study?  
 
You will not get paid for taking part in the study. 
 
If you agree to take part in this experiment, please contact: 
 
Linghan Bai 
Day time: 9925 7176   
Mobile: 0409131670 (Telstra) 
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Email: s3148731@student.rmit.edu.au 
This project has been reviewed and approved by the Human Research Ethics 
Committee of RMIT University 
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Appendix 3 Advertisement for the experiment two 
 
 
School of Health Sciences 
The Chinese Medicine Research Group 
 
Make a contribution to acupuncture research 
Volunteer needed! 
 
Are you eligible for the research? 
 
If you are between 18-50 years old, pain free and have not had acupuncture in the past one year, we 
welcome you to this experiment.  
 
What is this research about? 
 
We want to find out whether electro-acupuncture can reduce tenderness, called hyperalgesia, a very 
important feature of chronic pain, in healthy humans. 
 
What will you be asked to do? 
 
We will apply a layer of capsaicin (chili pepper) cream and moderate heat stimulation to your non 
dominant forearm for 35 minutes in total. The application will induce mild to moderate hot or 
burning sensation and temporary tenderness on your forearm. This sensation will peak within one 
hour of application, and gradually reduce to no pain within the next three to four hours.  
 
We then use nylon filaments to test the tender area around the capsaicin site. The stimulation from 
the nylon filaments may cause transient pain for a few seconds. After this a heat stimulator will be 
attached to the sensitized skin, and you are required to evaluate whether the heat sensation produced 
is painful or not and rate it on a visual analogues scale. These tests will be also conducted on the 
untreated skin on the other arm. Then these tests will be repeated after reheating the same site.   
 
According to your group assignment, you might receive either real or fake electro-acupuncture 
stimulation for half an hour after the removal of the capsaicin patch. You may experience pricking 
sensation caused by needle insertion. The sensations of numbness or heaviness may also be 
perceived at the acupuncture sites.  
 
How long does this experiment take? 
 
The whole experiment takes about 4 hours. 
 
Will you get paid for taking part in the study?  
 
You will not get paid for taking part in the study. 
 
Although your participation in the study might not benefit you directly, it will help us advance our 
knowledge of the mechanism of electro-acupuncture and lead us to better clinical applications for 
pain management. 
 
If you would like to take part in this experiment, please contact: 
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Linghan Bai 
Day time: 9925 7176   
Mobile: 0409131670 (Telstra) 
Email: s3148731@student.rmit.edu.au 
 
This project has been reviewed and approved by the Human Research Ethics Committee of 
RMIT University 
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Appendix 4 Plain language statement for experiment one 
 
 
School of Health Sciences 
The Chinese Medicine Research Group 
 
Plain Language Statement 
Information about the pilot study of capsaicin-induced hyperalgesia model 
PROJECT TITLE: The effect of electro-acupuncture on capsaicin-induced hyperalgesia 
in healthy volunteers: a randomised and sham acupuncture controlled study 
INVESTIGATOR: Linghan Bai, Masters Candidate 
 
Dear Volunteer, 
 
I am Linghan Bai, a master’s student at the division of Chinese Medicine Research Group, 
RMIT University. My current project is under the supervision of Dr. Zhen Zheng and Prof. 
Charlie Xue, A/Prof Chunguang Li (RMIT, Chinese Medicine Research Group). In this pilot 
study, I will use capsaicin, chili pepper solution, to produce a pain model in healthy humans to 
test the reproducibility of the capsaicin-induced tenderness, i.e. hyperalgesia. This is to provide 
you with relevant information about my study. 
 
1. Purpose of this study 
 
This is the first step of a bigger study, and aims to test the reproducibility of capsaicin-induced 
hyperalgesia. Will capsaicin produce the same level of hyperalgesia in the same subject after a 
period of one month? We will find it out after this study.  
 
2. What will you be asked to do during this study? 
 
If you agree to participate in the experiment, which consists of two sessions with one month interval, 
and each session takes about three hours. You will go though the following procedure in each 
session: 
1) Complete the questionnaire about your current health condition (only in the 1st session);  
2) Take part in the pre-capsaicin test.  We will use nylon filaments to test your pain threshold 
and your rating to mechanical stimulation. You will be asked to evaluate the sensation 
produced by these mechanical stimuli, and report whether the sensation painful or not, and 
how strong it is.  
3) Receive capsaicin treatment. We will put a piece of fillet paper absorbed with chili pepper 
solution, called capsaicin, on one of your forearms for 45 minutes;  
4) Take part in the 1st post-capsaicin test.  At the end of the 45 minutes, the filter paper will be 
removed, we will then repeat step 2 to test your sensitivity to mechanical stimulation. At this 
stage, your skin will become tender and sensitive to mechanical stimulation, which indicates 
the status of hyperalgesia.   
5) Take part in the 2nd post-capsaicin test. One hour after step 4, step 2 will be repeated again. 
Your sensitivity to mechanical stimulation may or may not change at this stage.  
 
3. What kind of pain you will experience? 
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In this pilot study, you might experience two types of pain: burning pain induced by capsaicin, 
evoked pain when testing hyperalgesia. 
 
In this study the majority of the painful sensation is caused by the topical application of capsaicin. 
This chemical compound will be dissolved and absorbed into a small patch of filter paper. And then 
this capsaicin patch will be applied onto the forearm. Within the area of the patch, you will feel a 
kind of mild burning sensation that peaks at about 20 to 40 minutes after the application and slowly 
diminishes after about one hour. Around the patch there will be an area of tenderness, which will 
disappear in 24 hours.  
 
During the test, we will use some mechanical device called von Frey filaments to elicit slightly 
painful pinprick sensation in order to determine the boundary of the tender area and the pain 
thresholds. All the induced painful sensations are temporary, mild to moderate in intensity, lasting 
up to 10 seconds, and will not cause any injury to the skin. 
 
4. Safety issue and potential discomfort of capsaicin 
 
Capsaicin is natural, processed vegetable matter that has been part of the human diet for many years. 
It is unlikely that it will pose a significant threat to human health. Excessive exposure to capsaicin 
may cause some slight eye and skin irritation. However in this experiment, only a tiny dose (0.1 ml) 
of capsaicin solution will be applied topically on the skin of one of the forearm. It will produce some 
minor burning sensation and hyper sensitivity within and around the area of application as required 
by the experiment. The tenderness will gradually wane and disappear within 24 hours. The 
sensitivity of the capsaicin treated site will return to the normal status after 24 hours. However the 
site might become less responsive to capsaicin than untreated area, and this de-sensitisation will 
resolve completely within one month. 
 
If you are allergic to chili, you should not take part in this study. 
 
5. Discontinuation and termination of your participation 
 
Your participation in this study is voluntary. You are free to withdraw from the study at any 
stage of the study. 
 
6. Confidentiality of information you provide 
 
All information provided by you and data collected through this study will be stored in a password 
protected computer program. Authorized auditors may inspect your records. You will have access to 
your records through the investigator. The result of this project might be published. Only group data 
or coded data will appear in any publication and all personal details and identifiable information will 
not be published. A summary of the results will be sent to you upon the completion of the study. 
 
7. Benefit of your participation 
 
Hyperalgesia is an important feature underlying clinical pain. Your participation will benefit 
human pain studies and improve our understanding of analgesic effect of acupuncture in treating 
clinic pain. There is no direct benefit to you. 
 
8. Your participation in other research projects 
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If you are participating in other research projects at the same time, please let us know before the 
commencement of acupuncture treatment. 
 
 
This project has been reviewed and approved by the Human Research Ethics Committee of 
RMIT University. 
 
If you have any questions about the experiment, please contact me (Tel: 9925 7176, E-mail: 
s3148731@student.rmit.edu.au) or my supervisor Dr. Zhen Zheng (Tel: 9925 7167) 
 
For any complain about this experiment please contact the HREC committee (Tel: 9925 1745, 
GPO Box 2476V, Melbourne, 3001) 
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Appendix 5 Plain language statement for experiment two 
 
 
 
School of Health Sciences 
The Chinese Medicine Research Group 
 
Plain Language Statement 
 
Information about acupuncture and pain study 
 
PROJECT TITLE: The effect of electro-acupuncture on hyperalgesia associated with 
heat/capsaicin model in healthy volunteers: a randomised sham acupuncture controlled study 
 
INVESTIGATOR: Linghan Bai, Masters Candidate 
 
Dear Volunteer, 
 
I am Linghan Bai, a master’s student at the Division of Chinese Medicine Research Group, 
RMIT University. My current project is under the supervision of Dr. Zhen Zheng and Prof. 
Charlie Xue, and A/Prof Chunguang Li (RMIT, Chinese Medicine Research Group). In this 
research, I will use capsaicin (chili pepper solution) combined with moderate heat stimulation to 
produce a pain model in healthy humans and then test the effect of electro-acupuncture on this 
model. This is to provide you with relevant information about my study. 
 
1. Purpose of this study 
 
This study aims to test the effect of electro-acupuncture on the tenderness, called hyperalgesia, 
induced by capsaicin and heat. Will electro-acupuncture reduce or enhance hyperalgesia or simply 
has no effect on it? We will find it out after this research. The outcome will further our 
understanding of the anti-pain mechanism of acupuncture; therefore improve our clinic practice of 
acupuncture. 
 
2. What will you be asked to do during this study? 
 
If you agree to participate in the experiment, which takes about 4 hours, you will go though the 
following procedure.  
1) Complete the questionnaire about your current health condition and sign the consent form;  
2) Take part in the baseline test.  We will use a computer-controlled device to test your heat pain 
threshold. A short-lasting, mild heat stimulation will be applied to both of your forearms and you 
will be asked to evaluate whether the sensation is painful or not by using a mouse.  
3) Then you will receive heat and capsaicin treatment. We will attach the same computer-controlled 
device to the middle of your non dominant forearm to deliver mild heat stimulation and then 
apply a layer of capsaicin cream on the heated area for 30 minutes.  
4) After removal of the capsaicin cream, you will be asked to rest quietly in the lab for 35 minutes.  
5) We will test your pain sensitivity again. We will put the same computer-controlled device to the 
same area to deliver mild heat stimulation for 5 minutes. We then use a nylon hair to test the area 
of the sensitized skin. After this, the previous test in step 2 will be repeated. 
6) At this stage you will receive electro-acupuncture treatment for 30 minutes while you rest on a 
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bed. 
7) Repeat step 5 twice.   
 
3. What kind of pain you will experience? 
 
In this study, you might experience three types of pain: mild burning pain induced by capsaicin, 
evoked pain when testing hyperalgesia, and pain on acupuncture. 
 
In this study the majority of the painful sensation is caused by the topical application of capsaicin 
and heat stimulation. Capsaicin cream will be applied onto the forearm. Within the application area, 
you will feel a kind of mild burning sensation that peaks at about 20 to 40 minutes after the 
application and slowly diminishes after one hour. Around the patch there will be an area of 
tenderness, which will disappear in 24 hours. The heat stimulation causes mild to moderate pain at 
45oC, and mild pain at 40oC.  
 
In the experiment, we will use a mechanical device called von Frey filaments to elicit slightly 
painful pinprick sensation in order to determine the boundary of the tender area. All the induced 
painful sensations are temporary, mild to moderate in intensity, lasting up to 10 seconds, and will 
not cause any injury to the skin. 
 
During acupuncture, needles will be inserted into eight acupuncture points on your arms and legs. 
You might experience minor transient sharp sensation caused by the penetration. During the 
treatment, you might also feel mild soreness, vibration, numbness or distention at the needle sites. 
These sensations will disappear once the needles are withdrawn.  
 
4. The real or placebo treatment 
 
It is necessary to have an inactive treatment group who will receive fake acupuncture, so that the 
true effect of electro-acupuncture treatment can be demonstrated. Fake electro-acupuncture is a 
form of placebo treatment with minimal effect on your body. It is used to show whether real 
treatment has a true effect. Once you have met the inclusion and exclusion criteria, you will be 
allocated randomly into one of the two groups (using real or sham acupuncture). Please note that 
you will have a 50% chance of being placed in an inactive treatment group. 
 
In real electro-acupuncture (REA) treatment groups, very fine needles will be inserted into your 
skin, and electrical current will be delivered to the needles in REA group. 
 
5. Safety issue and potential discomfort of capsaicin 
 
Capsaicin is natural, processed vegetable matter that has been part of the human diet for many years. 
It is unlikely that it will pose a significant threat to human health. Excessive exposure to capsaicin 
may cause some slight eye and skin irritation. However in this experiment, only a small dose of 
capsaicin cream (0.075%) will be applied topically on the skin of one of the forearm. It will produce 
some minor burning sensation and hypersensitivity within and around the area of application as 
required by the experiment. The tenderness will gradually wane and disappear within 24 hours. The 
sensitivity of the capsaicin treated site will return to the normal status after 24 hours. However the 
site might become less responsive to capsaicin than untreated area, and this de-sensitisation will 
resolve completely within one month. 
 
If you are allergic to chili, you should let the researcher know and should not take part in this study. 
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6. Safety issue and potential discomfort of electro-acupuncture 
 
Acupuncture procedure is widely used in everyday practice with an excellent safety profile. 
Only disposable needles will be used and they are much thinner than needles used for injections. 
Acupuncture has been reported to be associated, in a very few cases, with minor risks, such as 
fainting, infection, and hematoma. Needles may puncture small blood vessels during the 
procedures. Precautions will be taken to avoid inserting needles too deeply or into nerves or 
arteries. There is no evidence that acupuncture treatment may result in psychological damage. 
 
The electrical acupuncture stimulation machine to be used in this study has been approval by the 
Therapeutic Goods Administration of Australia. 
 
Some people may experience minor pricking sensations during the early phase of acupuncture. 
This normally subsides after a few seconds. The sensation of soreness, numbness or distension 
may be perceived at the acupuncture sites. 
 
7. Discontinuation and termination of your participation 
 
Your participation in this study is voluntary. You are free to withdraw from the study at any 
stage. 
 
8. Confidentiality of information you provide 
 
All information provided by you and data collected through this study will be stored in a password 
protected computer program. Authorized auditors may inspect your records. You will have access to 
your records through the investigator. The result of this project might be published. Only group data 
or coded data will appear in any publication and all personal details and identifiable information will 
not be published. A summary of the results will be sent to you upon the completion of the study. 
 
10. Your participation in other research projects 
 
Hyperalgesia is an important feature underlying clinical pain. Your participation will benefit human 
pain studies and improve our understanding of analgesic effect of acupuncture in treating clinic pain. 
There is no direct benefit to you. 
 
If you are participating in other research projects at the same time, please let us know before the 
commencement of this study. 
 
This project has been reviewed and approved by the Human Research Ethics Committee of 
RMIT University. 
 
If you have any questions about the experiment, please contact Linghan Bai (Tel: 9925 7176, E-
mail: s3148731@student.rmit.edu.au) or my supervisor Dr. Zhen Zheng (Tel: 9925 7167) 
 
For any complain about this experiment please contact the HREC committee (Tel: 9925 1745, 
GPO Box 2476V, Melbourne, 3001) 
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Appendix 6 General Information and Screening Questionnaire 
General information and questionnaire 
General Information 
 
Name: Gender:   Male      /    Female  
Date of birth (d/m/y):       /         /   
Address:                                                               Postcode:  
Contact No.:  
 
Screening Questionnaire 
 
1.  Did you receive any acupuncture treatment in the last one year?  Yes  / No  
 
2.  Are you allergic to chili?  Yes  / No  
 
3.  Are you currently taking any following medication at moment? 
 
Analgesics (Medication for relieving pain) Yes  / No  
Anti-inflammatory agents (Medication for reducing 
inflammation)   
Yes  / No  
Anti-anxiety agents (Medication for reducing anxiety)    Yes  / No  
Anti-depressants (Medication for reducing depression) Yes  / No  
Anti-psychotic agents (Medication for psychosis) Yes  / No  
 
4.  Do you have any history of the following conditions? 
 
Stoke Yes  / No  
Epilepsy   Yes  / No  
Diabetes Yes  / No  
Severe Alcoholism Yes  / No  
Peripheral Vascular Disease Yes  / No  
Peripheral Neuropathy Yes  / No  
Psychosis Yes  / No  
Heart disease Yes  / No  
Impaired circulation in hands or feet Yes  / No  
Wearing a cardiac pacemaker Yes  / No  
Pregnancy Yes  / No  
Have metal implant Yes  / No  
 
5.  Do you suffer from any chronic pain conditions?  Yes  / No  
 
Location Head  / Neck  / Back  / Arm: L  R  / Leg: L  R  
Duration Continuous     /    Intermittent  
Degree Weak  / Mild  / Moderate  / Strong  / Severe  
 
6.  Are you having any pain at moment?  Yes  / No  
 
Location Head  / Neck  / Back  / Arm: L  R  / Leg: L  R  
Degree Weak  / Mild  / Moderate  / Strong  / Severe  
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Appendix 7 Consent form 
Prescribed Consent Form For Persons Participating In Research Projects Involving Tests and/or Medical 
Procedures 
 
PORTFOLIO OF Science, Engineering and Technology 
SCHOOL OF Health Sciences 
Name of participant: 
 
Project Title: The effect of electro-acupuncture on hyperalgesia associated 
with the heat/capsaicin model in healthy volunteers: a 
randomised sham acupuncture controlled study 
 
 
Name(s) of investigators:    (1) Linghan Bai Phone: 9925 7176 
(2) Dr. Zhen Zheng Phone: 9925 7167 
(3) Prof. Charlie Xue Phone: 9925 7745 
(4) A/Prof. Chunguang Li Phone: 9925 7635 
(5) Meredith O’Loughlan Phone: 9925 7176 
2. I have received a statement explaining the tests/procedures involved in this project. 
 
3. I consent to participate in the above project, the particulars of which - including details of tests or procedures - have 
been explained to me. 
 
4. I authorise the investigator or his or her assistant to use with me the tests or procedures referred to in 1 above. 
 
5. I acknowledge that: 
 
(a) The possible effects of the tests or procedures have been explained to me to my satisfaction. 
(b) I have been informed that I am free to withdraw from the project at any time and to withdraw any 
unprocessed data previously supplied (unless follow-up is needed for safety). 
(c) The project is for the purpose of research and/or teaching.  It may not be of direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded and only disclosed where I have 
consented to the disclosure or as required by law.  
(e) The security of the research data is assured during and after completion of the study.  The data collected 
during the study may be published, and a report of the project outcomes will be provided to me. Any 
information which will identify me will not be used. 
 
 
Participant’s Consent 
 
 
Name: 
 
Date: 
 
(Participant) 
 
 
Name: 
 
Date: 
 
(Witness to signature) 
 
Where participant is under 18 years of age: 
 
I consent to the participation of ____________________________________ in the above 
project. 
 
Signature: (1)                                             (2) Date: 
 
(Signatures of parents or guardians) 
 
Name: 
 
Date: 
 
(Witness to signature) 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 Any complaints about your participation in this project may be directed to the Secretary, RMIT Human Research Ethics Committee, University 
Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 1745.   
Details of the complaints procedure are available from the above address. 
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Appendix 8 Pain threshold recording sheet 
 
Pain Threshold 
 
 
Name:                   Group:                      Date: 
 
 
Dominant arm 
(        ) 
Non-dominant arm (Capsaicin) 
(        ) 
 
Baseline Post-cap 1 Post-cap 2 Baseline Post-cap 1 Post-cap 2 
PT       
PT(1st HA)       
PT(2nd 
HA) 
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Appendix 9 Instructions for testing skin hypersensitivity 
 
Instructions for testing skin hypersensitivity 
 
 
Hypersensitivity to mechanical stimulation—definite stronger sensation 
 
Mechanical stimulation will be delivered with a nylon filament. When the 
stimulus is moved towards the chili pepper site your response to the 
stimulation might be changed and you might feel a definite increase in its 
intensity. Please indicate this point as soon as you feel it. 
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Appendix 10 VAS for mechanical stimulation 
 
VAS  
        Name:                  Group:              Date:               Stage: 
 
 
        
No sensation                 Just painful                 Worst pain possible 
 
 
 
       
 No sensation                 Just painful                 Worst pain possible 
 
 
 
      
 
    No sensation                 Just painful                 Worst pain possible 
 
 
 
  
      No sensation                 Just painful                 Worst pain possible 
 
 
 
 
        
  No sensation                 Just painful                 Worst pain possible 
 
 
 
       
 No sensation                 Just painful                 Worst pain possible 
 
 
 
        
 
No sensation                 Just painful                 Worst pain possible 
 
 
 
        
No sensation                 Just painful                 Worst pain possible 
 
 
 
        
No sensation                 Just painful                 Worst pain possible 
 
 
 
       
 
 No sensation                 Just painful                 Worst pain possible 
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Appendix 11 VAS for long thermal stimulation 
 
VAS Recording Sheet 
 
 Name:                           Group:                   Date:   /   /2008 
 
 
 
Stage 0 
05 
sec 
 
No sensation                Just painful               Worst pain possible 
 
15 
sec 
 
No sensation                Just painful                Worst pain possible 
 
25 
sec 
 
No sensation                Just painful                Worst pain possible 
 
35 
sec 
 
No sensation                Just painful                Worst pain possible 
 
45 
sec 
 
No sensation                Just painful                Worst pain possible 
 
55 
sec 
 
No sensation                Just painful                Worst pain possible 
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Appendix 12 Acupuncture treatment questionnaire 
 
Acupuncture treatment questionnaire  
 
 
Name:                                             Number:                                                  Date:     /     / 2008 
 
Please circle the answer. 
  
Section A 
 
How strong was your sensation of the acupuncture stimulation?  
 
(1) No pain 
(2) Slight / mild pain 
(3) Moderate pain 
(4) Severe pain 
 
Section B  
 
Please indicate which treatment you believe you had received. 
 
(1) Acupuncture 
(2) Placebo/sham 
(3) Don’t know 
 
If you answer either Acupuncture or Placebo/sham, what led to that belief? 
 
(1) The manner, attitude, or words of the acupuncturist 
(2) The manner, attitude, or words of the assistant 
(3) The sensation of the acupuncture stimulation  
(4) The results of the acupuncture treatment (eg, changes in pain threshold or rating) 
(5) The experience of the acupuncture procedure (eg, what the acupuncturist did and how it felt) 
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Appendix 13 Abbreviation List 
 
Abbreviation List  
ANOVA: analysis of variance     CMiHi: nociceptors: mechano-heat insensitive C nociceptors                           
 
AWR: Abdominal withdrawal reflex                    CH nociceptors: heat sensitive C nociceptors 
 
CCI: chronic constrictive injury 
 
CFA: complete Freund’s adjuvant 
 
CNS: central nervous system 
 
CRD: colorectal distention 
 
D-D: dense-disperse 
 
EA: electroacupuncture 
 
EMG: electromyogram 
 
IBS: irritable bowel syndrome 
 
ICTR: inferior caudal trunk resection 
 
NMDA: N-methyl-D-aspartic 
 
PPT: paw pressure threshold 
 
PTP: pain threshold pressure 
 
PWL: paw withdrawal threshold 
 
REA: real electroacupuncture 
 
SD: standard deviation 
 
SEA: sham electroacupuncture 
 
SEM: standard error of mean 
 
SPSS: statistical package for the social sciences 
 
SNL: spinal nerve ligation 
 
VAS: visual analogue scale 
 
WAS: water-avoidance stress 
 
WHO: World Health Organization 
 
